



US 20230104151A1

(19) **United States**

(12) **Patent Application Publication**
Mahne et al.

(10) **Pub. No.: US 2023/0104151 A1**

(43) **Pub. Date: Apr. 6, 2023**

(54) **A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS**

A61K 48/00 (2006.01)

C12N 5/0783 (2006.01)

C12N 15/63 (2006.01)

(71) Applicant: **Kyverna Therapeutics, Inc.**,
Emeryville, CA (US)

C07K 14/47 (2006.01)

A61K 35/17 (2006.01)

(72) Inventors: **Ashley Mahne**, San Francisco, CA (US); **John Lee**, Alameda, CA (US); **Lih-Yun Hsu**, San Francisco, CA (US); **Jeffrey Greve**, Berkeley, CA (US)

(52) **U.S. Cl.**

C07K 16/24 (2006.01)

C07K 16/28 (2006.01)

(73) Assignee: **Kyverna Therapeutics, Inc.**,
Emeryville, CA (US)

CPC *A61K 38/177* (2013.01); *A61K 38/1709*

(2013.01); *A61K 38/1774* (2013.01); *A61K*

38/1793 (2013.01); *A61K 39/3955* (2013.01);

A61K 48/0066 (2013.01); *C12N 5/0636*

(2013.01); *C12N 15/63* (2013.01); *C07K*

14/4705 (2013.01); *A61K 35/17* (2013.01);

C07K 14/4703 (2013.01); *C07K 16/248*

(2013.01); *C07K 16/2866* (2013.01); *C12N*

2501/60 (2013.01); *C07K 2317/622* (2013.01)

(21) Appl. No.: **17/979,437**

(22) Filed: **Nov. 2, 2022**

Related U.S. Application Data

(63) Continuation of application No. 17/523,431, filed on Nov. 10, 2021.

(60) Provisional application No. 63/111,905, filed on Nov. 10, 2020.

Publication Classification

(51) **Int. Cl.**

A61K 38/17 (2006.01)

A61K 39/395 (2006.01)


(57)

ABSTRACT

This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and one or more transcription factors are provided herein. Methods and materials for treating a mammal having an autoimmune disease comprising administering to a mammal having an autoimmune disease an effective amount of a T cell are also provided herein.

Specification includes a Sequence Listing.

Enforced FOXP3 expression imposes a core Treg program on CD4 T cells (eFOXP3 cells)



Core Treg suppressive mechanisms

- IL2 consumption (CD25 ↑)
- Adenosine (CD39 ↑)
- CTLA-4





FIG.1

**FIG. 2**

A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 17/523,431, filed on Nov. 10, 2021, which claims priority to U.S. Provisional Patent Application No. 63/111,905, filed on Nov. 10, 2020, the content of which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

[0002] This application contains a Sequence Listing that has been submitted electronically as an XML file named 47902-0016003_SL_ST26.xml. The XML file, created on Nov. 1, 2022, is 60,819 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.

BACKGROUND

[0003] This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, this document provides materials and methods for producing a T cell comprising a forkhead box P3 (FOXP3) polypeptide and one or more transcription factors. This document also provides methods and materials for treating a mammal having an autoimmune disease, where the methods include administering to a mammal having an autoimmune disease an effective amount of the T cell.

[0004] Autoimmunity is a common disease in the United States, with more than 20 million people suffering from one of 81 known autoimmune diseases. Regulatory T cells (Tregs) are a subpopulation of T cells that modulate the immune system and maintain tolerance to self-antigens. Tregs play a role in preventing or treating autoimmune disease (Sakaguchi et al., *Int'l Immun.*, 21(10):1105-1111 (2009)). FOXP3, a transcription factor expressed in Tregs, has been implicated in maintaining Treg immunosuppressive functions (Hort et al., *Science*, 299:1057-1061 (2003)). FOXP3⁺ Tregs may impair (e.g., eliminate and/or inhibit) responder T cells involved in causing autoimmune disease by a granzyme-dependent or perforin-dependent mechanism (Trzonkowski et al., *Clin. Immunol.*, 112:258-67 (2004)). FOXP3⁺ Tregs also may impair (e.g., eliminate and/or inhibit) responder T cells involved in causing autoimmune disease, by delivering a negative signal to responder T cells via up-regulation of intracellular cyclic AMP, which causes inhibition of responder T cell proliferation (Gondex et al., *J. Immunol.*, 174:1783-6 (2005)).

SUMMARY

[0005] This document provides methods and materials that can be used to treat mammals identified as having an autoimmune disease. For example, this document provides materials and methods for a T cell containing a FOXP3 polypeptide and one or more transcription factors. In another example, this document provides materials and methods for producing a T cell containing a FOXP3 polypeptide, one or more transcription factors, and a therapeutic gene product. This document also provides materials and methods for producing a T cell containing a FOXP3 polypeptide, one or more transcription factors, and a therapeutic gene product and/or a binding agent. In addition, this document provides methods and materials for treating a mammal having an

autoimmune disease, where the methods include administering to the mammal an effective amount of a T cell (e.g., any of the T cells described herein). The methods and materials provided herein can provide a way to enhance and/or stabilize the immunosuppressive effects of a T cell in order to treat the autoimmune disease.

[0006] In general, one aspect of this document features a method for increasing T cell function, where the method includes introducing into a T cell: (i) a first nucleic acid sequence encoding a FOXP3 polypeptide; and (ii) a second nucleic acid sequence encoding one or more transcription factors. In some embodiments, the one or more transcription activators, when present in a mammalian cell, elicit a T reg phenotype in the mammalian cell as compared to when the one or more transcription factors is/are not present in the mammalian cell. In some embodiments, the first nucleic acid sequence can include a mutation that results in nuclear localization of the FOXP3 polypeptide. In some embodiments, the mutation that results in nuclear localization of the FOXP3 polypeptide can be in a sequence encoding a nuclear export sequence. In some embodiments, the nuclear export sequence can include an amino acid substitution selected from the group of L69A, L71A, L74A, L76A, L242A, L246A, and L248A. In some embodiments, the first nucleic acid sequence can include a mutation that results in stabilization of the FOXP3 polypeptide. In some embodiments, the mutation that results in stabilization of the FOXP3 polypeptide can change the level of phosphorylation of the FOXP3 polypeptide compared to FOXP3 polypeptide not having the mutation. In some embodiments, the mutation can result in the expression of a FOXP3 polypeptide having an amino acid substitution selected from the group of S19A, S33A, S57A, S58A, S59A, T115A, S418D, and S422A. In some embodiments, the mutation that results in the stabilization of the FOXP3 polypeptide can change the level of acetylation of the FOXP3 polypeptide compared to FOXP3 polypeptide that not having the mutation. In some embodiments, the mutation can result in the production of a FOXP3 polypeptide having an amino acid substitution mutation selected from the group of K31R, K206R, K216R, K227R, K250R, K252R, K268R, and K277R. In some embodiments, the one or more transcription factors can be selected from the group of: BLIMP1, EOS, ROR-gt, FOXO1, GATA1, HELIOS, ID2, ID3, IRF4, LEF1, SATB1, GATA3, NFATc2, RUNX1, BC111b, Foxp1, Fox4, BACH2, STAT3, and XBP1. In some embodiments, the one or more transcription factors can be selected from selected form the group of: BLIMP1, EOS, GATA1, HELIOS, GATA3, and NFATc2. In some embodiments, the transcription factor can be BLIMP-1.

[0007] In some embodiments, the introducing step further includes introducing a nucleic acid construct, where the nucleic acid construct includes the first nucleic acid sequence and the second nucleic acid sequence. In some embodiments, the nucleic acid construct can further include a promoter operably linked to the first nucleic acid sequence. In some embodiments, the first nucleic acid sequence can be 5' positioned relative to the second nucleic acid sequence in the nucleic acid construct. In some embodiments, the nucleic acid construct further can include an additional nucleic acid sequence between the first nucleic acid sequence and the second nucleic acid sequence, where the additional nucleic acid sequence operably links the second nucleic acid sequence to the first nucleic acid sequence. In some embodi-

ments, the second nucleic acid sequence is 5' positioned relative to the first nucleic acid sequence in the nucleic acid construct. In some embodiments, the nucleic acid construct further includes an additional nucleic acid sequence between the second nucleic acid sequence and the first nucleic acid sequence, where the additional nucleic acid sequence operably links the first nucleic acid sequence to the second nucleic acid sequence. In some embodiments, the additional nucleic acid sequence can encode an internal ribosome entry site (IRES) sequence or a self-cleaving amino acid. In some embodiments, the additional nucleic acid sequence can include a promoter or enhancer.

[0008] In some embodiments, the introducing step further includes introducing a third nucleic acid sequence encoding a therapeutic gene product into the T cell, where the third nucleic acid sequence is operably linked to a promoter. In some embodiments, the therapeutic gene product can be an antigen-binding antibody fragment or antibody that is capable of binding to an IL-6, an IL-6R, an IFN alpha receptor, or a TGF beta receptor polypeptide. In some embodiments, the therapeutic gene product can be an antigen-binding fragment or antibody that is capable of binding to a IL-6 polypeptide or an IL-6R polypeptide.

[0009] In some embodiments, the nucleic acid sequence construct further includes a third nucleic acid sequence encoding the therapeutic gene product. In some embodiments, the introducing step further can include introducing a third nucleic acid sequence encoding a therapeutic gene product into the T cell, where the third nucleic acid sequence is operably linked to a promoter. In some embodiments, the therapeutic gene product can be an antigen-binding antibody fragment or antibody that is capable of binding to an IL-6, an IL-6R, an IFN alpha receptor, or a TGF beta receptor polypeptide. In some embodiments, the therapeutic gene product is an antigen-binding fragment or antibody that is capable of binding to an IL-6 polypeptide or an IL-6R polypeptide. In some embodiments, the third sequence can be 5' positioned relative to the first sequence and the second sequence, where the third sequence is operably linked a promoter. In some embodiments, the third sequence can be 3' positioned relative to the first and second sequence, where the third sequence is operably linked to the first sequence and/or the second sequence.

[0010] In some embodiments, the introducing step further includes introducing a fourth nucleic acid sequence encoding a binding agent into the T cell, where the fourth nucleic acid sequence is operably linked to a promoter. In some embodiments, the nucleic acid construct further includes a fourth nucleic acid sequence encoding a binding agent. In some embodiments, the binding agent can be an antibody or antigen-binding fragment. In some embodiments, the antigen-binding domain can be an antigen-binding fragment selected from the group of a Fab, a F(ab')₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the antigen-binding fragment can be a scFv that is capable of binding to an antigen on an autoimmune cell. In some embodiments, the scFv is capable of binding to a cell adhesion molecule. In some embodiments, the cell adhesion molecule can be ICAM-1, VCAM-1, or MADCAM-1. In some embodiments, the binding agent can be a LFA-1 polypeptide. In some embodiments, the binding agent is a chimeric antigen receptor, where the chimeric antigen receptor includes an extracellular domain, a transmembrane

domain, and an intracellular domain, where the extracellular domain includes an antibody or antigen-binding fragment capable of binding to an antigen on an autoimmune cell, and where the intracellular domain includes a cytoplasmic signaling domain and one or more co-stimulatory domains. In some embodiments, the antigen-binding domain is an antigen-binding fragment can be selected from the group of a Fab, a F(ab')₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the antigen-binding fragment can be a scFv that is capable of binding to an antigen on an autoimmune cell. In some embodiments, the scFv can be capable of binding to a cell adhesion molecule. In some embodiments, the cell adhesion molecule can be ICAM-1, VCAM-1, or MADCAM-1. In some embodiments, the cytoplasmic signaling domain can be a CD3 zeta domain. In some embodiments, the co-stimulatory domain can include at least one of a CD48, 4-1BB, ICOS, X-40, or CD27 domain. In some embodiments, the fourth sequence can be 5' positioned relative to the first sequence and the second sequence, where the fourth sequence is operably linked a promoter. In some embodiments, the fourth sequence can be 3' positioned relative to the first and second sequence, where the fourth sequence is operably linked to the first sequence and/or the second sequence.

[0011] In some embodiments, the nucleic acid construct further includes a third sequence encoding any of the therapeutic gene products described herein and a fourth sequence encoding any of the binding agents described herein. In some embodiments, the third sequence can be operably linked to a promoter and/or operably linked the first sequence and/or second sequence, and where the fourth sequence is operably linked to a promoter and/or operably linked the first sequence and/or second sequence.

[0012] In some embodiments, the nucleic acid construct can include a viral vector selected from the group of a lentiviral vector, a retroviral vector, an adenoviral vector, or an adeno-associated viral (AAV) vector. In some embodiments, the viral vector can be a lentiviral vector. In some embodiments, the introducing step includes viral transduction.

[0013] In some embodiments, the T cell is a CD4⁺ T cell or a CD4⁺/CD45RA⁺ T cell. In some embodiments, the method further includes: obtaining a T cell from a patient or obtaining T cells allogenic to the patient. In some embodiments, the method further includes: treating the obtained T cells to isolate a population of cells enriched for CD4⁺ T cells or CD4⁺/CD45RA⁺ T cells.

[0014] In another aspect, this document features a T cell produced by any of the methods described herein. In another aspect, this document features a composition including any of the T cells described herein.

[0015] In another aspect, this document features a T-cell including: a first nucleic acid sequence encoding a FOXP3 polypeptide; and a second nucleic acid sequence encoding one or more transcription factors. In some embodiments, the one or more transcription factors, when present in a mammalian cell, elicit a T reg phenotype in the mammalian cell as compared to when the transcription factor is not present in the mammalian cell. In some embodiments, the nuclear export sequence of the FOXP3 polypeptide can include an amino acid substitution selected from the group of L69A, L71A, L74A, L76A, L242A, L246A, and L248A. In some embodiments, the first nucleic acid sequence can include a

mutation that results in stabilization of the FOXP3 polypeptide. In some embodiments, the mutation that results in stabilization of the FOXP3 polypeptide can change the level of phosphorylation of the FOXP3 polypeptide compared to FOXP3 polypeptide not having the mutation. In some embodiments, the mutation results in the production of a FOXP3 polypeptide having an amino acid substitution selected from the group of S19A, S33A, S57A, S58A, S59A, T115A, S418D, and S422A. In some embodiments, the mutation that results in the stabilization of the FOXP3 polypeptide can change the level of acetylation of the FOXP3 polypeptide compared to FOXP3 polypeptide that not having the mutation. In some embodiments, the mutation results in the production of a FOXP3 polypeptide having an amino acid substitution mutation selected from the group of K31R, K206R, K216R, K227R, K250R, K252R, K268R, and K277R. In some embodiments, the one or more transcription factors can be selected from the group of: BLIMP1, EOS, ROR-gt, FOXO1, GATA1, HELIOS, ID2, ID3, IRF4, LEF1, SATB1, GATA3, NFATc2, RUNX1, BC111b, Foxp1, Fox4, BACH2, STAT3, and XBP1. In some embodiments, the one or more transcription factors can be selected from selected form the group of: BLIMP1, EOS, GATA1, HELIOS, GATA3, and NFATc2. In some embodiments, the transcription factor can be BLIMP-1. In some embodiments, the first nucleic acid sequence can be operably linked to a promoter. In some embodiments, the second nucleic acid sequence can be operably linked to a promoter.

[0016] In some embodiments, the T-cell further includes a third nucleic acid sequence encoding a therapeutic gene product into the T cell, where the third nucleic acid sequence is operably linked to a promoter. In some embodiments, the therapeutic gene product can be an antigen-binding antibody fragment or antibody that is capable of binding to an IL-6, an IL-6R, an IFN alpha receptor, or a TGF beta receptor polypeptide. In some embodiments, the therapeutic gene product can be an antigen-binding fragment or antibody that is capable of binding to a IL-6 polypeptide or an IL-6R polypeptide.

[0017] In some embodiments, the T-cell further includes introducing a fourth nucleic acid sequence encoding a binding agent into the T cell, where the fourth nucleic acid sequence is operably linked to a promoter. In some embodiments, the binding agent can be an antibody or antigen-binding fragment. In some embodiments, the antigen-binding domain can be an antigen-binding fragment selected from the group of a Fab, a F(ab')₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the antigen-binding fragment can be a scFv that is capable of binding to an antigen on an autoimmune cell. In some embodiments, the scFv is capable of binding to a cell adhesion molecule. In some embodiments, the cell adhesion molecule can be ICAM-1, VCAM-1, or MADCAM-1. In some embodiments, the binding agent can be a LFA-1 polypeptide.

[0018] In some embodiments, the binding agent is a chimeric antigen receptor, where the chimeric antigen receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain, where the extracellular domain includes an antibody or antigen-binding fragment capable of binding to an antigen on an autoimmune cell, and where the intracellular domain includes a cytoplasmic signaling domain and one or more co-stimulatory domains. In some

embodiments, the antigen-binding domain can be an antigen-binding fragment selected from the group of a Fab, a F(ab')₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the antigen-binding fragment can be a scFv that is capable of binding to an antigen on an autoimmune cell. In some embodiments, the scFv is capable of binding to a cell adhesion molecule. In some embodiments, the cell adhesion molecule can be ICAM-1, VCAM-1, or MADCAM-1. In some embodiments, the cytoplasmic signaling domain can be a CD3 zeta domain. In some embodiments, the co-stimulatory domain can include at least one of a CD48, 4-1BB, ICOS, X-40, or CD27 domain.

[0019] In another aspect, this document features a composition including a T cell produced using any of the methods described herein.

[0020] In another aspect, this document features a method of producing a T cell population expressing an exogenous FOXP3 polypeptide and one or more transcription factors, where the method includes culturing a T cell (e.g., any of the exemplary T cells described herein) in growth media under conditions sufficient to expand the population of T cells.

[0021] In another aspect, this document features a population of T cells produced using any of the methods described herein. In another aspect, this document features a composition including the population of T cells produced using any of the methods described herein.

[0022] In another aspect, this document features a vector including a first nucleic acid sequence encoding a FOXP3 polypeptide and a second nucleic acid sequence encoding a one or more transcription factors. In some embodiments, the one or more transcription factors, when present in a mammalian cell, elicit a T reg phenotype in the mammalian cell as compared to when the transcription factor is not present in the mammalian cell. In some embodiments, the nuclear export sequence of the FOXP3 polypeptide can include an amino acid substitution selected from the group of L69A, L71A, L74A, L76A, L242A, L246A, and L248A. In some embodiments, the first nucleic acid sequence can include a mutation that results in stabilization of the FOXP3 polypeptide. In some embodiments, the mutation that results in stabilization of the FOXP3 polypeptide can change the level of phosphorylation of the FOXP3 polypeptide compared to FOXP3 polypeptide not having the mutation. In some embodiments, the mutation results in the production of a FOXP3 polypeptide having an amino acid substitution selected from the group of S19A, S33A, S57A, S58A, S59A, T115A, S418D, and S422A. In some embodiments, the mutation that results in the stabilization of the FOXP3 polypeptide can change the level of acetylation of the FOXP3 polypeptide compared to FOXP3 polypeptide that not having the mutation. In some embodiments, the mutation can result in the production of a FOXP3 polypeptide having an amino acid substitution selected from the group of K31R, K206R, K216R, K227R, K250R, K252R, K268R, and K277R. In some embodiments, the one or more transcription factors can be selected from the group of: BLIMP1, EOS, ROR-gt, FOXO1, GATA1, HELIOS, ID2, ID3, IRF4, LEF1, SATB1, GATA3, NFATc2, RUNX1, BC111b, Foxp1, Fox4, BACH2, STAT3, and XBP1. In some embodiments, the one or more transcription factors can be selected from selected

form the group of: BLIMP1, EOS, GATA1, HELIOS, GATA3, and NFATc2. In some embodiments, the transcription factor can be BLIMP-1.

[0023] In some embodiments, the vector further includes a promoter operably linked to the first nucleic acid sequence. In some embodiments, the first nucleic acid sequence can be 5' positioned relative to the second nucleic acid in the vector. In some embodiments, the vector further includes an additional nucleic acid sequence between the first nucleic acid sequence and the second nucleic acid sequence, where the additional nucleic acid sequence operably links the second nucleic acid sequence to the first nucleic acid sequence. In some embodiments, the second nucleic acid sequence can be 5' positioned relative to the first nucleic acid sequence in the vector. In some embodiments, the vector further includes an additional nucleic acid sequence between the second nucleic acid sequence and the first nucleic acid sequence, where the additional nucleic acid sequence operably links the first nucleic acid sequence to the second nucleic acid sequence. In some embodiments, the additional nucleic acid sequence can encode an internal ribosome entry site (IRES) sequence or a self-cleaving amino acid. In some embodiments, the additional nucleic acid sequence can include a promoter or enhancer.

[0024] In some embodiments, the vector further includes a third nucleic acid sequence encoding a therapeutic gene product. In some embodiments, the therapeutic gene product can be an antigen-binding antibody fragment or antibody that is capable of binding to an IL-6, an IL-6R, an IFN alpha receptor, or a TGF beta receptor polypeptide. In some embodiments, the therapeutic gene product can be an antigen-binding fragment or antibody that is capable of binding to an IL-6 polypeptide or an IL-6R polypeptide. In some embodiments, the third nucleic acid sequence can be 5' positioned relative to the first sequence and the second sequence, where the third nucleic acid sequence is operably linked to a promoter. In some embodiments, the third nucleic acid sequence can be 3' positioned relative to the first and second nucleic acid sequence, where the third nucleic acid sequence is operably linked to the first nucleic acid sequence and/or the second nucleic acid sequence.

[0025] In some embodiments, the vector further includes a fourth nucleic acid sequence encoding a binding agent. In some embodiments, the binding agent can be an antibody or antigen-binding fragment. In some embodiments, the antigen-binding domain can be an antigen-binding fragment selected from the group of a Fab, a F(ab')₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the antigen-binding fragment can be a scFv that is capable of binding to an antigen on an autoimmune cell. In some embodiments, the scFv is capable of binding to a cell adhesion molecule. In some embodiments, the cell adhesion molecule can be ICAM-1, VCAM-1, or MADCAM-1. In some embodiments, the binding agent can be a LFA-1 polypeptide.

[0026] In some embodiments, the binding agent is a chimeric antigen receptor, where the chimeric antigen receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain, where the extracellular domain includes an antibody or antigen-binding fragment capable of binding to an antigen on an autoimmune cell, and where the intracellular domain includes a cytoplasmic signaling domain and one or more co-stimulatory domains. In some

embodiments, the antigen-binding domain can be an antigen-binding fragment selected from the group of a Fab, a F(ab')₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody. In some embodiments, the antigen-binding fragment can be a scFv that is capable of binding to an antigen on an autoimmune cell. In some embodiments, the scFv is capable of binding to a cell adhesion molecule. In some embodiments, the cell adhesion molecule can be ICAM-1, VCAM-1, or MADCAM-1. In some embodiments, the cytoplasmic signaling domain can be a CD3 zeta domain. In some embodiments, the co-stimulatory domain includes at least one of a CD48, 4-1BB, ICOS, X-40, or CD27 domain.

[0027] In some embodiments, the fourth nucleic acid sequence can be 5' positioned relative to the first nucleic acid sequence and the second nucleic acid sequence, where the fourth nucleic acid sequence is operably linked a promoter. In some embodiments, the fourth nucleic acid sequence can be 3' positioned relative to the first and second nucleic acid sequence, where the fourth nucleic acid sequence is operably linked to the first nucleic acid sequence and/or the second nucleic acid sequence. In some embodiments, the third nucleic acid sequence is operably linked to a promoter and/or operably linked the first nucleic acid sequence and/or second nucleic acid sequence, and where the fourth nucleic acid sequence is operably linked to a promoter and/or operably linked the first nucleic acid sequence and/or second nucleic acid sequence.

[0028] In some embodiments, the vector includes a viral vector selected from the group of a lentiviral vector, a retroviral vector, an adenoviral vector, or an adeno-associated viral (AAV) vector. In some embodiments, the viral vector can be a lentiviral vector.

[0029] In another aspect, this document features a composition including any of the vectors described herein. In another aspect, this document features a kit including any of the compositions described herein.

[0030] In another aspect, this document features a method of treating an autoimmune disease or disorder in a patient including administering any of the T cells described herein, or any of the compositions described herein. In some embodiments, the subject can be previously diagnosed or identified as having an autoimmune disease or disorder. In some embodiments, the autoimmune disease or disorder can be lupus, rheumatoid arthritis, multiple sclerosis, insulin dependent diabetes mellitus, myasthenia gravis, Graves disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, Crohn's disease, Celiac disease, or polyarteritis nodosa. In some embodiments, the administering of the autologous or allogenic T cell population can include intravenous injection or intravenous infusion. In some embodiments, the administering can result in amelioration of one or more symptoms of the autoimmune disease or disorder.

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present

specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0032] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF THE DRAWING

[0033] FIG. 1 is a diagram showing an exemplary targetable cell with enforced expression of a FOXP3 polypeptide. Enforced expression of a FOXP3 polypeptide results in a core Treg suppressive program (e.g., IL-2 consumption and increase in CD25 expression, an increase in adenosine, an increase in CD39 expression, and expression of CTLA-4).

[0034] FIG. 2 is a diagram showing an exemplary targetable cell with enforced expression of a FOXP3 polypeptide and a therapeutic gene product. Expression of a therapeutic gene product in addition to a FOXP3 polypeptide can result in enhancement of a core Treg program. Examples of suitable therapeutic gene products include, without limitation, IL6R scFv, IFN α R scFv, IL-10, IL-4, IL-13, and any other anti-fibrotic-related output.

DETAILED DESCRIPTION

[0035] This document provides methods and materials that can be used to treat mammals identified as having an autoimmune disease. For example, this document provides materials and methods for producing a T cell containing a FOXP3 polypeptide and one or more transcription factors (miRNA). In another example, this document provides materials and methods for producing a T cell containing a FOXP3 polypeptide, one or more transcription factors, and a therapeutic gene product. In a third example, this document also provides materials and methods for producing a T cell containing a FOXP3 polypeptide, one or more transcription factors, and a binding agent. In a fourth example, this document provides materials and methods for producing a T cell containing a FOXP3 polypeptide, one or more transcription factors, a therapeutic gene product, and a binding agent. In addition, this document provides methods and materials for treating a mammal having an autoimmune disease, where the methods include administering to the mammal an effective amount of a T cell produced using any of the methods described herein.

[0036] This document provides methods and materials for introducing into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell) a first nucleic acid sequence encoding a FOXP3 polypeptide and a second nucleic acid sequence encoding one or more transcription factors. In some embodiments, the one or more transcription factors, when present in a mammalian cell, elicits a Treg phenotype in the mammalian cell as compared to when the transcription factor(s) is/are not present in the mammalian cell.

[0037] In some embodiments, a first nucleic acid sequence encoding a FOXP3 polypeptide having one or more mutations is introduced into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell). For example, a mutation in the first nucleic acid sequence encoding a FOXP3 polypeptide can include, with-

out limitation, mutations that result in an amino acid substitution that changes the stability (e.g., level of phosphorylation or acetylation), function (e.g., transcriptional regulation), or sub-cellular localization (e.g., nuclear localization) of the encoded FOXP3 polypeptide.

[0038] In some embodiments, a FOXP3 polypeptide can have an amino acid substitution in one or more nuclear export sequences (NES) that can result in nuclear localization of the FOXP3 polypeptide. Transducing cells with a FOXP3 polypeptide having one or more amino acid substitutions, amino acid insertions, and/or amino acid deletions in the nuclear export sequences can result in establishment, maintenance, or enhancement of a FOXP3 polypeptide-dependent expression profile that is indicative of expression profiles seen in native Treg cells (e.g., Treg cells isolated from a healthy human). In some cases, a cell (e.g., a CD4⁺ T cell) with a FOXP3 polypeptide-dependent expression profile can have increased immunosuppressive function. For example, a cell transduced with a FOXP3 polypeptide having one or more amino acid substitutions, amino acid insertions, and/or amino acid deletions as described herein can have increased expression of genes that are transcriptional targets of a FOXP3. Increased expression of these genes (e.g., IL-2, CtlA-4, and Tnfrsf18) can result in increased Treg cell function (e.g., inhibition of responder cell proliferation). In some embodiments, a FOXP3 polypeptide can have one or more amino acid substitutions, amino acid insertions, and/or amino acid deletions within a sequence encoding a NES. In cases where the FOXP3 polypeptide includes one or more amino acid deletions, the one or more deletions can be within a part of a NES (e.g., deletion of a part of a NES, deletion of an entire NES, or deletion of a larger fragment containing a NES sequence (e.g., corresponding to exon 2 or exon 7 of a FOXP3 polypeptide). For example, a FOXP3 polypeptide having the amino acids corresponding to exon 2-deleted (FOXP3d2), amino acids corresponding to exon 7 deleted (FOXP3d7), or amino acids corresponding to exon 2 and 7-deleted (FOXP3d2d7) can result in the nuclear localization of the FOXP3 polypeptide. In some embodiments, point mutations in the first nucleic acid sequence encoding the nuclear export sequences (e.g., NES1, having an amino acid sequence set forth in SEQ ID NO: 4, and NES2, having the amino acid sequence of SEQ ID NO: 5) can be any mutation (e.g., nucleic acid substitution, insertion, and/or deletion) that results in a change within the amino acid sequence of NES1 and/or NES2 and renders the nuclear export signal non-functional. Amino acid substitutions in NES1 and/or NES2 that can result in nuclear localization of a FOXP3 polypeptide include, without limitation: of L69A, L71A, L74A, L76A, L242A, L246A, and L248A. FOXP3 polypeptides harboring any one or more of these amino acid substitutions, amino acid insertions, and/or amino acid deletions can sequestered to the nucleus.

[0039] In some embodiments, the first nucleic acid sequence encoding the FOXP3 polypeptide can encode one or more fragments of a full length FOXP3 polypeptide (e.g., a full length FOXP3 polypeptide such as version NP_001107849.1). In some embodiments, a cell can be transduced with a first nucleic acid sequence encoding a FOXP3 polypeptide that includes at least the regions of FOXP3 that have DNA-binding properties (e.g., polypeptide fragments of FOXP3 that can bind to a ATAACA DNA sequence) (Li et al., *Acta Biochim. Biophys. Sin.*, 49(9): 792-99 (2017)).

[0040] In some embodiments, an amino acid substitution in a FOXP3 polypeptide that changes the level of phosphorylation can stabilize the FOXP3 polypeptide (e.g., increase the half-life of the FOXP3 polypeptide). For example, a mutation in a first nucleic acid sequence encoding a FOXP3 polypeptide can result in an amino acid substitution that changes the level of phosphorylation of the FOXP3 polypeptide compared to a FOXP3 polypeptide not having the amino acid substitution. Non-limiting examples of amino acid substitutions that can change the level of phosphorylation of the FOXP3 polypeptide include S19A, S33A, S57A, S58A, S59A, T115A, S418D, and S422A.

[0041] In some embodiments, an amino acid substitution in a FOXP3 polypeptide is a phosphomimetic amino acid substitution. Phosphomimetics are amino acid substitutions that mimic a phosphorylated polypeptide or can encourage phosphorylation at a particular amino acid position, thereby activating or deactivating the polypeptide. For example, the phosphorylation of Ser418 can be enforced by a phosphoserine mimetic substitution of that residue into an alanine or aspartate. A mutation can be made in the first nucleic acid sequence encoding a FOXP3 polypeptide to produce a FOXP3 polypeptide having the S418D substitution. The S418D residue then serves as phosphomimetic amino acid residue. Additional amino acid residues that can be substituted to produce phosphomimetic amino acid residues include serines at positions 19, 33, 41, 88, and 422, threonines at sites 114 and 175 in FOXP3. See, Morawski, et al., *J Biol Chem.*, 288(34): 24494-24502 (2013). For example, phosphomimetics of these sites can be engineered by substituting the serine or threonine for alanine. These phosphomimetics can enhance the stability and immunosuppressive activity of a FOXP3 polypeptide.

[0042] In some embodiments, an amino acid substitution in a FOXP3 polypeptide that changes the level of acetylation can stabilize the FOXP3 polypeptide (e.g., increase the half-life of the FOXP3 polypeptide). For example, a mutation in a first nucleic acid sequence encoding a FOXP3 polypeptide can result in an amino acid substitution that changes the level of acetylation of the FOXP3 polypeptide compared to a FOXP3 polypeptide not having the amino acid substitution. Non-limiting examples of amino acid substitutions that can change the level of acetylation of the FOXP3 polypeptide include K31R, K206R, K216R, K227R, K250R, K252R, K268R, and K277R.

[0043] In some embodiments, a second nucleic acid encoding one or more transcription factors is introduced into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell) along with the first nucleic acid sequence encoding the FOXP3 polypeptide. In some embodiments, introducing a first nucleic acid sequence encoding a FOXP3 polypeptide and a second nucleic acid sequence encoding one or more transcription factors into a CD4⁺ T cell enhances the suppressive activity of the T cell. In some embodiments, introducing a second nucleic acid sequence encoding one or more transcription factors into a CD4⁺ T cell elicits a T reg phenotype (e.g., immune suppression phenotype) in the T cell as compared to when the one or more transcription factors is/are not present in the mammalian cell. For example, introducing a second nucleic acid sequence encoding an NFATC2 polypeptide into a T cell (e.g., CD4⁺ T cell or any of the other exemplary T cells described herein) can induce a T reg phenotype (e.g., immune suppression phenotype) in the T cell. In another

example, introducing a second nucleic acid sequence encoding a GATA3 polypeptide into a T cell (e.g., CD4⁺ T cell or any of the other exemplary T cells described herein) can induce a T reg phenotype (e.g., immune suppression phenotype) in the T cell. Non-limiting examples of transcription factors that can be used to enhance the T reg phenotype of a T cell include BLIMP1, EOS, ROR- γ t, FOXO1, GATA1, HELIOS, ID2, ID3, IRF4, LEF1, SATB1, GATA3, NFATc2, RUNX1, BC111b, Foxp1, Fox4, BACH2, STAT3, and XBP1. For example, a first nucleic acid sequence encoding the FOXP3 polypeptide and a second nucleic acid sequence encoding BLIMP-1 polypeptide can be introduced into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell). Dnmt3a is responsible for methylation of genomic DNA encoding FOXP3 causing downregulation of FOXP3 and reducing the immunosuppressive functionality of the T cell. BLIMP1 blocks the upregulation of Dnmt3a. (See Garg, et al., *Cell Reports*, 26:1854-1868 (2019)). Expression of BLIMP1 prevents methylation (e.g., silencing) of FOXP3 thereby enabling continued expression of FOXP3 and maintenance of the T reg phenotype in the T cell. A T reg phenotype can include, e.g., one or more of IL-2 consumption, an increase in CD25 expression, an increase in adenosine, an increase in CD39 expression, and expression of CTLA-4. Additional markers of a T reg phenotype are known in the art.

[0044] This document provides methods and materials for introducing into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell) a first nucleic acid sequence encoding a FOXP3 polypeptide (e.g., any of the exemplary FOXP3 polypeptides described herein) and a second nucleic acid sequence encoding one or more transcription factors (e.g., any of the exemplary transcription factors described herein), and a therapeutic gene product. Any appropriate therapeutic gene product that enhances the immunosuppressive effects of a T cell (e.g., a CD4⁺CD45⁺ T cell) can be used. Examples of therapeutic gene products include, without limitation, antigen or antigen-binding fragments directed to interferon alpha receptor 1 (IFNAR1), interleukin 10 (IL-10), interleukin 4 (IL-4), interleukin 13 (IL-13), interleukin 6 (IL-6), IL-6 receptor (IL-6R), and any other anti-fibrotic agent. In some embodiments, the therapeutic gene product can enhance the immunosuppressive effect of the transduced cell. For example, a therapeutic gene product can be any polypeptide or other agent that prohibits an IL-6 polypeptide from binding to an IL-6 receptor (IL-6R). In such cases, a therapeutic gene product can be an antagonist for IL-6R (e.g., an antibody or antigen-binding fragment that binds to IL-6R) and/or blocking antibody or antigen-binding fragment of IL-6 (e.g., a scFv capable of binding to IL-6). Additional examples of therapeutic gene products include, without limitation, cytokines, cytokine receptors, differentiation factors, growth factors, growth factor receptors, peptide hormones, metabolic enzymes, receptors, T cell receptors, chimeric antigen receptors (CARs), transcriptional activators, transcriptional repressors, translation activators, translational repressors, immune-receptors, apoptosis inhibitors, apoptosis inducers, immune-activators, and immune-inhibitors.

[0045] This document provides methods and materials for introducing into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell) a first nucleic acid sequence encoding a FOXP3 polypeptide (e.g., any of the exemplary FOXP3 polypeptides described herein)

and a second nucleic acid sequence encoding one or more transcription factors (e.g., any of the exemplary transcription factors described herein), a therapeutic gene product (e.g., any of the exemplary therapeutic gene products as described herein), and a binding agent. Also provided herein are methods and materials for introducing into a T cell (e.g., CD4⁺ T cell, CD4⁺CD45RA⁺ T cell, CD4⁺CD62L⁺ T cell, or central memory T cell) a first nucleic acid sequence encoding a FOXP3 polypeptide (e.g., any of the exemplary FOXP3 polypeptides described herein) and a second nucleic acid sequence encoding one or more transcription factors (e.g., any of the exemplary transcription factors described herein), and a binding agent.

[0046] As used herein, “binding agent” refers to any variety of extracellular substance that binds with specificity to its cognate binding partner. In some embodiments, a cell (e.g., a CD4⁺CD45RA⁺ T cell) can be transduced with nucleic acid sequences encoding a mutated FOXP3 polypeptide as described herein, one or more transcription factors, and a binding agent. In some embodiments, a binding agent can be any polypeptide that enhances the immunosuppressive effect of a T cell (e.g., a CD4⁺CD45RA⁺ T cell). In some embodiments, a binding agent can be a polypeptide that binds to molecules found specifically on autoimmune cells or tissues. For example, a binding agent can be a lymphocyte function associated antigen-1 (LFA-1) polypeptide. An LFA-1 can bind to cell adhesion molecules on the surface of cells associated with autoimmune diseases. Examples of binding partners for LFA-1 include, without limitation, ICAM-1, VCAM-1 and MADCAM-1. In another example, a binding agent can be a polypeptide that binds to a VCAM-1 polypeptide (e.g., a scFv capable of binding to a VCAM-1 polypeptide). In yet another example, a binding agent can be a polypeptide that binds to a MADCAM-1 polypeptide (e.g., a scFv capable of binding to a MADCAM-1 polypeptide). In some embodiments, a binding agent can be a chimeric antigen receptor (CAR) as described herein where the CAR has an extracellular domain, a transmembrane domain, and an intracellular domain. In cases where the binding agent is a CAR, the extracellular domain includes a polypeptide capable of binding to a molecule found specifically on autoimmune cells or tissues. For example, the extracellular domain can include an scFV capable of binding to antigen on an autoimmune cell.

[0047] As used herein, “FOXP3” refers to the FOXP3 gene or protein that is a transcription factor in the Forkhead box (Fox) family of transcription factors (Sakaguchi et al., *Int'l Immun.*, 21(10):1105-1111 (2009); Pandiyan, et al., *Cytokine*, 76(1):13-24 (2015)), or a variant thereof (e.g., a FOXP3 protein having one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty amino acid substitutions, amino acid deletions, or amino acid insertions as compared to a wildtype FOXP3 protein). In some embodiments, when preparing a T cell to be used in the treatment of a mammal having an autoimmune disease by administering to the mammal the T cell, FOXP3 refers to human FOXP3 or a variant thereof. An example of a wildtype human FOXP3 polypeptide includes, without limitation, NCBI reference sequence: NP 001107849.1 or a fragment thereof.

[0048] As used herein, “nuclear localization” means an increase in the level of FOXP3 (e.g., any of the FOXP3 polypeptides described herein) in the nucleus of a mamma-

lian cell (e.g., any of the T cells described herein) as compared to a control mammalian cell (e.g., a mammalian cell expressing wildtype FOXP3 or a mammalian cell not genetically modified to include any of a first, second, third, and fourth nucleic acid sequences as described herein).

[0049] In some embodiments referring to a first nucleic acid sequence encoding a FOXP3 (e.g., full length FOXP3) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 99% and 100%) identical to:

(SEQ ID NO: 1)
AGTTTCCCACAAGCCAGGCTGATCCTTTTCTGTCACTCCACTTCACCAAG
CCTGCCCTTGGACAAGGACCCGATGCCCAACCCAGGCCCTGGCAAGCCCT
CGGCCCTTCCTTGGCCCTTGGCCATCCCCAGGAGCCTCGCCAGCTGG
AGGGCTGCACCCAAAGCCTCAGACCTGTGGGGGCCCGGGCCAGGGG
AACCTTCCAGGGCCGAGATCTTCGAGGCGGGCCATGCCTCCTCTTCTT
CCTTGAACCCCATGCCACCATCGCAGCTGCAGCTCTCAACGGTGGATGCC
CACGCCCGGACCCCTGTGTCTGCAGGTGCACCCCTGGAGAGCCAGCCAT
GATCAGCCTCACACCACCACCACCAGCCACTGGGGTCTTCTCCCTCAAGG
CCCGCCTGGCCTCCACCTGGGATCAACGTGGCCAGCCTGGAATGGGTG
TCCAGGGAGCCGGCACTGCTCTGCACCTTCCCAATCCCAGTGCACCAG
GAAGGACAGCACCCCTTTCGGCTGTGCCCCAGAGCTCTTACCCTGCTGG
CAATGGTGTCTGCAAGTGGCCGGATGTGAGAAGGTCTTCGAAGAGCCA
GAGGACTTCTCAAGCACTGCCAGGCGGACCATCTTCTGGATGAGAAGGG
CAGGGCACAAATGTCTCTCCAGAGAGAGATGGTACAGTCTCTGGAGCAGC
AGCTGGTGTGAGAGAAGGAGAAGCTGAGTGCATGCAGCCACCTGGCT
GGGAAAATGGCACTGACCAAGGCTTCATCTGTGGCATCATCCGACAAGGG
CTCTGTCTGCATCGTAGCTGTGCGAGCCAAAGCCCTGTCTGCCAGCCT
GGTCTGGCCCCCGGAGGCCCTGACAGCCTGTTGTCTGTCGGAGGCAC
CTGTGGGTAGCCATGGAAACAGCACATTTCCAGAGTTCTCCACAACAT
GGACTACTTCAAGTTCACAAACATGCACCCCTTTCACCTACGCCACGC
TCATCCGCTGGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACACTCAAT
GAGATCTACCACTGGTTACACGCATGTTTGCCTTCTCAGAAACCATCC
TGCCACCTGGAAGAAGCGCCATCCGCCACAACCTGAGTCTGCACAAGTGT
TTGTGCGGGTGGAGAGCGAGAAGGGGGTGTGTGGACCGTGGATGAGCTG
GAGTTCGCAAGAAACGGAGCCAGAGGCCAGCAGGTGTTCCAAACCTAC
ACCTGGCCCTGACCTCAAGATCAAGGAAAGGAGGATGGACGAACAGGGG
CCAAACTGGTGGGAGGCAGAGGTGGTGGGGCAGGGATGATAGGCCCTGG
ATGTGCCACAGGGACCAAGAAGTGAGGTTTCCACTGTCTTGCCTGCCAG
GGCCCTGTTCCCCCGCTGGCAGCCACCCCTCCCATCATATCTTTG
CCCCAAGGCTGCTCAGAGGGGCCCGGTCTGGCCCCAGCCCCACCTCC
GCCCCAGACACACCCCCAGTCGAGCCCTGCAGCCAAACAGAGCCTTAC
AACCAGCCACACAGAGCCTGCCTCAGCTGCTGCACAGATTACTTCAGG

- continued

CTGGAAAAGTACACAGACACACAAAATGTACAATCCTGTCCCTCACTC
AACACAAACCCCAAAACACAGAGAGCCTGCCTCAGTACACTCAAACAACC
TCAAAGCTGCATCATCACACAATCACACACAAGCACAGCCCTGACAACCC
ACACACCCCAAGGCACGCACCCACAGCCAGCCTCAGGGCCACAGGGGCA
CTGTCAACACAGGGGTGTGCCAGAGGCCTACACAGAAGCAGCGTCAGTA
CCCTCAGGATCTGAGGTCCCAACACGTGCTCGCTCACACACACGGCCTGT
TAGAATTACCTGTGTATCTCAGCATATGCACACGCACAGCCCCCAGT
GGGTCTCTTGTAGTCCCGTGCAGACACACAGCCACACACTGCCTTGC
CAAAAATACCCCGTGTCTCCCTGCCACTCACCTCACTCCCATTCCTTGA
GCCCTGATCCATGCCTCAGCTTAGACTGCAGAGGAAGTACTCATTATTT
GGGATCCAAGGCCCAACCCACAGTACCGTCCCAATAAATGCAGCCG
AGCTCCCCA.

[0050] In some embodiments referring to a first nucleic acid sequence encoding a FOXP3 polypeptide having a mutation in exon 2, the nucleic acid sequence corresponding to FOXP3 exon 2 is at least 80% (e.g., at least 85%, 90%, 95%, 99% and 100%) identical to: CCTGCCCTTGGACAAGGACCCGATGCC-CAACCCAGGCCTGGCAAGCCCTCGGCCCTTCCTTGGCCCTTGGCCCATCCCCAG-GAGCCTCGCCAGCTGGAGGGCTGCACCCA AAGCTCA-GACCTGTGGGGGCCCGGGGCCAGGGG-GAACCTTCCAGGGCCGAGATCTTCGAGGCGGGCCCATGCCTCCTTCTTCCTT-GAACCCATGCCACCATCGCAG CTGCAG (SEQ ID NO: 2). In some embodiments referring to a first nucleic acid sequence encoding a FOXP3 polypeptide having a deleted exon 2, the nucleic acid sequence that is deleted from full length FOXP3 polypeptide (SEQ ID NO: 1) is SEQ ID NO: 2 or a fragment of SEQ ID NO: 2.

[0051] In some embodiments referring to a first nucleic acid sequence encoding a FOXP3 polypeptide having a mutation in exon 7, the nucleic acid sequence corresponding to FOXP3 exon 7 is at least 80% (e.g., at least 85%, 90%, 95%, 99% and 100%) identical to: CTGGTGTG-GAGAAGGAGAAGCTGAGTGCCATGCAGGCC-CACCTGGCTGGGAAAAT GGCCTGACCAAGGCTT-CATCTGTG (SEQ ID NO: 3). In some embodiments referring to a first nucleic acid sequence encoding a FOXP3 polypeptide having a deleted exon 7, the nucleic acid sequence that is deleted from full length FOXP3 (SEQ ID NO: 1) is SEQ ID NO: 3 or a fragment of SEQ ID NO: 3. In some embodiments referring to a first nucleic acid sequence encoding a FOXP3 polypeptide having a deleted exon 2 and a deleted exon 7, the nucleic acid sequences that are deleted from full length FOXP3 (SEQ ID NO: 1) are SEQ ID NO: 2 or a fragment thereof and SEQ ID NO: 3 or a fragment thereof.

[0052] In some embodiments referring to a mutation in a nuclear export sequence of FOXP3, the amino acid sequence corresponding to the NES1 is QLQLPTLPL (SEQ ID NO: 4). In some embodiments referring to a mutation in a nuclear export sequence of FOXP3, the amino acid sequence corresponding to the NES2 is VQSLEQLVL (SEQ ID NO: 5).

[0053] As used herein, the term “chimeric antigen receptor” or “CAR” refers to a chimeric antigen receptor comprising an extracellular domain, a transmembrane domain, and an intracellular domain. In some cases, the extracellular domain can comprise an antigen-binding domain as described herein. In some cases, the transmembrane domain can comprise a transmembrane domain derived from a natural polypeptide obtained from a membrane-binding or transmembrane protein. For example, a transmembrane domain can include, without limitation, a transmembrane domain from a T cell receptor alpha or beta chain, a CD3 zeta chain, a CD28 polypeptide, or a CD8 polypeptide. In some cases, the intracellular domain can comprise a cytoplasmic signaling domain as described herein. In some cases, the intracellular domain can comprise a co-stimulatory domain as described herein.

[0054] As used herein, “T-cell function” refers to a T cell’s (e.g., any of the exemplary T cells described herein) survival, stability, and/or ability to execute its intended function. For example, a CD4⁺ T cell can have an immunosuppressive function. A CD4⁺ T cell including a first nucleic acid sequence encoding a FOXP3 polypeptide can have a FOXP3-dependent expression profile that increases the immunosuppressive function of the T cell. For example, a cell transduced with a mutated FOXP3 polypeptide as described herein can have increased expression of genes that are transcriptional targets of a FOXP3 that can result in increased T reg cell function. In some embodiments, a T cell is considered to have T reg function if the T cell exhibits or maintains the potential to exhibit an immune suppression function.

[0055] As used herein, the term “activation” refers to induction of a signal on an immune cell (e.g., a B cell or T cell) that results in initiation of the immune response (e.g., T cell activation). In some cases, upon binding of an antigen to a T cell receptor (TCR) or an exogenous chimeric antigen receptor (CAR), the immune cell can undergo changes in protein expression that result in the activation of the immune response. In some cases, a TCR or CAR includes a cytoplasmic signaling sequence that can drive T cell activation. For example, upon binding of the antigen, a chimeric antigen receptor comprising an intracellular domain that includes a cytoplasmic signaling sequence (e.g., an immune-receptor tyrosine-based inhibition motifs (ITAM)) that can be phosphorylated. A phosphorylated ITAM results in the induction of a T cell activation pathway that ultimately results in a T cell immune response. Examples of ITAMs include, without limitation, CD3 gamma, CD3 delta, CD3 epsilon, TCR zeta, FcR gamma, FcR beta, CD5, CD22, CD79a, and CD66d.

[0056] As used herein, the term “stimulation” refers to stage of TCR or CAR signaling where a co-stimulatory signal can be used to achieve a robust and sustained TCR or CAR signaling response. As described herein, a co-stimulatory domain can be referred to as a signaling domain. In some cases, a signaling domain (e.g., co-stimulatory domain) can be a CD27, CD28, OX40, CD30, CD40, B7-H3, NKG2C, LIGHT, CD7, CD2, 4-1BB, or PD-1.

[0057] In some embodiments where the chimeric antigen receptor polypeptide includes a CD3 zeta cytoplasmic signaling domain, the CD3 zeta cytoplasmic signaling domain has an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 95%, 99% and 100%) identical to: MKWKA-LFTAAAILQAQLPITEAQSFLGDDPKLCYLLDGL-

FIYGVILTALF LRVKFSRSADAPAYQQGQNQLY-
 NELNLGRREEYDVLDRKRRGRDPEMGGKPK
 QRRKNPQEGLYNELQKDKMAEAYSEI-
 GMKGERRRGKGHDLGLYQGLSTATK DTY-
 DALHMQUALPPR (NCBI Reference No.: NP_932170)
 (SEQ ID NO: 13), or a fragment thereof that has activating
 or stimulatory activity.

[0058] In some embodiments where the chimeric antigen
 receptor polypeptide includes a CD28 co-stimulatory
 domain, the CD28 co-stimulatory domain is at least 80%
 (e.g., at least 85%, 90%, 95%, 99% and 100%) identical to:

(SEQ ID NO: 6)
 IEVMYPPPYLDNEKSNGTI IHVKGKHLCPSPFPKPFVWLVVVGVL
 ACYSLLVTVAFI IFWVRSKRSLRHSDYMNMTPRRPGPRKHYPYAPPR
 DFAAY.

Transcription Factors

[0059] As used herein, the term “transcription factor”
 refers to a polypeptide possessing one or more domains that
 bind to a DNA-regulatory sequence (e.g., promoter,
 enhancer, or silencer) to modulate the rate of gene transcrip-
 tion. This may result in increased or decreased gene transcrip-
 tion, protein synthesis, and subsequent altered cellular
 function.

[0060] As used herein, BLIMP1 also known as PRDM1
 refers to PR/SET domain 1 polypeptide. When preparing a
 T cell or treating a mammal with a T cell, BLIMP1 or
 PRDM1 refers to human BLIMP1 or PRDM1. An example
 of a human BLIMP1 or PRDM1 polypeptide includes,
 without limitation, NCBI reference sequence: NP_001189.2.
 In some embodiments referring to a second nucleic acid
 sequence encoding a BLIMP1 (e.g., full length BLIMP1)
 polypeptide, the nucleic acid sequence is at least 70% (e.g.,
 at least 75%, at least 80%, at least 85%, at least 90%, at least
 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 7)
 AACACAGACAAAGTGTGCCGTGACACTCGGCCCTCCAGTGTTCGGGAGA
 GGCAAGAGCAGCGACCGCGGCACCTGTCCGCCGGAGCTGGGACCGGGC
 GCCCGGGCGGGCGGACGAAGCGAGGAGGGACCGCGAGGTGCGCTCTGT
 GCGGCTCAGCCTGGCGGGGACCGCGGGGAGAATGTGGACTGGGTAGAGAT
 GAACGAGACTTTTCTCAGATGTTGGATATTTGCTTGAAAAACGTGTGGG
 TACGACCTTGGCTGCCCCAAAGTGTAACTCCAGCACTGTGAGTTTCAGG
 GATTGGCAGAGGGGACCAAGGGGACCATGAAAAATGGACATGGAGGATGCG
 GATATGACTCTGTGGACAGAGGCTGAGTTTGAAGAGAAGTGTACATACAT
 TGTGAACGACCACCCTGGGATTCTGGTCTGATGGCGTACTTCGGTTT
 AGGCGGAGGCATCCTTACCAAGGAATCTGCTTTTCAAGTATGCCACCAAC
 AGTGAAGAGGTTATTGGAGTGTAGTAAAGAATACATACCAAGGGCAC
 ACGTTTTGGACCCCTAATAGTGAAATCTACACCAATGACACAGTTCTCTA
 AGAACGCCAACAGGAAATATTTTGGAGGATCTATTCAGAGGGGAGCTT
 CACCACCTCATTGACGGCTTTAATGAAGAGAAAAGCAACTGGATGCGCTA

-continued

TGTGAATCCAGCACACTCTCCCCGGGAGCAAAACCTGGCTGCGTGTGAGA
 ACGGGATGAACATCTACTTCTACACCATTAAGCCCATCCCTGCCAACCCAG
 GAACCTCTGTGTGGTATTGTTCGGGACTTTGCAGAAAGGCTTCACTACCC
 TTATCCCGGAGAGCTGACAATGATGAATCTCACACAAAACACAGAGCAGTC
 TAAAGCAACCAGGACTGAGAAAAATGAACCTGCCCCAAGAATGTCCCA
 AAGAGAGAGTACAGCGTGAAGAAATCCTAAAATTGGACTCCAACCCCTC
 CAAAGGAAAGGACCTCTACCGTTCTAACATTTACCCTCACCATCAGAAA
 AGGACCTCGATGACTTTAGAAGACGTGGGAGCCCCGAAATGCCCTTCTAC
 CCTCGGGTCTGTTTACCCCATCCGGGCCCTCTGCCAGAAGACTTTTGTAA
 AGCTTCCCTGGCCTACGGGATCGAGAGACCCACGTACATCACTCGCTCCC
 CCATTCATCCTCCACCCTCAAGCCCTCTGCAAGAAGCAGCCCCGAC
 CAAAGCCTCAAGAGCTCCAGCCCTCACAGCAGCCTGGGAATACGGTGTG
 CCGTGTGGGCCCGGCTCTCAAGAGCACCGGGACTCCTACGCTTACTTGA
 ACGCGTCTACGGCACGGAGGTTTGGGCTCCTACCCTGGCTACGCACCC
 CTGCCCCACCTCCCGCCAGCTTTCATCCCTCGTACAACGCTCACTACCC
 CAAGTTCCTCTTGGCCCCCTACGGCATGAATTGTAATGGCTGAGCGCTG
 TGAGCAGCATGAATGGCATCAACAACCTTTGGCCTCTTCCCGAGGCTGTGC
 CCTGTCTACAGCAATCTCCTCGGTGGGGGAGCCTGCCCAACCCATGCT
 CAACCCCACTTCTCTCCGAGCTCGCTGCCCTCAGATGGAGCCCGGAGGT
 TGCTCCAGCCGGAGCATCCAGGGAGGTGCTTGTCCCGCGCCCCACAGT
 GCCTTCTCCTTTACCGGGGCCCGCCAGCATGAAGGACAAGGCTGTAG
 CCCCCAAGCGGGTCTCCACCGCGGGAACAGCCGCCACGGCAGAACATG
 TGGTGCAGCCCAAGCTACCTCAGCAGCGATGGCAGCCCCCAGCAGCGAC
 GAAGCCATGAATCTCATTA AAAACAAAAGAACATGACCGGCTACAAGAC
 CCTTCCCTACCCGCTGAAGAAGCAGAACGGCAAGATCAAGTACGAATGCA
 ACGTTTGCCTCAAGACTTTCGGCCAGCTCTCCAATCTGAAGGTCCACCTG
 AGAGTGCACAGTGGAGAACGGCTTTCAAATGTCAGACTTGCAACAAGGG
 CTTTACTCAGCTCGCCACCTGCAGAAAACACTACCTGGTACACACGGGAG
 AAAAGCCACATGAATGCCAGGTCTGCCACAAGAGATTTAGCAGCACCAGC
 AATCTCAAGACCCACCTGCGACTCCATTTCTGGAGAGAAACATACCAATG
 CAAGGTGTGCCCTGCCAAGTTCAACCAGTTTGTGACCTGAAACTGCACA
 AGCGTCTGCACACCCGGGAGCGGCCCCACAAGTGTCTCCAGTGCACAAAG
 AACTACATCCATCTCTGTAGCCTCAAGTTTCACTGAAAGGAACTGCGC
 TGCGGCCCGCGCCTGGGCTGCCCTTGAAGATCTGACCCGAATCAATG
 AAGAAATCGAGAAGTTTGCATCAGTGACAATGCTGACCGGCTCGAGGAC
 GTGGAGGATGACATCAGTGTGATCTCTGTAGTGGAGAAGGAAATCTCGGC
 CGTGGTGCAGAAAAGAGAAAAGAAAAGTGGCTGAAAGTGTCTTTGCAAA
 GAAACATGGGGAATGGACTCCTCTCCTCAGGGTGCAGCCTTTATGAGTCA
 TCAGATCTACCCCTCATGAAGTTGCTCCAGCAACCCACTACCTCTGGT

-continued

ACCTGTAAAGGTCAAACAAGAAACAGTTGAACCAATGGATCCTTAAGATT
TTCAGAAAACACTTATTTTGTCTTAAAGTTATGACTTGGTGAGTCAGGG
TGCCGTAGGAAAGTGGCTTGTACATAATCCCAGCTCTGCAAAGCTCTCTC
GACAGCAAATGGTTTCCCTCACCTCTGGAATTAAGAAGGAACTCCAAA
GTTACTGAAATCTCAGGGCATGAACAAGGCAAAGCCATATATATATATA
TATATATATCTGTATACATATATATATACTTATTTACACCTGTGTCTAT
ATATTTGCCCTGTGTATTTGAATATTTGTGTGGACATGTTTGCATAGC
CTTCCATTACTAAGACTATTACCTAGTCATAATATTTTTTCAATGATA
ATCCTTCATAATTTATATACAAATTTATCATTGAGAAAGCAATAATTTAA
AAAGTTTACAATGACTGGAAGATTCCCTGTAATTTGAGTATAAATGTAT
TTTTGTCTTGTGGCCATCTTTGTAGATAAATTTCTGCACATCTGTATAAG
TACCTAAGATTTAGTTAAACAATATATGACTTCAGTCAACCTCTCTCTC
TAATAATGGTTTGAATAAGAGTTTGGGTAATTTGCCAATGTTGGACAGTT
GATGTGTTTATTCTTGGGATCCTATCATTGAAACAGCATTGTACATAACT
TGGGGTATGTGTGCAGGATTCCCAAGAATAACTTAAGTAGAAGAAACA
AGAAAGGGAATCTGTATATTTTGTGTGATAGTTTATGTTTTTCCCCAG
CCACAATTTTACCGAAGGGTGACAGGAAGGCTTTACCAACCTGTCTCTC
CCTCCAAAAGAGCAGAATCTCCACCCTGCCCCCTCCACCAGGATCC
TGTGGCCATTGAGCGGCCACATGACTTTTGCATCCATTGTATTATCAG
AAAAATGTGAAGAAGAAAAAATGCCATGTTTTAAAACCACTGCGAAAATT
TCCCCAAAGCATAGGTGGCTTTGTGTGTGTGCGATTGGGGCTTGTAGTC
TGGGTGGTGTTTTGTGTGTTTTTGTGTCTTTTTTTTTTTTTTTTTTT
TTAATGTCAAAATGACACAACATGGTGTCTTACCAGGAAGGATTCGAGG
TAGATAGGCTCAGGCCACACTTTAAAAACAACACACAAACAACAAAAA
CGGGTATTCTAGTCATCTTGGGGTAAAAGCGGGTAAATGAACATTCCTATC
CCCAACACATCAATGTATTTTTCTGTAAAACCTCAGATTTTCTCAGTA
TTTGTGTTTTTACATTTTATGGTTAATTTAATGGAAGATGAAAGGGCATT
GCAAAGTTGTTCAACAACAGTTACCTCATTGAGTGTCCAGTAGTGACAG
GAAATGATGTCTTATCTAATGATTTGCTTCTCTAGAGGAGAAACCGAGTA
AATGTGCTCCAGCAAGATAGACTTTGTGTTATCTATCTTTTATTCTGCT
AAGCCCAAAGATTACATGTTGGTGTCAAAGTGTAGCAAAAAATGATGTA
TATTTATAAATCTATTTTATACCACTATATCATATGTATATATATTTATAA
CCACTTAAATGTGAGCCAAGCCATGTAAGATCTACTTTTTTCTAAGGG
CAAAAAAAAAAAAAAAAAAAGAACACTCCTTTCTGAGACTTTGCTTA
ATACTTGGTGACCTCACAATCACGTCGGTATGATTGGGCACCCCTTGCCTA
CTGTAAGAGACCCTAAAACCTTGGTGCAGTGGTGGGGACCACAAAACAAC
CAGGGAGGAAGAGATACATCAATTTTTTAGTATTAAGGACCATCTAAGACA
GCTCTATTTTTTTTTTGGCCACTTTATGATTATGTGGTCACACCAAGTCA
CAGAAATAAAAAACGACTTTACCCTGCAATTTTTCTGTTTTCTCTCTT

-continued

ACTAAACTGATACATTAATCCAATCTATTTTATAATTATTTTGACAT
TTTGTTCACATCAACTAATGTTCCACCTGTAGAAGAGAACAATTTTGAAT
AATCCAGGGAAACCAAGAGCCTTACTGGTCTTCTGTAACCTCCAAGACT
GACAGCTTTTTATGTATCAGTGTGATAAACACAGTCTTAACTGAAGG
TAAACCAAGCATCACGTTGACATTAGACCAAATACTTTTGATTCCCAAC
TACTCGTTTGTCTTTTTTCTCTTTTGTGCTTTCCCATAGTGAGAATTTT
TATAAAGACTTCTTGTCTCTCACCATCCATCCTTCTCTTTTCTGCCTC
TTACATGTGAATGTTGAGCCACAATCAACAGTGGTTTTATTTTTTCTCTC
TACTCAAAGTTAAAACGACCAAGTTACTGGCTTTTTACTTTGTCTAGAA
CAACAACTATCTTATGTTTACATACTGGTTTACAATGTTATTTATGTGC
AAATGTCAAAATGTAAATTAATATAAATGTTCATGCTTTACCAAAA.

[0061] As used herein, EOS also known as Ikzf4 refers to Ikaros family zinc finger 4 polypeptide. When preparing a T cell or treating a mammal with a T cell, EOS or Ikzf4 refers to human EOS or Ikzf4. An example of a human EOS or Ikzf4 polypeptide includes, without limitation, NCBI reference sequence: NP_001338018.1. In some embodiments referring to a second nucleic acid sequence encoding a EOS (e.g., full length EOS) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 8)

CCCTTCTCAGGTGAAGCTGCTGATGGAGATGGAGCC
GCCGCCACCGCCGCTCTGAGCGCCCGGGTCTGGC
TCCGGCCCGGCGACTGCCCGCCCTCAGTGACCCCA
CTCCCCCGCACTGGGCCCGCCGGCCAGAGTGGGG
GACCCCCGCCCTCGCTCCTCTCCCCAACACT
GTCCCCCTCCCCAACCCCTCACAGCCTGCGCGCGC
GCGGAGACACCTCAGTCTACATGGGGAGGACAGAGA
AGCGCAAAGAACAAGAGAAAAGATGCATCCATCTGA
GATCTAAAAGGAGACAATGAGAATCTCTTTAAAATG
GACATAGAAGACTGCAATGGCCGCTCTATGTGTCT
GTAGGACCAATGAAGGAATTATTGGCATGCACTAAA
GGAGATAGCAAGATGGGTGAGACACACATATGAGAG
TCATTGGCAACACCGGGTAAATGAAGGAATCCAGC
CTTCTTGAAGGTGAGTGGCTGGGCTCACCCTGCC
TGCCACTGAGACGCAGACATGCATACACCACCCGCA
CTCCTCGCCGTTTTCCAAGGCGCGCGCGCTTCCG
ACCCAGGGTCTCACCAGGGAAGGATAATCTG
GAGAGGATCCCTCAGGAGGTGTGTTCCGGATTTCT
TTGCCTCAGGCCAAGACTCCAACATTTTATAATG

-continued

GAATCTTTATTTGTGAAAGTAGCGGGGACTCATCT
 CTGGAGAAGGAGTTCCTCGGGGCCCCAGTGGGGCCC
 TCGGTGAGCACCCCAACAGCCAGCACTCTTCTCCT
 AGCCGCTCACTCAGTGCCAACTCCATCAAGGTGGAG
 ATGTACAGCGATGAGGAGTCAAGCAGACTGCTGGGG
 CCAGATGAGCGGCTCCTGGAAAAGGACGACAGCGTG
 ATTGTGGAAGATTCATTGTCTGAGCCCCGCGGTAC
 TGTGATGGGAGTGGGCCAGAGCCTCACTCCCCTGGG
 GGCATCCGGCTGCCCAATGGCAAGCTCAAGTGTGAC
 GTCTGCGGCATGGTCTGTATTGGACCCAACGTGCTC
 ATGGTGCACAAGCGCAGTCACTGGTGAAGGCC
 TTCCATTGCAACCAGTGTGGTGCCTCCTCACCCAG
 AAGGGGAACCTGCTGCGCCACATCAAGCTGCACTCT
 GGGGAGAAGCCCTTAAATGTCCCTTCTGCACTAT
 GCCTGCCCGCGCTGTATGCACTCACTGGTCACTC
 CGCACACACTCAGTCTCCTCTCCACAGTGGGCAAG
 CCCTACAAGTGAAGTACTGTGGCCGGAGCTACAAA
 CAGCAGATACCCCTGGAGGAGCACAAGGAGCGGTGC
 CATAACTACCTACAGAGTCTCAGCACTGAAGCCAA
 GCTTTGGTGGCCAACCAGGTGACGAAATACGTGAC
 CTGGAGATGGTGCCAGACTCCTGCTGCACTCATCC
 TCTGAGCGGCCAACTTTCATCGATCGTCTGGCCAAT
 AGCCTCACCAACGCAAGCGTTCACACCCAGAAAG
 TTTGTAGCGCAAAAGCAGATGCGCTTCAGCCTCTCA
 GACCTCCCCTATGATGTGAACTCGGGTGGCTATGAA
 AAGGATGTGGAGTTGGTGGCACACCACAGCCTAGAG
 CCTGGCTTTGGAAGTTCCTTGGCCTTTGTGGGTGCA
 GAGCATCTGCGTCCCCTCCGCTTCCACCCACCAAT
 TGCATCTCAGAAGTACAGCCTGTATCAGCTCTGTC
 TACACCCAGATGCAGCCCCCTCCCTGGTGCAGTGGAG
 CTTCCAGGATCCCAGAAAGCAGGTGAGGGACCTGAG
 GACCTGGCTGATGGAGTCCCCTCCTCTACCGGCC
 CGAGGCCCCCTGACTGACCTGGGGCATCCCCAGC
 AATGGCTGCCAGGACTCCACAGACACAGAAAGCAAC
 CACGAAGATCGGGTGGGGGGTGGTATCCCTCCCT
 CAGGGTCCCCACCCAGCCACCTCCCACCATTTGTG
 GTGGGCCGGCACAGTCTGCTACGCCAAAGAGGAC
 CCCAAGCCACAGGAGGGTTATGCGGGGCCACCCCA
 GGCCCTCCAAGGAAGTGTCTCGGGTGGTGGGCGAG

-continued

AGTGGTGAGCCTGTGAAGGCCTCAAGTGTGAGCAC
 TGCCGTATCCTCTTCTGGACCACGTCATGTTCACT
 ATCCACATGGGCTGCCATGGCTCAGAGACCCCTTT
 GAGTGCAACATCTGTGGTTATCACAGCCAGGACCCG
 TACGAATCTCTTCCACATTGTCCGGGGGGAGCAT
 AAGGTGGGCTAGCAACCTCTCCCTCTCTCAGTCT
 CACCACTCCACTGCCCTGACTACAGGCATTGATCCC
 TGTCCCCACCATTTCACAGGAGTTTGTCTTGTAG
 CCCTCACTACTGGCCACCTGACCTCACACCTGACCC
 TGACCCCTCCTCACCTATCTCTTCTCTATCCTGA
 CCGATGTAAGCATTGTGATGAAACAGATCTTTTGT
 TATGTTTTCTTTTTTATCTCTCTCATCCAGCAT
 ACTGAGTTATTTATTAATAGTTGATTTATTTTTGC
 CTTTTTAAATTTAACTTATATCAGTCACTTGCCAC
 TCCCCACCCCTCCTGTCACAACTCCTTCCACTTT
 AGGCCAATTTTTCTCTCTTAGATCTCCAGCAGCCC
 CAGGGTAGGAAGCTCCTCTTAGTACTAAGAGACTT
 CAAGCTTCTGCTTTAAGCTCTCACCCCTTACATTA
 TCTAATCTTCAGTTTTGATGCTGATACCTGCCCC
 GGCCCTACCTTAGCTCTGTGGCATTATATCTCCTCT
 CTGGGACTCTTCAACCTGGTACTCCATACCTTTGT
 GCCCTCTCACTTTAGGCAGCTTGCACTATCTTGAA
 TGAATGAAGAATTATTTCTCATTGGAAGTAGGAG
 GGACTGAAGAAATTCCTCCAGGCACTGTGGGACTG
 AGAGTCTATTTCCCTAGTAATAGGTCATATTTCCC
 TAGTAATATGAGTTCTCAAAGCCTACATTCAGGATC
 TCCCTCTAGGATGTGATAGATCTGGTCCCTCTCCT
 GAACTACCCCTCCACAGCTCTAGTCCCTTCAACT
 ACCGGTCTATTAAGTGGTGGCTTTTCTCTCCTTGA
 GTGCCCCAATTTTATTTCTCAGGGGCCAAGGCTAG
 GTCTGCAACCCCTCTGTCTCTGACAGATTGGGAGCCA
 CAGGTGCCTAATTGGGAACAGGGCATGGGAAAGGA
 GTGGGTCAAATTTCTTCTTCTCTCCCTCCACTCTC
 AAACCTCTTCACTATAGTGACCTTCTAGGCTCTCA
 GGGGCTCCTTCAGTCCCCTCCTATGAGAACTAGT
 GGGTGTGCTGCTGATGACAAGGGGTGTTTTCAGCCC
 CTCAGTCATGCTGCTTCTGTGCTCCCTCCCAGCA
 GGATTCACCTCTCATTCCCGGGCTCCTGGGCCCTG
 TTCTTAGGATCAGTGGCAGGAGAAACGGGTATCTC

-continued

TTTTCTCTCTCTAATTTTCAGTATAACCAAAAATT
ATCCCAGCATGAGCACGGGCACGTGCCCTTACCCCC
ATTCCACCCTTGTTCCAGCAAGACTGGGATGGGTAC
AACTGAACTGGGGTCTTCCCTTACTACCCCTTCTA
CACTCAGCTCCCAGACACAGGGTAGGAGGGGGACT
GCTGGCTACTGCAGAGACCCTTGCTATTTGAGTAA
CCTAGGATTAGTGAGAAGGGGCAGAAGGAGATACAA
CTCCACTGCAAGTGGAGGTTTCTTCTACAAGAGTT
TTCTGCCCAAGGCCACAGCCATCCCACTCTCTGCTT
CCTTGAGATTCAAACCAAAGGCTGTTTTCTATGTT
TAAAGAAAAAAAAGTAAAACCAACACACAACACC
TCACAAGTTGTAACCTCTGGCTTCTCTCTCTCCT
TTTCTCTCCCTTCCCTCCCTTCCATCTTTCTTTC
CACATGTCCTTTCCTTATTGGCTCTTTTACCTCCTA
CTTTTCTCACTCCCTATCAGGGATATTTGGGGGG
GATGGTAAAGGGTGGGCTAAGGAACAGACCCTGGGA
TTAGGGCTTAAGGGCTCTGAGAGGAGTCTACCTTG
CCTTCTTATGGGAAGGGAGACCCTAAAAAATTTCT
CCTCTTTGCTCCTCTTTTCTCCCCACTCTGAGGT
TTCCCAAGAGAACCAGATTGGCAGGGAGAAGCATT
GTGGGGCAATTGTTCTCCTTGACAATGTAGCAATA
AATAGATGCTGCCAAGGGCAGAAAATGGGGAGGTTA
GCTCAGAGCAGAGTAGTCTCTAGAGAAAGGAAGAA
CCTCAACGGCACCTTGGGGTCTAGCTCCTTTTAG
AATGTCAGCAGAGCTGAGATTAATATCTGGGCTTTT
CCTGAACTATTCTGGTTATTGAGCCCTTCTGTTAG
ACCTACCGCTCCCACTCTTCTGTGTCTGTGTGT
ATTTGGTGACACTTCATAAGGACTAGTCCCTTCTGG
GGTATCAGAGCCTTAGGGTGCCCCATCCCTTCCC
CAGTCAACTGTGGCACCTGTAACTCCCGAACATG
AAGGACTATGCTCTGAGGCTATACTCTGTGCCCATG
AGAGCAGAGACTGGAAGGGCAAGACCAGGTGCTAAG
GAGGGGAGAGGGGCATCTGTCTCTCCAGACCA
TCACTGCACTTTAACCAGGGTCTTAGGTACAAAATC
CTACTTTTCAGAGCCTTCCAGCTCTGGAACCTCAAA
CATCTCATGCTCTCTCCAGCTCCTTTGCATAAA
AAAAAAGTAAAGAAAAAGAAAAAATAACACACA
CACTGAAACCCACATGGAGAAAAGAGGTGTTTCTT
TTATATTGCTATTCAAATCAATACCACCAACAAA

-continued

TATTTCTAAGTAGACACTTTTCCAGACCTTTGTTTT
TTTGTGTGAGTGTCCAGCTGCAGATAGGATTTTGT
AATACTTCTGGCAGCTTCTTTCCTTGTGTACATAAT
ATATATATATACATATATATATATATTTTAAATCAG
AAGTTATGAAGAACAAAAAGAAAAATAAACACAGA
AGCAAGTGAATACCACCTCTCTTCTCCCTCTCTCC
TAGGGTTTCTTTGTAGCCTATGTTGGTGTCTCTT
TTGACCTTTACCCCTTCCCTCTCTCTCTCTCTT
TGATTCCCTCCCTCTTTTAAAGAGTTTTTCT
CCTTTCTCAAGGGGAGTTAACTAGCTTTTGGAGCT
TATTGCAAAGCATTGTTATATGTAATATATTGTAA
GTAATATTTGTGTAACGGAGATATACTACTGTAAG
TTTTGTACTGTACTGGCTGAAAGTCTGTTATAAATA
AACATGAGTAATTTAACA.

[0062] As used herein, GATA1 refers to a GATA binding protein 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, GATA1 refers to human GATA1. An example of a human GATA1 polypeptide includes, without limitation, NCBI reference sequence: NP_002040.1. In some embodiments referring to a second nucleic acid sequence encoding a GATA1 (e.g., full length GATA1) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 9)

ACACTGAGCTTGCCACATCCCAAGCGGGCCGAACC
CTCCGCAACCACCAGCCAGGTTAATCCCAAGAGGC
TCCATGGAGTTCCCTGGCCTGGGTCCCTGGGGACC
TCAGAGCCCTCCCCAGTTTGTGGATCCTGCTCTG
GTGTCCTCCACACCAAGATCAGGGGTTTCTTCCCC
TCTGGGCTGAGGGCTTGATGCAGCAGCTTCCCTCC
ACTGCCCGAGCACAGCCACCGCTGCAGCTGCGGCA
CTGGCCTACTACAGGGACGCTGAGGCCTACAGACAC
TCCCCAGTCTTTCAGGTGTACCCATTGCTCAACTGT
ATGGAGGGGATCCCAGGGGCTCACCATATGCCGGC
TGGGCTACGGCAAGACGGGGCTCTACCTGCCTCA
ACTGTGTGTCCACCCGCGAGGACTCTCTCCCCAG
GCCGTGGAAGATCTGGATGAAAAGGCAGCACCAGC
TTCTGGAGACTTTGAAGACAGAGCGGCTGAGCCCA
GACCTCTGACCTGGGACCTGCAGTGCCTTCATCA
CTCCCTGTCCCAATAGTGTATTGGGGCCCTGAC
TTTTCCAGTACCTTCTTTCTCCACCGGGAGCCCC

-continued

CTCAATTCAGCAGCCTATTCCTCTCCCAAGCTTCGT
 GGAACCTCTCCCCCTGCCTCCCTGTGAGGCCAGGGAG
 TGTGTGAACCTGCGGAGCAACAGCCACTCCACTGTGG
 CGGAGGGACAGGACAGGCCACTACCTATGCAACGCC
 TCGCGCCTCTATCACAAGATGAATGGGCAGAACAGG
 CCCCTCATCCGGCCCAAGAAGCGCCTGATTGTCACT
 AAACGGGCAGGTACTCAGTGCACCAACTGCCAGACG
 ACCACCACGACACTGTGGCGGAGAATGCCAGTGGG
 GATCCCGTGTGCAATGCCTGCGGCCTCTACTACAAG
 CTACACCAGGTGAACCGGCCACTGACCATGCGGAAG
 GATGGTATTCAGACTCGAAACCGCAAGGCATCTGGA
 AAAGGGAAAAAGAAACGGGGCTCCAGTCTGGGAGGC
 ACAGGAGCAGCCGAAGGACCAGCTGGTGGCTTTATG
 GTGGTGGCTGGGGCAGCGGTAGCGGGAAATTGTGGG
 GAGGTGGCTTCAGGCTGACACTGGGCCCCAGGT
 ACTGCCCATCTCTACCAAGGCCTGGGCCCTGTGGTG
 CTGTCAGGGCCTGTAGCCACCTCATGCCTTCCCT
 GGACCCCTACTGGGCTCACCACGGGCTCCTTCCCC
 ACAGGCCCATGCCCCACCACCAGCACTACTGTG
 GTGGCTCCGCTCAGCTCATGAGGGCACAGCATGG
 CCTCCAGAGGAGGGTGGTGTCTTCTCTCTTGTA
 GCCAGAATTCTGGACAACCCAAGTCTCTGGGCCCA
 GGCACCCCTGGCTTGAACCTTCAAAGCTTTTGTA
 AATAAAACCACCAAAGTCTTGAAA.

[0063] As used herein, IKZF2 refers to a IKAROS family zinc finger 2 polypeptide. When preparing a T cell or treating a mammal with a T cell, IKZF2 refers to human IKZF2. An example of a human IKZF2 polypeptide includes, without limitation, NCBI reference sequence: NP_001072994.1. In some embodiments referring to a second nucleic acid sequence encoding a IKZF2 (e.g., full length IKZF2) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 10)

GCTAACCTGCTCCTCGCTGAAGATGGAGGAAGTAA
 AAACAGGATTACCCTTAGCTACAGATCCACTGCCTT
 AGTTTCCACCACCAACTGCAGTGCACAAACACACGT
 TAGGCACAGGAAAGAAAGAAAGACAGAGGACACATT
 AACAGTAAACACAAACAAAAGGGTATGGGATTATT
 TTACTGCATGCACTGCTGAGCCGACATTTGTCACCT
 CCTCTTTGAGGGTTAGAAGAGCTGAGATCTCCCG

-continued

ACAGAGCTGGAATGGTATGAATCTTTTAAATCA
 AAGGACAATTTCTTTTCATTGCACCTTTGACTATGGA
 AACAGAGGCTATTGATGGCTATATAACGTGTGACAA
 TGAGCTTTCACCCGAAAGGGAGCACTCCAATATGGC
 AATTGACCTCACCTCAAGCACACCCAATGGACAGCA
 TGCCTCACCAAGTACATGACAAGCACAAATTCAGT
 AAAGCTAGAAATGCAGAGTGTGAAGAGTGTGACAG
 GAAACCCCTGAGCCGTGAAGATGAGATCAGGGGCCA
 TGATGAGGGTAGCAGCCTAGAAGAACCCTAATTGA
 GAGCAGCGAGGTGGCTGACAACAGGAAAGTCCAGGA
 GCTTCAAGGCGAGGGAGGAATCCGGCTTCCGAATGG
 TGAACGCCCTTCCACTGTAACAGTGTGAGCTTC
 TTTTACTCAGAAGGGCAACCTTCTGAGACACATAAA
 GTTACACTCTGGAGAGAAGCCGTTCAAATGTCTTT
 CTGTAGTACGCCTGTAGAAGAAGGGACGCCCTCAC
 AGGACACCTCAGGACCCATTCTGTGGGTAAACCTCA
 CAAGTGCAACTACTGTGGACGAAGCTACAAGCAGCG
 CAGTTCACTGGAGGAGCACAAGGAACGCTGCCACAA
 CTATCTCCAGAATGTCAGCATGGAGGCTGTGGGCA
 GGTGATGAGTACCATGTACTCTTATGGAAGATTG
 TAAGGAACAAGAGCCTATTATGGACAACAATATTC
 TCTGGTGCCTTTTGAGAGACCTGTGTATAGAGAA
 GCTCACGGGGAATATGGGAAAACGTAAAAGCTCCAC
 TCCACAAAAGTTGTGGGGAAAAGCTCATGCGATT
 CAGCTACCCAGATATTCACCTTGTATGAACTTAAAC
 ATATGAGAAGGAGGCTGAGCTGATGCAGTCTCATAT
 GATGGACCAAGCCATCAACAATGCAATCACCTACCT
 TGGAGCTGAGGCCCTTCAACCTCTGATGCAGCACCC
 GCCAAGCACAATCGCTGAAGTGGCCCCAGTTATAAG
 CTCAGCTTATTCTCAGTCTATCATCCAATAGGAT
 AGAAAGACCCATTAGCAGGGAACCTGTGATAGTCA
 TGAAAACAACATGGATGGCCCCATCTCTCATCAG
 ACCAAAGAGTCGACCCAGGAAAGAGAGGCCCTCTCC
 CAGCAATAGCTGCCTGGATTCCACTGACTCAGAAAG
 CAGCCATGATGACCACCAGTCTTACCAAGGACACCC
 TGCCTTAAATCCCAAGAGGAAACAAAGCCCAGCTTA
 CATGAAGGAGGATGTCAAAGCTTTGGATACTACCAA
 GGCTCTTAAGGGCTCTCTGAAGGACATCTACAAGGT
 CTTCAATGGAGAAGGAGAACAGATTAGGGCCTTCAA

- continued

GTGTGAGCACTGCCGAGTCCTTTTCTAGACCATGT
CATGTACACCATTACATGGGTTGCCATGGCTACCG
GGACCCACTGGAATGCAACATCTGTGGCTACAGAAG
CCAGGACCGTTATGAGTTTTTATCACACATTGTTTCG
AGGGGAGCACACATTCCACTAGGCCTTTTCATTCCA
AAGGGGACCCCTATGAAGTAAAGAACTGCACATGAA
GAAATACTGCACCTTACAATCCCACCTTTCCTCAAAT
GTTGACATACCTTTTATTTTTTTAATATTATTACT
GTTGATAATTCTTATTTTGTGGAGCAGTGTCAATT
GCTCTGCCTAATTACGATAAGGAAGAAACAGAAGAG
AGAAGGGGCGGAATATTGTTTCTTATCACCTGGC
TTGTTTATTTTGTGGGAATTAAGAGCAGTCCATTT
CTACCAAGGCATATCATGCTTTGAAAAATCACTTGA
TTCATAAAGATTCACCTAAGAGATTCTGATTTGCCA
CTGATATTCAGAATTATGATGGAAGACAGGAAAGTT
CAGAGTTTTCTGGGTAGGACTTTGGTGGTTTTAAAA
TGGTATAAGTAACTTTATCTTGAAAGAAGAAATGTG
TTTCAAACGTAAACCAATTTTTGTCTTCAGAGA
TCATGGAACACAAACACATTGTTATTTTCAGTGATA
ACTCCTAAGAGGAGCTGAGTTGTTGTGGGTTCTATG
TTTACTTCCCCTATGGAATTTATAATTCAGTATGTT
TTACACTGTACCATATAGCAAACTTTTAAACTACA
GGTAGTTAAGGGCCACTACAATACATCTGAGGTCC
TGTGATCTTATTTTCTAAACGTAAGCACTGTTTTT
CCATAGTTTTGATGACTGGCATTATATAGACACCCCT
GGCAGCCTTACTTTTAAACACCTTTAAGGAATAGTAT
TTTTATGTAGTTTTTCAAGTAAACATATGGTCTAAGA
GTGGATAAAAAGGCAGTCAATAATTTCTGGGAGGGAC
TTCTACTTTTATAAATTTGTTGAGAGGTTTTCTTT
TAAAGTTGTAATGTGATGGCAGCATAGTATATGTAT
TTGTTTCTAAAAGTATGCTTACGATTGTCACTTTAT
CAGCATTTAATCAGTGTTAACCAGTCAGCAGAAAAA
TATAATTATGCTAACAGTAGGGGAGAAAAACCCACT
TAGAAATCCCTTTTCTGGTATTTCTCTTTTCACTAG
TTTTTTTCAAGATGTGACCTCCCGGTGTTCTGTCCA
TAGTTCATTCACTCTTTACTCTTCGAGTAGAAGGTC
TTAAAAGTCTTCTGTGCGGCTGTTTCTTTCAAATC
TCCTCAGAGCAATTGCTAATTTGGCCTGAATCTGGT
AACTTGAACCTGTAAAGTTACAGAACTAGGGCTAT

- continued

TTATTTTAGCATTTCTTCAGTAGTATTACTACTCT
TGTTGCAAAGAAAAGGGAATGGGACTTCTTTGTAAC
CTGTACCTTGACACACAGATAAAAAGAAACAAAAAA
TAAGAAAGTTTACTTTTACCCTTCTTGGAGTCTAGA
ATGTGACAGAACCCCAAAGGAAAGTCTGCACATT
TTTCTGTTTTCCAAAACATTTAATTTGTGTAAGTCTTT
GTCAGAAATGAATCTCAATCCCTTAGTATAGAATTC
CCCTTACATGGTATAGGTTGCCATATTTTATGTGCA
GATTTTAATTTTCAATTTATGTGGGCGCTGTTTTTT
CTTTGCAGTCCAGCCACATTAGAGGGGAGGAACCGA
GTGATATTGATTCAAGTCATTTTAGGGGACATACT
TGGAAGGCAGAACTGCTGCTTCTGTTTGGGGAGGA
CAGACCTGACTGTGACTGGATTATCTGATAACCATT
TGTGAATACTGAAATCTGTTAGGCAGTAACTGATA
ACTGCTCTAAAGGATCATTAAATAGGATGCTGAAAT
TATGTATCTTAATACAGTGTGGTATGAGAATTACCA
AGTCAAGAGAATTGTGGACATAAGCAAGTTTGGCCC
CAATACTGCTCTTAACTCATTTTCCAGCTTACTATT
TGCTATTTAAATGGTAGGCACCAGCTAAGCACTTCT
AAGCACTAACACAGCTAGAACTAGGCCAAAAATGGTT
AGAACTCAGCTCTCTTCTACTAGTCCCTGTGATAAT
TATTTTTGGGAAAATGTCAAAACCTGCCCTTTTAAA
TCTAAGGGAAATGCACAAAACAGAGATATATAGAAAT
GTCAACCATTTTCAATTTTTTTTTTCTGCATGCCTTG
GTACATAGTGAACATACAACCTATTTAAGATAAAG
CATGTTTTTGGAGACTCGCTCACCCCCCCCCACCCAA
CCACTCCCAAATAATAATTTGGGATGCCATTTTTTTT
CCTTTTGGATGAGGTAATAATTTAAGGTTACAAA
TTTTTGCTTTTACTGCAATTTAAGGAAACATTTGGA
TGTGAGTCAATATGTTTATAATTTTGGCTGTGTGCG
AATTTCTGCTGGCATTATCTATGAATTTTCTTCTTA
CTTATTTTTTTTTCAGTATATGAACAATCATGTATC
TACCTGCCCCAGGATGAACTAAATTTAGGTGGACC
CTAAACCTTATGAAGACAGTGTGAGGCACTTTCTT
TTTCTGATTTTCACTTTTTTGGGAATCTGTTTTATTG
AAGGTAGTTAGTAGTTGAGAGTGCATTTGCTACAAG
CATATACTTGATCTTCTTAGCTTCATGAGGAACAG
AAAGAGGTGGATATGGCTCAGGGTGTGGCAGGGACA
ATTGAGGACAAAGTCAATTCAAATTTGTGGGTCAGA

-continued

AAGAATTTTGTGGACGTAGTGTTTTGGAGAACT
 CTGGATGGTTATATGTGCATGCCTTTCTTCAAAG
 GAAATACGCAAGGTTGTAGCATCTAAAAATAACAT
 AAGAGTCAGACACCAAATAAATCAAGTTTTACATAA
 CAGTTGTATGCCAGTTTGTAGGTGAGATTTAC
 ATTACAGAAAGTATTTGAGGAGCATGAAAAATGGGTT
 ATCTTCTGATTTTCCAGTTTGGCAAAGTTCAGAA
 TTTTCATCACATGCTTTGCCCTAATTTGCCAGAA
 TTTTATCTTAGCCTCTCTGACAGTGATGAATCAT
 GCTCAAAGCCATTCTAATTGGACCTTTTAAAGACA
 GGGAAAGGGATCAGTAGGCGGATTGGAAGAAATTC
 AAGTCATTGAAATATCCATTGAGATTTCTAAAGG
 GACAAAATTGGGAAAATAAGAACTACGACTTAGAT
 TTGGCTACGTAGTAGAAAGTATCTCCCTACATACA
 TACAGGCAATTGTATGTATGAATCATAGGGTATATG
 TGTGTGTATACTACACACACATCTTTAAAGAGAA
 TTCATGGAAAAAAGCAGTTGGAGTGATCAGATGT
 ATTGCAAAAACATACAGAGAATTTAAATGACAGTTA
 ATACCAAGAAATTAGTTGGGTTTACTTTATCAGGTC
 GTAATAGGAATCACTAAGAAGTTACTAGTGTGTCT
 TTAGGACCAGTGGCACTCTTAACTAAAATTTGG
 GTCCTTATTATCTACTTACAGAACAAAGTGAAACAA
 ACAATGATTAAGCTGATTGGATATACATTCAAAGAT
 ATTTAATGTAAGTTTTTGGAAATACGAAGAAAATT
 CAGAAAATAAATATATCAACAGTTACTTATTGGCA
 AATAGAGAAAGACAAGAAATAGTTTAGTGAGCCCGT
 ATTTTGTTTTTATAGTTTTTATCTCAGTTGTACAAC
 TCACAAAACCATGAAGTCTTTGGTATTTTATAAATG
 TTTAACAAAATTTACATCAGATTAAGGCATTTAGAT
 GAAAATTATTATGTCTCCTATCTTCCAAATTTTA
 TTTTCATCTATCTCCAAAATGATTCTTAGGGTACA
 AAAAGAGCAGACGGGGCTGTAATAATACAAGCAAAA
 AACTGTGTGCCCTAGTTTCAGGCGAAGTAAACT
 GTCAGAGTACTAGCTACATGATTTGTTTTTAACT
 TTGGATTGTTACAGTCCAAAAATGGATAAATTACAT
 TTGTGTTTATCATCAGTTGCATTTTATGTATTATTT
 TAATAAATACTATCTGAATGAAGACTATTCTAAACC
 AGAAAATTCCCCAATCCAAAAGAAAAAAGTGG
 GAAGAGGTGAAATGAAGTTTGTGTATATGAAAGTT

-continued

ATCTTAGACATATTTTAAATCTCCAGTTTCTGCAA
 AATAATTAATAATACAGTAAGTCTCCTAAATC
 CTGAATTTAATGTATTAATACTTATGTTCTTTATA
 TTGGTGCCTTTTAAATGCATGAGAGTGTGGTT
 AGCTGTTGCAGCTGTACAACACTTTTAAATATGCATT
 TTTAAAAATCACTTAAATGAGTACTATATAATTC
 ATCTCTGCATTTTGTAGTCAAAATCTTTAGAGCAATT
 TCTAATAGAGAAATTTTCAGCTCAGCTGTAAAAGG
 AAAAGGAACTTTGAAACTAGACTTTACTACCTTTT
 TAGTTTCATAGTATTTCTGAATATGATTACAAGATT
 ATGCAGGTAAAATATAGAGTGAAACTTTACCTGTGA
 ATTGAATTATAATTTGTGTTTTGTTTTGTTTTTAA
 GGAAGAATAAGTTCTGTATCAACAAGAATTTATTA
 GATAATTTTTGGTCAATAAAATACAGTATTCATTT
 GGATTTTCATCTCCAGACTAGTATGTTCTAGTCTT
 GGAATCTGTATTTTCTAATCTGTTAGAAAATAGAGA
 TTGAAAATTGATGGAATAATGTGAAAAAGCAGGTAA
 TTAATTCCTTGAACAAAGCAAACTGAACAGTCA
 TATCACATTGCTATTTCTCAAAGCATAATCTCAAAT
 GGTTCATATCATGGTTGTGTATTACTTGCAATGGG
 TGTGTTAGGATATGACAGCTTTTTAAAAAATGAGC
 TGCTGGTTATACAAAGCAAAATGGCATATGACCAAGA
 AGCTGTGATATGCTAGTGTCTTTTTTATCATAGTG
 TATTAAGGCAAAATATGACACCTTGAATATTTT
 TACATTTATGCGAAACCTTAAACTTTGGAAATTC
 CATAAGGTTTTTATGTAATATTCTATTTCTAGCTTT
 TTAGTTTTATCTTGCTGTACTGTAAGTTTGAGGATA
 TTTTTCACCTGCCTTTAGGAATAAGTTTATAAAT
 CTGTTTATGGGGCTTTCTCCATAACACTGCATTT
 GTATATTTCTGTATAAAATATGTGTTGTGTATTAA
 CCTTTATCCCATACAGAGAGTGGTACATGAATGACT
 AGTTTTCTAAGATGTCCTTTTTATTTGTGAATAAAAT
 ATAAAAGTTAAAGGCCCTCTGCTAAGTACATAAAG
 TACAGCATATAAGTTCATATAGGTACAAAATAAATGA
 GTTTGCAGTGAATGGGCCTTCAAATACCTCAAGT
 GACAGATAGTAAGAAAAGCTTCTTGAGCAGGTGGAG
 GTCAGTGAATCCCTACTATGCACCTTACCAAGATTT
 TACTTACTTTAATTTACTGGAAATGATTTTTTAAA
 AAATGACTACACTGTAAACAAGGAAGGGATCTGGGT

-continued

TTTTTGTGTTTTATTCTGTTTTTTTTAAGTAGT
TCAAATCTGAAACTGTGATTTAAAAATTTTTTACA
GTCAAGCATTCTGATTTTGAACATAACTCCCTTCCC
TTTCTGTGAACAAAGGCTCTCTGTTATCTCTTAA
ATTTTGTACATCTCCCTCAGCCTCTTTCTTTGTCC
GTCTCCCTTCTGTCAATGTCTATGGATGTTTACCTC
TCTGTTCTCCTAAAAGTTTGAAGATTAGGTCAACTC
TTATTCTAGTTCATTGGTAATTTAATCTTAATTTT
TTTTTCGTGATTTTGTGGTGTATAATCTGCTGA
CGTATTTTATACTCAAGTGTAGTTTCTATTAAAA
AGAAAAGTGGTGGATTAAAAATAGTAAGCTATGTA
ACCCTCATGTTACTTTCACCTTCAAAATATTGGGTAC
CTAAAACATTACTTTCAGAGATTATGTAATCCTATTA
TAGTATGTTTGCTTTCTTTTATTGTTGGATTTTACA
TTCTGATTTGGCTTTCTCCAAAAATGTATATCAT
GAAAGACTAGACAGTTATTGCAAGTGTGAAAG
GTGTTAAAAATGTAAAGCAAAGAGTCTTAACTTTCT
CCTAATGGGAGAAAAATGCTTTAACATTACTATAA
TAATATTCCAGGTTTGGAGGGGCTCCAGGCCCA
TATTTGCTGTTAATAGTTGGACCTTTTAGACCATGT
GTTATTTGCAATCCAGAAATGATGCTTCTGCTATT
AGTTAAAAGATACTATTTCTTTTCTTCTGTACAAG
TGCAATACTCCCTTGAAGTCTTAAAACTATGGTG
ATTTTTTTTTCTTTCTGACCTATCTTCTTTAGC
TAATGACAAAAAGAACTCATAAAAGTCATAGTATG
TTAAAGGACACAACAAGCAAAGAGAAAAACTCCA
CAATCAAAGATTACAGAAATGTGAAACCACTAGTC
TGATCTCATGGTATCTTTATTTAAGCTAAATTTCCA
TGGAAATTAGTAATCTTTTGCTTGAAAAATGTGTCC
TAAAGTTGAATTTTTTACAGATTGAATCTTCTTAGA
CCCTCGCCCAATGCTCTAAATTAAGAACCTAATACT
TAATATTTTTATTTACTTCTCCCTTTTAGAAATA
AACTTTTAAATAAAGCAAAGCACTTAGCTGAGTTT
TAAACACTTACATATCACCTATTGGAGAAATTTTTT
TTAAAAATATTGGAGCAGTCTGTTTTTACATAAAA
TTAAGTAAGAGGTATTTTTCTTATACATATTTATA
TGTAGTGTGCTAATTTCTTTTTTATACCTGTGTC
CCTGTAGTAAACTGCTGTAATATAAATACATGTTT
TGTTAAAAGATAACATTTCTTTGGCATTCTTTTAA

-continued

AGGCAGTTACTGCATTTCTGCATTTGTACAGTATGT
GTCTTGGCCATTTTAGATATCTTTCTTTAACAATA
CCAAAGGTAATTAGACTATTTTAAAGACTAATTGCT
TGACAGTTTCTAGGGTATTTTGTGTTTAGAAGCAA
AAAAAGAAAAAAAATAGGTCAAACCAGTAAACCTC
ATTTTTTTTCAAACATAAATTTGGGGAATAAAAA
CTATTGTTTAAAAAAGAAATATATATATATATATA
AAATATATATGTAAAGTTAAATTCATACCTTGTA
TGTCAGGTTTGTCTAAGTGAATGTAGTTTTTTAAG
GCTCAAATACCATACTCAGAAAAATGAGGTTACTA
TGGAAACTGAAACAGTCTTTGACAGCTGTGTGACA
AGTCACTTACTACATACTGATTTGGAGACCTCCGC
TAAATAGTTTTATCACTGCAGACTAAAATGTGGGAC
TTGTATCTTCTTTGTTTTAATGCACACACATACAT
GTTCTGTGCATGTATGTGGTTACTGTGTATATGTGT
ATGAGTGTGTATATGCATGTGTGAGTGTGTGTCTG
TATGTGTGTACAACATAAAGAGCTGCAGAACTTTG
TAATACTTTGTGAAAAGGATTATATTATAAAGTTT
GTACTGTCTGAGTGCACAGCTACTGGAATAAATTTA
GGGAATCTCAGGAACAAGCATATAATTTGTCCAAGA
TTTATTTCTTCTCAGAAGTGAAGTGCAGTTTTTAA
TTCTGTATATTATTAAATTTTTTACCAATAAAATAA
ACTTCTGACATAAAAA.

[0064] As used herein, GATA3 refers to a GATA binding protein 3 polypeptide. When preparing a T cell or treating a mammal with a T cell, GATA3 refers to human GATA3. An example of a human GATA3 polypeptide includes, without limitation, NCBI reference sequence: NP_001002295.1. In some embodiments referring to a second nucleic acid sequence encoding a GATA3 (e.g., full length GATA3) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 11)

GAACACTGAGCTGCCTGGCGCGTCTTGATACTTTCT
AGAAAGAATGCATTCCTGTAAAAAATAAAAAA
TACTGAGAGAGGGAGAGAGAGAGAGAAGAAGAGAGA
GAGACGGAGGGAGAGCGAGACAGAGCGAGCAACGCA
ATCTGACCGAGCAGGTCGTACGCCGCCCTCTCTCC
TCCTCTCTGCTCTTCTGCTACCCAGGTGACCCGAGGA
GGGACTCCGCTCCGAGCGGCTGAGGACCCCGGTGC
AGAGGAGCCTGGCTCGCAGAATTGCAGAGTCGTGCG

- continued

CCCTTTTACAACTGGTCCCGTTTTATTCTGCCGT
 ACCCAGTTTTGGATTTTTGTCTTCCCCTTCTCTC
 TTTGCTAAACGACCCCTCAAGATAATTTTTAAAA
 ACCTTCTCCTTTGCTCACCTTTGCTTCCAGCCTTC
 CCATCCCCCACCAGAAAGCAAAATCATCAACGACCC
 CCGACCCCTCCGACGGCAGGAGCCCCCGACCTCCCA
 GCGCGACCGCCTCCCTCCCGCGCGGGTTCCGG
 GCCCCGGCAGAGGGCGGAGCACAGCCGAGGCCATG
 GAGGTGACGGCGGACAGCCCGCTGGGTGAGCCAC
 CACCACCCCGCTGCTCAACGGGCAGCACCCGGAC
 ACGCACCACCCGGGCTCAGCCACTCTACATGGAC
 GCGGCGCAGTACCCTGCGGAGGAGGTGGATGTG
 CTTTTTAACATCGACGGTCAAGGCAACCACGTCCCG
 CCTACTACGGAACTCGGTCCAGGGCCCGGTGCAG
 AGGTACCCTCCGACCCACACGGGAGCCAGGTGTGC
 CGCCCGCCTCTGCTTATGGATCCCTACCCTGGCTG
 GACGGCGCAAAGCCCTGGGCAGCCACCACACCGCC
 TCCCCCTGGAATCTCAGCCCTTCTCCAAGACGTCC
 ATCCACCACGGCTCCCGGGCCCTCTCCGTCTAC
 CCCCCGGCCTCGTCTCTCTCTGTGCGGGGCCAC
 GCCAGCCCGCACCCTTTCACCTTCCCGCCACCCCG
 CCGAAGGACGTCTCCCGGACCCATCGCTGTCCACC
 CCAGGCTCGGCCGGCTCGGCCCGGCAGGACGAGAAA
 GAGTGCCCTCAAGTACCAGGTGCCCTGCGGACAGC
 ATGAAGCTGGAGTCTGCCACTCCCGTGGCAGCATG
 ACCGCCCTGGGTGGAGCCTCTCTCGTCGACCCACCAC
 CCCATCACCACTACCCGCCCTACGTGCCGAGTAC
 AGCTCCGGACTCTTCCCCCAGCAGCCTGTGGGC
 GGCTCCCCACCGGCTTCGGATGCAAGTCCAGGCC
 AAGGCCCGTCCAGCACAGAAGGCAGGAGTGTGTG
 AACTGTGGGGCAACCTCGACCCACTGTGGCGGCGA
 GATGGCACGGGACACTACCTGTGCAACGCTGCGGG
 CTCTATCACAAAATGAACGGACAGAACCAGCCCTC
 ATTAAGCCCAAGCAAGGCTGTCTGCAGCCAGGAGA
 GCAGGGACGTCTGTGCGAACTGTGAGCCACCACA
 ACCACACTCTGGAGGAGGAATGCCAATGGGACCCCT
 GTCTGCAATGCCTGTGGCTCTACTACAAGCTTAC
 AATATTAACAGACCCCTGACTATGAAGAAGGAAGC
 ATCCAGACCAGAAACCGAAAATGTCTAGCAAATCC

- continued

AAAAAGTGCAAAAAAGTGCATGACTCACTGGAGGAC
 TTCCCAAGAACAGCTCGTTTAAACCCGGCCGCCCTC
 TCCAGACACATGTCTCCCTGAGCCACATCTCGCCC
 TTCAGCCACTCCAGCCACATGCTGACCAGCCACG
 CCGATGCACCCGCCATCCAGCCTGTCTTTGGACCA
 CACCACCCCTCCAGCATGGTACCGCCATGGGTAG
 AGCCCTGTCTCGATGCTCACAGGGCCCCAGCGAGAG
 TCCCTGCAGTCCCTTTCGACTTGCATTTTTGCAGGA
 GCAGTATCATGAAGCTAAACGCGATGGATATATGT
 TTTTGAAGGCAGAAAGCAAAATATGTTGCCACTT
 TGCAAAGGAGCTCACTGTGGTGTCTGTGTCCAACC
 ACTGAATCTGGACCCCATCTGTGAATAAGCCATTCT
 GACTCATATCCCCTATTTAACAGGGTCTCTAGTGT
 GTGAAAAAAAAAATGCTGAACATTGCATATAACTTA
 TATTGTAAGAAATACTGTACAACTGACTTTATTGCAT
 CTGGGTAGCTGTAAGGCATGAAGGATGCCAAGAAGT
 TTAAGGAATATGGGAGAAATAGTGTGAAATTAAGA
 AGAAACTAGGTCTGATATTCAAATGGACAACTGCC
 AGTTTTGTTTCTTCTCACTGGCCACAGTTGTTGAT
 GCATTAAGAGAAAATAAAAAAGAAAAAGAGAAA
 AGAAAAAAAAAGAAAAAGTTGTAGGCGAATCATTT
 GTTCAAAGCTGTGGCCTCTGCAAAGGAAATACCAG
 TTCTGGGCAATCAGTGTACCGTTACCAGTTGCCG
 TTGAGGGTTTCAGAGAGCCTTTTCTAGGCCATACAT
 GCTTTGTGAACAAGTCCCTGTAATGTGTGTTGTAT
 GTATAATTCAAAGCACAAAATAAGAAAAGATGTAG
 ATTTATTTTCATCATATTTATACAGACCGAATGTTGT
 ATAAATTTATTTACTGCTAGTCTTAAGAACTGCTTT
 CTTTCGTTTGTGTTTCAATATTTCTCTCTCTCT
 CAATTTTGGTTGAATAAACTAGATTACATTCAGTT
 GGCCTAAGGTGGTTGTCTCGGAGGGTTTCTGTTTT
 CTTTTCCATTTGTTTTTGGATGATATTTATTAAT
 AGCTTCTAAGAGTCCGGCGGCATCTGTCTTGTCCCT
 ATTCCTGCAGCCTGTGCTGAGGGTAGCAGTGTATGA
 GCTACCAGCGTGCATGTCAGCGACCCCTGGCCCGACA
 GGCCACGTCCTGCAATCGGCCCGGCTGCCCTTTCGC
 CCTGTGCTGTTCTGTGTTAGTGATCACTGCCTTTAA
 TACAGTCTGTTGGAATAATATTATAAGCATAATAAT
 AAAGTGAAAATATTTTAAACTA.

[0065] As used herein, NFATC2 refers to a nuclear factor of activated T cells 2 polypeptide. When preparing a T cell or treating a mammal with a T cell, NFATC2 refers to human NFATC2. An example of a human NFATC2 polypeptide includes, without limitation, NCBI reference sequence: NP_001129493.1. In some embodiments referring to a second nucleic acid sequence encoding a NFATC2 (e.g., full length NFATC2) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 12)
GCGTTGCCTCTGGAGTAAGCCGGATCGCGAGCCGC
GCCGACTCCGCCGAGCCGGGAGCCGGGAGGCGCGCA
GCTCCCGGGTCGCTCCGAGGCTCCTCGGCCAGGGCA
GCCCCGCGGGCACGCGGTAGAGAAGACGGCGTCCCC
TCGGCTGTGGTCGATACAAACAGATCCCCCTTTCC
AAACACGCGCCAAGTCCCCTGTCCTCCAGATGCAG
AGAGAGGCTGCGTTTCAGACTGGGGCACTGCCATCCC
CTCCGCATCATGGGGTCTGTGGACCAAGAAGAGCCG
AATGCACATAAGGTCGCGAGCCACCCTCCGACCC
GCATACCCCGATGATGTCTCTGGACTATGGCCTCAAG
CCATACAGCCCCCTTGCTAGTCTCTCTGGCGAGCCC
CCCGGCCGATTCCGAGAGCCGGATAGGGTAGGGCCG
CAGAAGTTTCTGAGCGCGGCAAGCCAGCAGGGGCC
TCGGGCTTGAGCCCTCGGATCGAGATCACTCCGTCC
CACGAAGTATCCAGGCACTGGGGCCCTCCGCATG
AGAGACGCGGGCTCCTGGTGGAGCAGCCGCCCTG
GCCGGGTGGCCCGCAGCCGAGGTTACCCCTGCC
GTGCCCGGCTTCGAGGGCTACCCGAGCCGCTTTGC
TTGAGCCCGCTAGCAGCGGCTCCTCTGCCAGCTTC
ATTTCTGACACCTTCTCCCCCTACACCTCGCCCTGC
GTCTCGCCCAATAACGGCGGGCCGACGACCTGTGT
CCGCAAGTTCAAACATCCCTGCTCATTATTCCCCC
AGAACCTCGCAATAATGTCACCTCGAACCGCCTC
GCCGAGGACAGCTGCCTGGGCGCCACTCGCCCGTG
CCCCGTCCGGCTCCCGCTCCTCATCGCCTGGTGCC
AAGCGGAGGCATTCGTGCGCCGAGGCTTGGTTGCC
CTGCCGCCCGGAGCCTCACCCAGCGCTCCCGGAGC
CCCTCGCCGAGCCCTCATCTCAGTGGCACCCAG
GACCACGGCTCCCCGGCTGGGTACCCCTGTGGCT
GGCTCTGCGGTGATCATGGATGCCCTGAACAGCCTC
GCCACGGACTCGCCTTGTGGGATCCCCCAAGATG

-continued
TGGAAGACCAGCCCTGACCCCTCGCCGGTGTCTGCC
GCCCCATCCAAGGCCGGCCTGCCTCGCCACATCTAC
CCGGCCGTGGAGTTCCTGGGCGCTGCGAGCAGGGC
GAGAGGAGAACTCGGCTCCAGAATCCATCCTGTCTG
GTTCCGCCCACTTGCCCAAGCCGCTGGTGCCTGCC
ATTCCCATCTGCAGCATCCAGTACTGCATCCCTC
CCTCCACTTGAGTGGCCGCTGTCCAGTCACTCAGGC
TCTTACGAGCTGCGGATCGAGGTGCAGCCCAAGCCA
CATCACCGGGCCACTATGAGACAGAAGGCAGCCGA
GGGGCTGTCAAAGCTCCAACCTGGAGGCCACCCTGTG
GTTCACTCCATGGTACATGGAAACAGCCTCTG
GGACTTCAGATCTTCATTGGGACAGCTGATGAGCGG
ATCCTTAAGCCGCACGCCCTTCTACCAGGTGCACCGA
ATCACGGGAAACTGTACACACCACCAGCTATGAG
AAGATAGTGGCAACACCAAAGTCTTGAGATAACC
TTGGAGCCAAAAACAACATGAGGGCAACCATCGAC
TGTGCGGGATCTTGAAGCTTAGAAACGCCGACATT
GAGCTGCGGAAAGGCGAGACGACATTGGAAGAAAG
AACACGCGGGTGGAGCTGGTTTTCCGAGTTCACATC
CCAGAGTCCAGTGGCAGAATCGTCTCTTACAGACT
GCATCTAACCCATCGAGTGTCCAGCGATCTGCT
CACGAGCTGCCCATGGTTGAAAGACAAGACACAGAC
AGCTGCCTGGTCTATGGCGCCAGCAAATGATCCTC
ACGGGGCAGAACTTTACATCCGAGTCCAAAGTTGTG
TTTACTGAGAAGACCACAGATGGACAGCAAATTTGG
GAGATGGAAGCCACGGTGGATAAAGACAGAGCCAG
CCCAACATGCTTTTGTGTGAGATCCCTGAATATCGG
AACAAAGCATATCCGCACACCTGTAAGTGAACCTTC
TACGTCAATCAATGGGAGAGAAAAAGTCAAGCTT
CAGCACTTACCTACCACCCAGTCCAGCCATCAAG
ACGGAGCCACGGATGAATATGACCCCACTCTGATC
TGCAGCCCCACCCATGGAGGCTGGGAGCCAGCCT
TACTACCCCGCAGACCCGATGGTGGCCGAGTCCCC
TCTGCTCGTGGCCACCATGGCTCCCTGCCAGCAG
TTCGCGACGGGGCTCTCATCCCTGACGCCCGCTAC
CAGCAACAGAACCAGCGCCGTACTCTACCAGCGG
AGCAAGAGCCTGAGCCCGAGCCTGCTGGGCTATCAG
CAGCCGGCCCTCATGGCCGCCCGCTGTCCCTTGGC
GACGCTCACCGCTCTGTGCTGGTGCACGCCGGCTCC

-continued

CAGGGCCAGAGCTCAGCCCTGCTCCACCCCTCTCCG
ACCAACCAGCAGGCTCGCCTGTGATCCACTACTCA
CCCACCAACCAGCAGCTGCGCTGCGGAAGCCACCAG
GAGTTCAGCACATCATGTACTGCGAGAATTTGCA
CCAGGCACCACCAGACCTGGCCCGCCCGGTCAGT
CAAGGTCAGAGGCTGAGCCGGGTTCTACCCACA
GTCATTGAGCAGCAGAATGCCACGAGCCAAAGAGCC
GCCAAAACGGACCCCGGTGAGTACCAAAGGAA
GTATTACCTGCGGGGGTACCATTAAACAGGAGCAG
AACTTGGACCAGACCTACTTGGATGATGAGCTGATA
GACACACACCTTAGCTGGATACAAAACATATTATGA
AACAGAATGACTGTGATCTTTGATCCGAGAAATCAA
AGTTAAAGTTAATGAAATATCAGGAAGGAGTTTTTC
AGGACCTCCTGCCAGAAATCAGACGTAAAAGAAGCC
ATTATAGCAAGACACCTTCTGTATCTGACCCCTCGG
AGCCCTCCACAGCCCTCACCTTCTGTCTCCTTTCA
TGTTCACTCCCAGCCCGGAGTCCACACCGGATCA
ATGTATGGGCACTAAGCGGACTCTCACTTAAGGAGC
TCGCCACCTCCCTCTAAACACCAGAGAGAACTCTTC
TTTTCGGTTTATGTTTTAAATCCCAGAGAGCATCCT
GGTTGATCTTAATGGTGTTCCTCCAAATAGTAAGC
ACCTGCTGACCAAAGCACATTCTACATGAGACAGG
ACACTGGAACCTCTCTGAGAACAGAGTACTGGAGC
TTGGGGGATGGACGGGGGACAGAAGATGTGGGCAC
TGTGATTAACCCAGCCCTTGCCTTCGTTTTTCCA
GGTCACAGATACAGCTCCTGTACCTTTTGAAGGCAA
GGAGTTCACAGAGCAACCAAAGGAACGTGACCCAAG
AGCCAGCTTACAGGCTGAAGAAACCCAAAACCCCTC
GATAGAGACAGAACTGAACGTGTCAGTCTTAGAGC
TCGCCAGTCCATGCCACAACCTGGGCCACAGCTAAA
GCTTTATTTTTGAATTCTCATTCCAAAACCAAACCTG
TCTTGCCAGACAAGATCACCTGTTAAGACTTCTTG
GCGTTAAGTTATGACATGTATACGCTTTGTTATTA
TTATTTTTCTGCTTTAAAAGGCTGACCAGGGCACC
TAGCCCTGGAGCTGTCTTGGCGAGCTGTTCTTTAAC
CCCTGCAGCACGAGTCTGTCTAACACAATTTCCAT
AGACTTGGGGGCTGACCCAGGCTGCAGAGAGCAAG
CACCTGTCTGTGACGCTGTACAACCTGGATGCTTT
GCAAGGTTCCGGCTTGCTTTCTCCTAGCAGCCAGA

-continued

GTGCTTTTCCGTAAGCGGTGGAGAATCTCAAGCAT
GTGCATTTAATTGAGGAATAGCAGAAGGGCTAAAGC
AACCAAGAAAAGAAGTGTGGGTATTTTGTAAAGTA
AAACAGCCCAAGTGTCTCTGGAGGTGGGTTTCTACC
AAGATAGAGGAAAAGGGCTGAATTCCTCTAAGTGG
GACAGCCGAGCTCAGGATGTGCTTCCAGCTTCACT
GGTTAATTTGACCTGAACCTATTTAAAGATCCCTTC
TGCCCTGAAGACCTATCCGCACTCAAATTTAACA
TGAAGAAATCTACTCGAATGCATCCTTTACTTTGAA
TGAGCTCTATTGCGTTCATGTTATATGTGATTTCC
TTCCTCCCACTGTTCCTACTGAGCGCACCCAGTCT
CCCCTAGTCTTCTCTGTGGGTGTGATTTTGTGAT
TTTTACAAACAAAACCCCTGAAGTCTTGGCAGATG
TGTTTGTCTCTGTTTGCATGTACTGCAGATACCCCA
GGACAAGCGGGGATTCATTTTCAGCCATTCAGTT
GTTTCTCAATAATCCGCAGCAAAGTGAATAATTC
TTAGCACTCAGACTGTACTTAGAGTGTTTTCTCAGT
CCAGTCTGTACAGTCTGTAGGACAGAAGCCCTCAGAA
GAAAGTCATGGCCACTCAGTGCCACTGTGGGCTTT
GTAAGTCTGGCTCTCCCGTCAAGGTTACCCAGAGG
TAAAAGCTTCTGGGAGTGGGGCCAGGTGTGTTGG
CACTCCAGATAGAAGGCAAAATGCTCAGATTCCGGC
CTGTGCACTTGTATGCAACCTGTCCGTCGATACCTA
GCATTTATTTTTCTCCTGACAATGAACGACCTTTCC
TCACCCACCCCTAAGCTCAAAGAGTTTAGCAAAATTC
TCTTTTAAATAAACAGAAATGCCAGTAAAGAGGTTGAC
CCCTACCATGGAACCTTCTGGGATGCTAAATACTTCC
TCATGAACAAAATAAGTTCCTTATATAAGTTCCTT
ATACTAGCAGCTTCACTAAAGAAATTTCTCTCCAG
CAATATTGACTTCACTGGGGAAAAGCCAAGAGTGTG
TGGTGAAGTATTTGTTCTCACTCGACCTGGCTAGGA
CTGGCTAGGAGCTGTTTTTTGTACATGAGGGAATTT
GGGCTTTCTCAGTTATCTGAATGTTTACCCAAGT
GCCTTCTGCTATTGTAGCAAAGTAGCTCAGCTTCC
TTGTCCACAGGGTGAAAAGGACTAATGCATTTTCC
ATCAGTTTTCTAACTATGTTAGCAAAAACGGCCCTCC
TGGTAGCTCAACCTCCTGTACCGTGTGTGTGTGTA
ATACACACACAAAATAAACCCCTCTGTTTTTCTAAGA
CATCTTAGCTGGATATTATAGGAAGCACTTTCATAA

-continued

ACAACTGTAAACAAATCGCAAAGGAAAGAGAAACAAA
 AGCATTAGATTGAGACATAAACAGGCAAGAGAAAG
 TGTATTAGGAACTGACAGCTATCAAGGAAGTTTTGT
 CAGTTACAAATGCTAGGAGGAAATTTTGCCAAGAAG
 GATGGCTCATGAAATATTTCCAGTACGGGAAGAGGC
 AATAAGATCCTCTAAGAGAATGAGAAAGTAGGGGTG
 TCTAAATGGTAAAGATGGGTGTGTGCACGTGTGTT
 AGAAGGATCTCAGTTGAGTGAAGTTTGCACGTGCTA
 CATCTAAGTTAATGTAATATGTAGCACTCTGACAG
 GTCTACCGTGTGCTGAATGTAGTATATTTCCAAAG
 TTTGCAAGTCTTCCTGTATTGTACAAGATGCTGCT
 GCTTGATAAATATGTATAGCAATCCAGATTAGTATGT
 TATTAAATTTTATTTTCTTACCTGTATTTTATGCT
 TTTTACCTGTCTCAAATATTACACCCCTGTTGGA
 ATTAGATTATATTATAAATGGTCAGAAATCTTTT
 TAAGTGTCTCTTTTACACATAGGTTGATTTTTTTT
 TCTTAAGAGAAATGATGTATTTCTTGAAACATTTGTT
 ACTCATTCCAGGAAACAAAACCCATAATAAAAC
 CCCCCTCAGAGCCTGTTAGTCACTCTCTAGAAGA
 TGGCATCTCAGGAGAAGGAATGGCTTTGTGGAAGAA
 GGAATCACCTTTTTCTTGCTCAAGAATTATGCTGAC
 TTCAGCCCTGAGCCTGGATCTGGTCACTGAGAATCA
 TCAAGTGTCTAGATCCTCCCCCAAATAACTAATT
 TAGTAGGTGATTTTGATTTTAAAAAATGACACCAA
 AACCTGCCTGCATTGTAATGGAATTCGAAAAGAA
 TCATGTTACAGAACTCAAGTTACAGCTAATATTT
 ACAGAAGGGACCAAATCTAAATCCTGGTAGATACT
 CCTGTATGCTTTATCCAAAGGACACCCACAGTTTTTC
 CAGCATAGATATAACCAAGGATGAATTGATTCCTTC
 AAAGAACTGGGAGGCACGGATATTGCATTTTTTGT
 TACATCCAGTAGCCAAGACGCCTCAGTGAGCCAGTC
 TTGGCAGAGGCTGTCACATTTAGCAGATTGGAAG
 TTGGTATGTTCTAATTTCACTCTGGACTACAGTGA
 GGCTGAATTTATCATGTCAAAAAAAAAAAAAAAAAA
 AGACCTTTCCAAGTCTTTCTATTGCTCAGAATTGA
 AAGAATGTTTTCAATTCAGTTTACAAGAGGCATGG
 ATGGAGTTGTGACGTTCTTGACAAGCTGGGCTAACC
 TTTCCCAACTTGTTTCCCGAGGCAAGGTGCTCGG
 TGACCAGCGCATCTAACCTTGGGTCTCCTAGGCT

-continued

CGAGGCTAGGCATTACGTTTTCTGTGGAACCAAAGCA
 GCCAATTGCATAGCAAGTATTTTCTCGCATCCCAAT
 TAAATGCTTAAGAAAAAGCAGCATCCTATAAAATTG
 TGATCATAAACATCCATTTCCCTCAGCTTTTGTGAG
 TGCCTTGACTTACAGCCAACATCACTGTTTAACTCA
 GTCTGTTTAAAAACAACCTTTTCTGGTGGTTGATAA
 CAGAGAGTTGCTCCCTGAGCCATCAGGGTCTGGGA
 GCTGGAAGTGAAGGGTTATTAACATTCTACCTTTA
 TGCAGCTGTTGGCTGACCAGAATAAACCTCCCTGCTG
 AGTTCAAGCTTTGAATGGATGGATGCAAATGATGT
 TGTTCCATTAGAGCAGGTGCTCAGCATTCTGAT
 TGGCCTGAGCAGACCAGGCTATGGCTGTTGGGACA
 AGCTTAGCATCCTGGACATCTTGTCAAAGAACCTCA
 CTCACCCCTCTGGCCTCTACAGCCCTCAGAGGAGAG
 AAAACCAATCTCCAACAACAGGTCTCTCCAACAT
 GGTGGTGTGGCAGGCTTAGGTTTAGAAAATCCTGA
 CTGTTAAAGGCGTTTGAATACATCACATTCTATGC
 AAATGTTTTTAACTCCAGTTAATGTAGTTTATTT
 TTCCTATATGTAAAGTATTTTATACGGCTTGTATC
 ATGATAGTTTAGCAATAAAACAGTTGGAAGCAA.

[0066] As used herein, XBP1 also known as refers to an X-box binding protein 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, XBP1 refers to human XBP1. An example of a human XBP1 polypeptide includes, without limitation, NCBI reference sequence: NP_005071.2. In some embodiments referring to a second nucleic acid sequence encoding a XBP1 (e.g., full length XBP1) polypeptide, the nucleic acid sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100%) identical to:

(SEQ ID NO: 14)

GAGCATGCTCCCGCTGCAGTTAACTAGCCCAACCTA
 TTTCTTTAATTAGCCCATCCCTTCGTTTCCCTTAA
 GGGATACTTTTAGTTAATTTAATATCTATAGAAACA
 ATGCTAATGACTGGTTTGTGTTAATAAATATGTGG
 GTAATCTCTGTTCAAGGTTCTCAGCTCTGAAGGTT
 GTAAGATCCCTGATTTCCCACTTCACACCTCTATAT
 TTCCTTTTTTTTTTTTTTTTTTTTTTTGAGACAGAGTC
 TCACTCTCGCCAGGCTGGAGTGCAGTGGCAGCATC
 TCTGCTCACTGCAAGCTCCGCTCCCGGTTTCACGC
 CATTCTCCCGCTCAGCTTCCGAGTAGCTGGGACT
 ACAGGCGCCCGCACTACGCCGGCTAATTTTTTGT

-continued

ATTTTGTAGTAGAGACGGGGTTTACCCGTGTTAGCCA
 GGATGGTCTTGATCTCCTGACTTCGTGATCCGCCTG
 CCTCGGCCTCCGAAAGTCTGGGATTACAAGCGTGA
 GCCACCGCGCCCGCCTCACACCTCTATATTTCTGT
 GTGTGTGTCTTTAATTCCTCTAGCACTGCTGGGTTA
 GGGTCTCCCTGACCAGCTGGTCTCGGCAGATAAGG
 TTTACCATGTTGGCCAGGCTGGTCTCAAATCCTG
 ACTTCAGGGGATCCCGCCCGAGCTCCCAAAGAGC
 TGGGATTACGGGCATGAGTACCCGTGCCAGCCAAT
 TTTCTTTTGTTTTTTCTTTTGGAGACAGGATCTCACT
 CTGTCACCCAGGCTTGAATGCAGTGGTACCATCTCG
 GCTCACTGCAGCCTCAATCTTCTGGGCTCAAATGAT
 CCTCCACCTTAGCCTCCCGAGCAGCTGGGGCTACA
 AGTGCACACTACCAAGCCAGCTAATTTTTTTTTT
 TTTTTTTTTTTTGGAGACAGAGTCTTGCTGTGTC
 TCACCCAGGTTGGAGAGCAGTGGTTCGATCTTGCT
 CACTACAACCTCTGCCTCCCGTGTTCAGCAATTCT
 CGTGCTCAGCCTCCTCAGTAGCTGGGATTACAGGC
 ACGTGCCACCATGCCAGTTAATTTTTTGTATTTT
 ATAGAGACGGGGTTTCGCCATGTTGACCAGGCTGGT
 CTTGAACCCCTGACCTCAGCCTCCCAAAGTCTGAG
 ATTACAGTGTGAGCCGACATGCTAGGCTTATACAT
 TTCAAAATTATGTTGCTATGTTTATAAAGATGTATA
 TATGGTAACTTGTACCTCAATCAACATGAAATACC
 CTTCTTTGTCTTTTAAATGCCTTTATGATAAATTCT
 GTCTCATATTAATATTGCTACATATGCTTTCTTTCC
 ATAACATTTCCATAAACATAAAAATGGCTGGTAA
 TCATTTTCTTTTTTTTAAAAAATTTTTGTTTTTT
 AGAGGCAGGAGCTCATCTGTCTCCAGGTTGGAGT
 ACAATGGTTCAATCATAGCTCATAGTTTACTGCAGC
 CTCGAACCTCTGGGTTCAAGGGATCTTACCACCTCC
 GTCTTCCGAGCAGCTGGGACTACAGGTGCAAGTCAC
 CACGCTGGTTAATTTTTTTTAAATTTTTTGTAGAGA
 CAAGGTCACAATATGTTTCCAGCCTGGTCTGAA
 TCCTGGCCTCAAGCAATCCTCTGCCTTGAGAAATA
 TAGTAAACAAAAATGTGAAATAACATGGCAGAAAT
 AAGTCCAAATAAATAAATAAATAAATAAATAAATA
 ATGATTTATATCTCTTTTAAAGAGAGCTCTGAG
 AAACCCCAAGCCAGCTATATGTTGTTTATAAAGAG

-continued

ACATACATAAAAACAAAACAGCATGATTAAGAAGATA
 ATATAACCCATTTCACATTTATGTTTTATTATTATA
 TATTTGGACTTATTCCTGCCATGTTATTTCTGTTTT
 TCTGCTTACCAGTGTACAGTATTTTTCTGTTTTCCC
 TTTTCTGGAATGCCTATTTATTTCTGTTCTGTTTT
 GTCCACCCTTTCTGACTGATTCTTCTGAATAATG
 ACTTTTTTTTTTTTTTTTTTTTTTTTGGAGAAAGTC
 TCACTCTGTTGACCAGGCTGGAGTGAATGGCACA
 TCTTGGCTAATTGCAACCTCTGCCTCCAGGTTCAA
 GACATTATCTGCCTCAGCCTCCCGTAGCTGAGA
 TTACAGGCGCCCCCACCATGTCCGGCTAATTTTTG
 TATTTTTAGTAGAGACTGGGTTTACCATGTTGGCC
 AGGCTGGTCTCGAACTCTGATCTCAGGTGATCTGC
 CCACCTCGGCCTCCCAAAGTGTGGGATTACAGGGG
 TGAGCCACCGGCTTGGCCTCAAAGACCGAGAAGT
 TGTAATTATATATTTTATAGCTCTTATCACAGGTG
 TCTAGTAAATATTTTTAAACACTTATGGCACCTGAT
 GCAAGAATTACCAGGTTCAATTTTATAGAGAGGATAT
 GAAACTGTCCAAGGGTTGGACTCACATGTTCAAGA
 CTGCATGGACAGCAATCTGATGTTGGTCAAATTATT
 GTTTTTAGTATGATTTAAAGTGTGTTGTTCAAAAAT
 AAAAGTTTTGAAAAAAGCTGGGGAAGTGAATTTCA
 ATATCGCATTAACATAAGATCAAAGTGAATTCATCA
 ACCTTTTTTCCCATCCCGCACCTCTGTCTTCTCT
 ACTCAGTTACTCACTACACCTCTGCTGGACTAAAAGG
 GTCCTCCAGCATTTTCTTTCTTACACAGTGAAAGAC
 ATTTCTTGGCATTAATAAATGTTTCACTTAATAAAT
 AAAAAAGGCCGGGCTCTGTGTTCTGCTGCAATC
 CCAGCAGTTTGGGAGGCCAAGGCAAGAGGATCGCTT
 GAGCCTAGGAGTTCAGCCTAGGCAACGTGGCGAAA
 CCCAGTCTCAAAAAAAAAAAAAAAAAAGGAAAAAAAAAGGC
 ATCAAAAAATAAAACGTAACAGGTGGCATGACATGA
 CATGACTTTTCTAACAGCCTCTTACAGCTTTCCAAG
 GTCTTTTAAATATGAAGCTATAGGTTCTCGGTAGAAG
 ACACCTCCAGACTTCTCCAAAACATTTAGAGGGCC
 CGGAGTAAGTCTCCACATCTGAAGGCACATCAGA
 ACCCAGGTGGCCCAAGCTGATGAGAGTTAAACAGGA
 AGTTGGTTTCTTGGTCCGGCAGAGACTCCAATCACC
 CCCACCTTTTTTCAACCCACAGGACAGCAGCTGCT

-continued

CAGGAGGCTCTGGAGTTGGGACAGCCCAGTTAAAAA
AAAAAAATCATTGATTTCCCTCCCAACGAAGAGGG
AGAAAACACGTTAGGAGACTCGTGGCCAGTCCCTGG
CAAAAACCAAACATGTCCCTTTAGAGGGCTTAGA
TATCAAGAGATGGACTTGCTTTTAGTTCTTTTCCC
ATCCTGTTCCCTCCCTACCAAAATAAAATTGACCAG
CTAATCCGACTTAATAACACTAAAGAATTACTTAGG
AACCTGCTATCTTAAACATTTCACTTTTTGCATATCC
TCCAAATACCAGGTAGCAGTCTTACTACTGTTTGCA
CCCCTAGAACCTGGAATAGTGTGCCCGCAGAGGAG
GAAGCAATAATTACTTGTTAGAGAAGGTATTGCTGT
GCATTTCTGGGGAATTTACATTTTGTAAATTTGCTT
TAAAAAAGTGGACAGGCATATTTACGGGGTTTCT
CGGACTTCTCCATGTTAATATTCGTGTGTATAAATC
GCTCCCGTGTCTCTCTGGGGCCCTCTTTCACA
AACACCTGGCCACCTCACGCCACAATGCCAGGCA
GGAACCTCGACCTCCCTCGGAGAGGGGCTCAGGG
TCAACCCCGGGTCTCAGTCTCTACATGTGACGTTT
TCCTGTCCCTCATTTAAAAATAACAAGAGGTGGGC
GCAGTGGCTTACGCCTGTAATCCCAGCACTTTGGGA
GGCCGAGGCGGGCAGTACAGAGGTGAGAGATGGAG
ACCATCCTGGCCAACACGGTAAACCCCGCCTCTAC
TAAACTACAAAAATTAGCCGGTGTGGTGGCGGGC
GCCTGTAGTCCCAGTACTCGGGAGGCTGAGGCAGG
AGAATTGCTTGAACCCGGAGGCGAAGGTGCAAGTGA
GCTGAGATCTCGCCACTGCACTCCAGCCTGGTGACA
GAGCCTGACTCCGTCTCAAAAAATAAGAAAAA
TAAAAATAAAAAATAAGAGGCCGAAGCGGGAGGTT
ACTTGAGCTCAGAAGTTCGAGATCAGCCTGGGCAAC
ACAGTGAGACCTCGTTTCTATTTAAAAATAAATA
AAACTAAATTTAAAAAATGACGCTCATAGTACAA
ACTTTAGAAATGGAACGAAAACTAAAAATTGAAGT
ATTCCCTCCAACCCAGAGATAACACCTATCGTTTA
TTAAGCCCTCACTATTGTTAAACTTAGTTTTAAAGG
GCACGATCTCATTTCTTAAAGACTTCTATTCCGAG
AATTTCTTTCCAGGCTTTTTCTTTTCTTTTTTTG
AGACGGAGTCTCGCTCTGTGCGCCAGGCCGGGTGC
AGTGGCGGATCTCGGCTCACTGAAACCTCTGTCCA
GTCTTTTCAACCCAGGCCAACTGCGCTCTATCT

-continued

CGACTTTCGGCTCCACTCGGATCCCGAAGTGGCGCA
CGAGATAAAATGTTGTGAGGCTGAGGTAATTTCTCTG
TTAGTCCCGTAAAAATTCGTGACTCTGGAAGCTC
TCGGTTTGAATTAATTTCTGTCACTCCGGATGGAA
ATAAGTCCGCTTAAGGGGGAAAAATCCGTTTGTGGA
GGACACGCTCCCGCACGTAACCCCGCGGAAAATG
ACCCCAAGTACCTTTGGCCAGGGATTGCCGTGCCA
CGCCGACTCCATAGCCAGGTCTGAAACGCCCCG
CCGGCAGGCCGACCAATGGACGCCGAGCTCGGCC
GTGCGTCACGCGACGCTGGCCAATCGCGGAGGGCCA
CGACCGTAGAAAGGCCGGGCGCGGAGGCTGGGCG
CTGGGCGGCTGCGGCGCGGTGCGCGGTGCGTAGT
CTGGAGCTATGGTGGTGGTGCAGCCCGCCGAACC
CGGCCGACGGACCCCTAAAGTTCTGCTTCTGTCCG
GGCAGCCCGCTCCGCCCGGAGCCCGGCCGGCC
AGGCCCTGCCGCTCATGGTGCAGCCAGAGAGGGG
CCAGCCCGAGGCAGCGAGCGGGGGCTGCCCCAGG
CGCGCAAGCGACAGCGCTCACGCACCTGAGCCCG
AGGAGAAGCGCTGAGGAGTGGGCGAGGGCCGGG
GTCTGGGGCCAGATCTGAAGCCGGACTAGGGACAG
GGGCAGGGCAGGGCTGGGAGCGGGGACCCAGCAC
TGGCCGCCCGCAGGGCTCCGTGCGCTTTGGCCTGG
CGGGTCGGTGCAGCGTGGCGGGGGCGGGCAGGA
AGCCCGACTGACCGGATCCGCCACGCTGGGAACCT
AGGGCGGCCAGGGCTTTTTCTGTACTTTTTAACT
CTCTCGTTAGAGATGACCAGAGCTGGGGATGCGGGC
ACCTGTCTTCCAGGCCCTCTTGTGTGTGGCCGAG
ACTGGTGGTTCAGCCTCTTAACTCGGACATGAGGTC
GAATAATCTGTTTTGGTTTACTGCTATTTCTGGAGA
GGCGCGGAGCTGAAATAACAGAGCTGTGAAAGGGC
TGGGAATCTGCGAGGCTCACTGGTCTAGCTCAGTA
TCTGCGTTCTTAAAAATGGAACCTACTTCATGAGGTC
TTGGGGAGATTGAGACTTGGATATAATGTGCCTAG
CACTTAGTCTCCGTAATGTTCACTCTTTTGTGAT
CATGTGCCTTCTGTGATTTATGAAGTGTCTCTTCT
GAGTTAATCTTTTTAAAAAAGTGTCTCTCCCA
ACAGACACGGACCCATCAGCAGGTCACTGCCTAGGA
TCTCAACACTAGAGATCAGGGAGTGGCATCAGCCTC
TCCCTTTTCTAAATGGACTGGGGACGGAGGGTTG

-continued

ATGTCATAGCAAGATTGCAGCCTTCACTAGATTAAT
GAGGCCAGGTTGGATCCTGTTTAAAGAGAACTGGAGA
CAGGAAGCAGCGGGGAATAGATGGGGAAAGAGGAA
AGTTCCTTATGATGCAAGATGAATAGTGTGTGTGTC
CAGCCCCAGTGCTGTGACGGGGATGAGTCTGAGGTG
GACGGATGATGCAATATAGGAGAGAATAAAGCAGGT
CTTCGAGCTAGATTGACAGAAGACTGTATTTTTTAT
TTTGTTTTATTGAGGGGAGGAGCCTGAAGTGTATTT
TATCATTAGTCTGTCTTACTGTAAATAAAAATGA
AAGCACCAGCTGGTAAAGTTTTCAAATAAGACATA
AATAAGGTTTGATATGACTCAGTGTGGTATGTTCCCT
TCTCTCCTAGGAAACTGAAAACAGAGTAGCAGCT
CAGACTGCCAGAGATCGAAAGAAGGCTCGAATGAGT
GAGCTGGAACAGCAAGTGGTAGATTTAGAAGAAGAG
GTAAACTACTTAAGGTCAAACCTTTTATCCATTG
TATAACCCTTCCCTGGTGAATGTCTGTATTTGCTT
CCCATCCCAAGTTGTTTCAGCCCCATTAGAAATACA
ATTGAATATATGATTAAAGTTAAACTAGGCTGGGC
ATGGTGGCTCATGCCTGTAATCCAGCCTTTGGGA
GCCTGAGTTGGGCAGATCACTTGAAGCCAGCAGTTT
GAGACCAGCCTAGCCAACATGGTAAATCCCCTCTC
TACCCAAAAATATACCAAAAAAATAAAAAAAAAA
GGCCAAGCGTGAGTGCCTGTAGTCCAGCTACTCGG
GAGTTGAGGTGGGAGGATTGTTTGAACCTGGGAGA
GGGAGGTTGCAGTGTGAGTGCAGTGCACACTGCAC
TCCAGCCTGGGCAACAGAGTGAGACTCTGTCTCAAG
AAAAAAAAAAAAAGTTTGTGGGCACGGGGCTCAC
ACCTGTAATCCAGCACTTTGGGAGGCCAAGGTGGG
TAGATAACTTGAGATCAGGAGTTCGAGACCAGCCTG
ACCAACGTGGTGAACCCCATCTCTATTAAAAATAC
AAAAATTAGCCGGTGTCTGGCAGGCACCTGTAAT
CCCAGCTGCTCCGGAGGCTGACGCAGGAGAATCACT
TGAACCCAGGAGGCGGAGGTTGCAGTGTGAGTGTGAT
CACGAGATCATGCCACTGCACCTCCAGCTGGGCGAC
AGAGCAAAAACCTGTCTCAAAAAAATAAAAAAGT
TAATCTAAGTTAGGACAGAGAGTTGGTGAAGTGGTG
AAGCTTGTGGGGCAGAGTGTGACTTTGTGGC
ATTTGGTGTAGATGTATCTCAAAGTAGATGGATTT
AACAAATGTTTATTGAGTTTGTAGTAAGAAATTAGCA

-continued

AGGGCTAATAGGAAATAATTGCTTAAACTTTACATT
CTTCTGGCATGGCCAGAAATTTACTAAAGTTCCCT
TTCCCCCTCTAGGGTCCACCTGTTAATCAATCTTAA
ATTGTGCAATTACACATCTGAATACATAGAGAT
TATTTATATTGTTTTTTTAAACCCTTGGTCAATTTG
CATATATTGAGCTTTTTAAAGTTTTAATCATTAGTT
GGTTCCTTAAGAATCATGAGTCAGGAGCAGGGATT
TTTTTTAACTTATTTTGGATTTATAGTCACCACTAC
CACTTTTATTATTACCTGCCAGTTCAGATAGTTAT
TTATTTTATTTTATATTATTATTATTATTATATC
ATCATCATTATTTTGGATGGAGTCTCACTCTGTTG
CCCAGGCTGGAGTGCAGTGGTCAATCTCGGCTCAC
TGCAACCCTGCCTCCAGGTTCAAGCAATCTCCC
TGCTTCAGCCTCCAGATTAGCTGGGATTACAGGCAC
CCCTCACCATCCAGCTAATTTTTGGATTTTTTAG
TAGAGATGGGGTTTGCCATGTTGCCAGGCTGGTT
TTGAACTCTTGACCTCAGGTGATCCACCTGCCTTGG
CCTCCCAAAGTGTAGGATTACAAGTGTGAGCCACC
GAGCCTGGCCAAGATAGTTTTAAAAAAAAAATTATAT
CTACATTAAGCCACAAGTCACCCCTTGTGTAAGTTC
AGTATTAGTAGTTGGAAGCAGTGTGTTATTCTTGAC
CCCATGAAGTGGCACTTATTAAGTAGCTTGCTTTTC
CATAATTATGGCCTAGCTTTTTAAAACCTACTATGA
ACACCACAAGCATAGAGTTTTCCAAAAGTTCAAGAA
GGAAAGGAAACCAATTATACTGAATCAGGTAGATTC
TTAACTGAAATAATTAGATGTTTTAATAGCCTCTTA
TGAACCTTCTTCCAGAACCAAAACTTTTGTAGAA
AATCAGCTTTTACGAGAGAAAACCTCATGGCCTTGT
GTTGAGAACCAGGAGTTAAGACAGCGCTTGGGGATG
GATGCCCTGGTGTGCTGAAGAGGAGGCGGAAGCCAG
GTAAATCATCTCCTTTATTTGGTGCCTCATGTGAGT
ACTGGTTCCAAGTGACATGACCCAGCGATTATGTTT
ACAGTCTGGACTTCTGATCAAGAGCGTCTTGAAT
TTTCCTTCAGTTTTAAGACATTTTCATGCAGGCAGA
GTGTTCTTCCCCTAAAGGCACTTGACACTCATTTTT
TAAGTGTGTAGTGAACAGTACTAAGATCTAATAATG
AAAACAAGTTACATGGCTCCCTAAGAACAAGTACTA
ACAAATGCAGTAGCCAACAAGATTACCATGCAATCA
TTAAGGAGAACCAGTAAGAGAGCCACTCAAACCA

-continued

GATTTTGAACGCTACTAAAATTAAGTAGTTCTTTG
 ATGAATATGAATGAGTAGGGAAAGGATTCTTTGTAA
 TAGTGATACCTCTGTGTAAGAGAAGGGTGGTATGT
 GAGTTTTAGTCTACAGATTATGGCAAATTCAGTGAC
 AACAAATCAAATGGTCTAAGATTGACAGTAGCACAGT
 TTTACTCTGTGAAGGTAATGTTTCAGGACAAATTTCA
 AGAAAAC TAGAAAACCATTTCTTTACAGCTGAAATCT
 TTCCCTAACCATTTGTTATTTCCACTTTTAAGTCCTC
 AAGAGATGAGAAAAGGGAGGTAAGGCTTCCTTATAC
 ATTTCCCTGCACAATGAAACATTTTTCTCCCTCCAGG
 CAAAGATTCAAGCAGAACTGGCAAATATCTTATCTT
 GCTCTTCTCAATAATAATAATGTTGTTAGATAATAA
 AGTTCTATAGCAATTTAACCTAGAATCTTTTGAA
 AAGTAATCTTTAAAGTTGAGAATCACAGCTGTCTA
 GCAAGCATTCTTGGGCACCTGAAGCTGTTTATTC
 ACTTTGGTCTTTCTCCAGGGGAATGAAGTGAGGC
 CAGTGCCCGGTCTGCTGAGTCCGCAGCACTCAGAC
 TACGTGCACCTCTGCAGCAGGTGCAGGCCAGTTGT
 CACCCCTCCAGAACATCTCCCATGGATTCTGGCGG
 TATTGACTCTTCAGATTCAGAGGTAGGGATCATTCT
 GACTTATTAAGAGCTATATAACCAGTTAATTCAT
 CTGTTTGATGCTTGACATCCCTAAGTAGACAGATGA
 GGGTTGAAGTTAGTTTTTGGTGGGGTTGGAGGTGAA
 CATCAACTACCTTCTAGTTCCAGGTAATATAGAAC
 ATGGAGTGAAGTGTAGATAAATGGGCTGTTGGGTC
 CCGAGGTCATCTTATCACATAATGACTAATTTACAT
 TATGGAACCCAGTACAAAGTGTCCAGTTAGATTTT
 CCATTGTATTCTGACAGTTGTAATTTAATTTT
 TGCCTCTTACAGTCTGATATCCTGTTGGGCATTCTG
 GACAACTTGGACCCAGTCATGTTCTCAAATGCCT
 TCCCCAGAGCCTGCCAGCTGGAGGAGCTCCAGAG
 GTCTACCCAGAAGGACCCAGTTCTTACCAGCCTCC
 CTTTCTCTGTAGTGGGACGTCATCAGCCAAGCTG
 GAAGCCATTAATGAACTAATTCGTTTTGACCACATA
 TATACCAAGCCCTAGTCTTAGAGATACCCCTCTGAG
 ACAGAGAGCCAAGCTAATGTGGTAGTAAAAATCGAG
 GAAGCACCTCTCAGCCCTCAGAGAATGATCACCCCT
 GAATTCATTGTCTCAGTGAAGGAAGAACCTGTAGAA
 GATGACCTCGTCCGGAGCTGGGTATCTCAAATCTG

-continued

CTTTCATCCAGCCACTGCCCCAAGCCATCTTCCTGC
 CTTACTGGATGCTTACAGTGACTGTGGATACGGGGT
 TCCCTTTCCCATTCAGTGACATGTCTCTCTGCTT
 GGTGTAACCATTCTTGGGAGGACACTTTTGCCAAAT
 GAACTCTTTCCCCAGCTGATTAGTGTCTAAGGAATG
 ATCCAATACTGTTGCCCTTTTCTTGACTATTACAC
 TGCCTGGAGGATAGCAGAGAAGCCTGTCTGACTTC
 ATTCAAAAAGCCAAAATAGAGAGTATACAGTCCTAG
 AGAATTCCTCTATTGTTTCAGATCTCATAGATGACC
 CCCAGGTATTGTCTTTTGACATCCAGCAGTCCAAGG
 TATTGAGACATATTACTGGAAGTAAGAAATATTACT
 ATAATTGAGAACTACAGCTTTTAAGATGTACTTTT
 ATCTTAAAAGGGTGGTAGTTTTCCCTAAAATACTTA
 TTATGTAAGGGTCATTAGACAAATGTCTTGAAGTAG
 ACATGGAATTTATGAATGGTCTTTATCATTCTCT
 TCCCCCTTTTGGCATCCTGGCTTGCCTCCAGTTTT
 AGGTCTTTAGTTTGTCTGTAAGCAACGGGAACA
 CCTGCTGAGGGGCTCTTTCCCTCATGTATACTTCA
 AGTAAGATCAAGAATCTTTTGTGAAATATAGAAAT
 TTACTATGTAATGCTTGATGGAATTTTTCTCGCT
 AGTGTAGCTTCTGAAAGGTGCTTTCTCCATTTATTT
 AAAACTACCCATGCAATTAAGGTACAAATGCAGCA
 TCCTTGTGTTGATTTCTCTAGGGCCGTAAGTCTTGT
 TTTCTCTCCAGATGTTTATCTGTGTGCTGTGGTAGG
 AATTAATCCAAGTGAAGTGAAGCTAACGCTTTTTAA
 AGTGACTGAAGGCTTTTCCACCTAATTTACTGCCTG
 CTTTAATCTGACTGCCATAAGTGATATAAGCTAT
 AATTTGAGCAGTTACTGTCTTTCTGAGACAGATTTCT
 TGAGCCTAACTGACCAATATCACAGCTAGTAAGTGG
 AAGAGCTAGAACCCTAACCACTATTGCTACACCAT
 CTTATAAATGTTAAAACAAGGACACACCATCACATAT
 CGAGATCTCTTGCCCTTATTATGGGAATTAAGAGC
 ATTTTCTAGACTGAAACTCCCTATTTTCAACTCTGC
 CACTGGTAAGCTGGGTAACCCAGGGGTATATATAA
 TCACCTATTCTCTCATCTGTAAGTTGGATAATGGT
 ATCTCTAAAGGTTAAGATTCAAAGAGACGATGCATT
 ATAAGCATTTAGTATATGCTAGGCACCATCTTAAAC
 ACTGGAAAGTTAGTTAGTTATTATCTCCTAATCCAC
 TTTGGAAAGGTTTTAATCTCTCCAGAATATATTT

-continued

ACTCAAGAATTGTTCATCAAAGAATAAACCTCGG
 CCAGGCGCGGTGGCTCATGCCTGTAATCCCAGCACT
 TTGGGAGGCTGAGGCGGGTGGATCACGAGGTCAGGA
 GATCGAGACCATCCTGCCTAACATGGGGAAACCCCTG
 TCTCTACTAAAATTACAAAAAATTAGCCAGGCGTGG
 TGGTGGGCGCCTGTAATCCCAGCTACTTGGGAGGCT
 GAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGC
 TTGCGGTGAGGGGAGATCGCGCCACTGCACTCCAGC
 CTGGGCAACAGAGCGAGACTCTGTCTCAAAAAATAA
 AATAAATAAATAAATAAATAAATAAATAAACCTCTTC
 AAGAAAAATCCTAGTGATATTAATACAACCTCCCAA
 AGACTTGATAACCTCCTCATCCTTCATAGCATCTTT
 TCCTTGGAATCTTACAAGGTTTTACAGACTTTTAC
 TTATTTATAAAAATTCACCTATGCCAGTAGATGAA
 ATCATTCTATGCCAATTTAGCATTTAAATGCTATGT
 TCCCAACTTACAAAGACTAACTCTGGGAGGTCAA
 GTGAATGAGTAGAAAAAGGCAGGATTCAGAGAATC
 CCAAGCAGCAAGGCAAGTGGATTATAGAATACCTT
 TGGTGTAGGCCAGGTGTAGTGGCTCACGCTTGTAA
 CCCAACACTTTGGGAGGCTGAGGTGGGCGGATCAC
 TGAGGTCAGGAGTTCATGGCCAGCTGACCAACATA
 GTGAAACCCCTCTCTAGTAAAAATACAAAATTAGC
 TGGGTGTGGTGGCGCATATGCCTGTAATCCCAGCTA
 CTCAGGAGGCTGAGGCGGCAGAATCACTGAAACCG
 GGAGGCAGAGGATGCAGCGAGCCGAGATCGTGCCAT
 TGCACTCCAGCCTGGGCAACAAGAGCGAAATCCAT
 TTAATAAAGAAAAAATAAATAAATAAATAAATAA
 TAGTGACTGGAGGCAAGTCAGCTAGCTGCCTTCAAG
 ATCCGGTCTGTGAAGCCAGGGCCCAATCCTGGTGCT
 CAGCAATACAACCTTGCTTAGGCTCTTAAGTTTCTT
 CAGAAACAGGCCAGGCATGGTGGCTCACACCTATAA
 TCCCAGCACTTTGGGAGGCCGAGGCCAGCAGATTGC
 TTGGTTCAAGACTAGCTGGACAACATGGCAAACCC
 GTCTCTCCATGAAAAGTAAAAAATAAATAAATAA
 TGGTGGTGTGCACTGGTGGTCCAGCCACTCAGGAA
 GCTGAGGTGGGAGGATCGCTTGAGGCCAGGGGGCAG
 AGGTTGCAGTCAGCAAGATCGCAGCACTGCACTCC
 AGACTGGGTGAAAAAGCAAGACTGCCTAAAAAATAA
 AAGGTTCTGTATATAAG.

[0067] As used herein, FOXO1 refers to a forkhead box 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, FOXO1 refers to human FOXO1. An example of a human FOXO1 polypeptide includes, without limitation, NCBI reference sequence: NP_002006.2.

[0068] As used herein, ID2 refers to an inhibitor or DNA binding 2 polypeptide. When preparing a T cell or treating a mammal with a T cell, ID2 refers to human ID2. An example of a human ID2 polypeptide includes, without limitation, NCBI reference sequence: NP_002157.2.

[0069] As used herein, ID3 refers to an inhibitor or DNA binding 3 polypeptide. When preparing a T cell or treating a mammal with a T cell, ID3 refers to human ID3. An example of a human ID3 polypeptide includes, without limitation, NCBI reference sequence: NP_002158.3.

[0070] As used herein, IRF4 refers to an interferon regulatory factor 4 polypeptide. When preparing a T cell or treating a mammal with a T cell, IRF4 refers to human IRF4. An example of a human IRF4 polypeptide includes, without limitation, NCBI reference sequence: NP_001182215.1.

[0071] As used herein, LEF1 refers to a lymphoid enhancer binding factor 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, LEF1 refers to human LEF1. An example of a human LEF1 polypeptide includes, without limitation, NCBI reference sequence: NP_001124185.1.

[0072] As used herein, SATB1 refers to a SATB1 homeobox 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, SATB1 refers to human SATB1. An example of a human SATB1 polypeptide includes, without limitation, NCBI reference sequence: NP_001124482.1.

[0073] As used herein, RUNX1 refers to a RUNX family transcription factor 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, RUNX1 refers to human RUNX1. An example of a human RUNX1 polypeptide includes, without limitation, NCBI reference sequence: NP_001001890.1.

[0074] As used herein, BCL11b refers to a BAF chromatin remodeling complex subunit BCL11b polypeptide. When preparing a T cell or treating a mammal with a T cell, BCL11b refers to human BCL11b. An example of a human BCL11b polypeptide includes, without limitation, NCBI reference sequence: NP_001269166.1.

[0075] As used herein, FOXP1 refers to a forkhead box P1 polypeptide. When preparing a T cell or treating a mammal with a T cell, FOXP1 refers to human v. An example of a human FOXP1 polypeptide includes, without limitation, NCBI reference sequence: NP_001012523.1.

[0076] As used herein, FOXP4 refers to a forkhead box P4 polypeptide. When preparing a T cell or treating a mammal with a T cell, FOXP4 refers to human v. An example of a human FOXP4 polypeptide includes, without limitation, NCBI reference sequence: NP_001012426.1.

[0077] As used herein, BACH2 refers to a BTB domain and CNC homolog 2 polypeptide. When preparing a T cell or treating a mammal with a T cell, BACH2 refers to human BACH2. An example of a human BACH2 polypeptide includes, without limitation, NCBI reference sequence: NP_001164265.1.

[0078] As used herein, STAT3 refers to a signal transducer and activator of transcription 3 polypeptide. When preparing a T cell or treating a mammal with a T cell, STAT3 refers to

human STAT3. An example of a human STAT3 polypeptide includes, without limitation, NCBI reference sequence: NP_001356441.1.

[0079] As used herein XBP1 refers to an X-box binding protein 1 polypeptide. When preparing a T cell or treating a mammal with a T cell, XBP1 refers to human XBP1. An example of a human XBP1 polypeptide includes, without limitation, NCBI reference sequence: NP_005071.2.

Antigen-Binding Domains

[0080] As used herein, the term “antibody,” “antigen-binding domain,” or “antigen-binding fragment” refers to an intact immunoglobulin or to an antigen-binding portion thereof. In some embodiments, a binding agent refers to an intact immunoglobulin or to an antigen-binding portion thereof. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Examples of antigen-binding portions include Fab, Fab', F(ab')₂, Fv, domain antibodies (dAbs), and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies, triabodies, tetrabodies, and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen-binding to the polypeptide. As used herein, the term “scFv” antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Included in the definition are single domain antibody, including camelids. In some cases, the antibody is human or humanized.

[0081] In some embodiments, any of the “antigen-binding domains,” “antibodies,” “ligand binding domains,” or “binding agents” described herein can bind specifically to a target selected from the group of: CD16a, CD28, CD3 (e.g., one or more of CD3 α , CD3 β , CD3 δ , CD3 ϵ , and CD3 γ), CD33, CD20, CD19, CD22, CD123, IL-1R, IL-1, VEGF, IL-6R, IL-4, IL-10, LAG3, PDL-1, TIGIT, PD-1, TIM3, CTLA4, MICA, MICB, IL-6, IL-8, TNF α , CD26a, CD36, ULBP2, CD30, CD200, IGF-1R, MUC4AC, MUC5AC, Trop-2, CMET, EGFR, HER1, HER2, HER3, PSMA, CEA, B7H3, EPCAM, BCMA, P-cadherin, CEACAM5, a UL16-binding protein (e.g., ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6), HLA-DR, DLL4, TYRO3, AXL, MER, CD122, CD155, PDGFDD, a ligand of TGF- β receptor II (TGF- β RII), a ligand of TGF- β RIII, a ligand of DNAM1, a ligand of NKp46, a ligand of NKp44, a ligand of NKG2D, a ligand of NK30, a ligand for a scMHCI, a ligand for a scMHCII, a ligand for a scTCR, a receptor for IL-1, a receptor for IL-2, a receptor for IL-3, a receptor for IL-7, a receptor for IL-8, a receptor for IL-10, a receptor for IL-12, a receptor for IL-15, a receptor for IL-17, a receptor for IL-18, a receptor for IL-21, a receptor for PDGF-D, a receptor for stem cell factor (SCF), a receptor for stem cell-like tyrosine kinase 3 ligand (FLT3L), a receptor for MICA, a receptor for MICB, a receptor for a ULP16-binding protein, a receptor for CD155, a receptor for CD122, and a receptor for CD28.

[0082] In some embodiments, any of the “antigen-binding domains,” “antibodies,” “ligand binding domains,” or “binding agents” further include a secretion signal peptide. For example, a nucleic acid sequence encoding a binding agent further includes a nucleic acid sequence encoding a secretion signal peptide.

[0083] As used herein, ICAM-1 refers to intercellular adhesion molecule 1 polypeptide. When preparing the T cell or treating a mammal with the T cell, ICAM-1 refers to human ICAM-1. An example of a human ICAM-1 polypeptide includes, without limitation, NCBI reference sequence: NP_000192.2 or a fragment thereof.

[0084] As used herein, VCAM-1 refers to vascular cell adhesion molecule 1 polypeptide. When preparing the T cell or treating a mammal with the T cell, VCAM-1 refers to human VCAM-1. An example of a human VCAM-1 polypeptide includes, without limitation, NCBI reference sequence: NP_001069.1 or a fragment thereof.

[0085] As used herein, LFA-1 also known as ITGB2 refers to lymphocyte function associated antigen-1 (LFA-1) polypeptide or integrin subunit beta 2 (ITGB2) polypeptide. When preparing the T cell or treating a mammal with the T cell, LFA-1 or ITGB2 refers to human LFA-1 or ITGB2. An example of a human LFA-1 or ITGB2 polypeptide includes, without limitation, NCBI reference sequence: NP_000620.2 or a fragment thereof.

[0086] As used herein, TGFBR2 refers to transforming growth factor beta receptor 2. When preparing the T cell or treating a mammal with the T cell, TGFBR2 refers to human TGFBR2. An example of a human TGFBR2 polypeptide includes, without limitation, NCBI reference sequence: NP_001020018.1 or a fragment thereof.

[0087] As used herein, IFNAR1 refers to interferon (alpha and beta) receptor 1. When preparing the T cell or treating a mammal with the T cell, IFNAR1 refers to human IFNAR1. An example of a human IFNAR1 polypeptide includes, without limitation, NCBI reference sequence: NP_000620.2 or a fragment thereof.

Methods of Producing T Cells

[0088] As described herein, any appropriate method of producing cells (e.g., T cells) comprising a FOXP3 polypeptide and one or more transcription factors can be used to generate the T cells as described herein. In some embodiments, a cell (e.g., a T cell) that is transduced with the nucleic acid sequences described herein is isolated from a mammal (e.g., a human) using any appropriate method (e.g., magnetic activated sorting or flow cytometry-mediated sorting). In some cases, nucleic acid sequences encoding a FOXP3 polypeptide and one or more transcription factors can be transformed into a cell (e.g., a T cell) along with nucleic acid sequences encoding a therapeutic gene product and/or a binding agent. For example, a T cell can be made by transducing nucleic acid sequences encoding a FOXP3 polypeptide and one or more transcription factors into a cell (e.g., a T cell) using a lentivirus. In another example, a T cell can be made by transducing nucleic acid sequences encoding a FOXP3 polypeptide, one or more transcription factors, and a therapeutic gene product into a cell (e.g., a T cell) using a lentivirus. In yet another example, a T cell can be made by co-transducing nucleic acid sequences encoding a FOXP3 polypeptide, one or more transcription factors, a therapeutic gene product, and a binding agent into an immune cell (e.g., a T cell) using a lentivirus. In all cases described herein, the nucleic acid sequences are operably linked to a promoter or are operably linked to other nucleic acid sequences using a self-cleaving 2A polypeptide or IRES sequence.

[0089] Methods of introducing nucleic acids and expression vectors into a cell (e.g., a eukaryotic cell) are known in

the art. Non-limiting examples of methods that can be used to introduce a nucleic acid into a cell include lipofection, transfection, electroporation, microinjection, calcium phosphate transfection, dendrimer-based transfection, cationic polymer transfection, cell squeezing, sonoporation, optical transfection, impalefection, hydrodynamic delivery, magnetofection, viral transduction (e.g., adenoviral and lentiviral transduction), and nanoparticle transfection. As used herein, “transformed” and “transduced” are used interchangeably.

[0090] In some embodiments, the transformed cell can be an immune cell, an epithelial cell, an endothelial cell, or a stem cell. In some embodiments, the transformed cell is an immune cell selected from the group consisting of a T cell, a B cell, a natural killer (NK) cell, a dendritic cell, a macrophage, a regulatory T cell, a helper T cell and a cytotoxic T cell. In some examples, the immune cell is a NK cell, and the detection of a memory NK cell can include, for example, the detection of the level of one or more of IL-12, IL-18, IL-33, STAT4, Zbtb32, DNAM-1, BIM, Noxa, SOCS1, BNIP3, BNIP3L, interferon- γ , CXCL16, CXCR6, NKG2D, TRAIL, CD49, Ly49D, CD49b, and Ly79H. A description of NK memory cells and methods of detecting the same is described in O’Sullivan et al., *Immunity* 43:634-645, 2015. In some examples, the immune cell is a T cell, and the detection of memory T cells can include, e.g., the detection of the level of expression of one or more of CD45RO, CCR7, L-selectin (CD62L), CD44, CD45RA, integrin $\alpha\beta 7$, CD43, CD4, CD8, CD27, CD28, IL-7R α , CD95, IL-2R β , CXCR3, and LFA-1. Additional examples of T-cells that can be transduced are described herein.

Nucleic Acids/Vectors

[0091] Also provided herein are nucleic acid sequences that encode any of the polypeptides described herein. For example, nucleic acid sequences are included that encode for a FOXP3 polypeptide, one or more transcription factors, a therapeutic agent comprising a polypeptide, and a binding agent comprising a polypeptide. Also provided herein are vectors that include any of the nucleic acid sequences encoding any of the polypeptides described herein. For example, the polypeptides include, without limitation, a FOXP3 polypeptide, one or more transcription factors, a therapeutic agent comprising a polypeptide, and a binding agent comprising a polypeptide.

[0092] Any of the vectors described herein can be an expression vector. For example, an expression vector can include a promoter sequence operably linked to the sequence encoding any of the polypeptides as described herein. Non-limiting examples of vectors include plasmids, transposons, cosmids, and viral vectors (e.g., any adenoviral vectors (e.g., pSV or pCMV vectors), adeno-associated virus (AAV) vectors, lentivirus vectors, and retroviral vectors), and any Gateway® vectors. In some cases, a vector can include sufficient cis-acting elements that supplement expression where the remaining elements needed for expression can be supplied by the host mammalian cell or in an in vitro expression system. Skilled practitioners will be capable of selecting suitable vectors and mammalian cells for making any of the T cells as described herein. Any appropriate promoter (e.g., EF1 alpha) can be operably linked to any of the nucleic acid sequences described herein. Non-limiting examples of promoters to be used in any of the vectors or constructs described herein include EF1a, SFFV, PGK, CMV, CAG, UbC, MSCV, MND, EF1a hybrid, and/or CAG

hybrid. As used herein, the term “operably linked” is well known in the art and refers to genetic components that are combined such that they carry out their normal functions. For example, a nucleic acid sequence is operably linked to a promoter when its transcription is under the control of the promoter. In another example, a nucleic acid sequence can be operably linked to other nucleic acid sequence by a self-cleaving 2A polypeptide or an internal ribosome entry site (IRES). In such cases, the self-cleaving 2A polypeptide allows the second nucleic acid sequence to be under the control of the promoter operably linked to the first nucleic acid sequence. The nucleic acid sequences described herein can be operably linked to a promoter. In some cases, the nucleic acid sequences described herein can be operably linked to any other nucleic acid sequence described herein using a self-cleaving 2A polypeptide or IRES. In some cases, the nucleic acid sequences are all included on one vector and operably linked either to a promoter upstream of the nucleic acid sequences or operably linked to the other nucleic acid sequences through a self-cleaving 2A polypeptide or an IRES.

Compositions

[0093] Also provided herein are compositions (e.g., pharmaceutical compositions) that include at least one of any of the polypeptides (e.g., FOXP3 polypeptides, one or more transcription factors, therapeutic polypeptides, and binding agent polypeptides), any of the cells, or any of the nucleic acids or vectors described herein. In some embodiments, the compositions include at least one of the any of polypeptides (e.g., FOXP3 polypeptides, one or more transcription factors, therapeutic polypeptides, and binding agent polypeptides) described herein. In some embodiments, the compositions include any of the cells (e.g., any of the cells described herein including any of the cells produced using any of the methods described herein). In some embodiments, the pharmaceutical compositions are formulated for different routes of administration (e.g., intravenous, subcutaneous). In some embodiments, the pharmaceutical compositions can include a pharmaceutically acceptable carrier (e.g., phosphate buffered saline).

Cells

[0094] Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the nucleic acid sequences described herein that encode any of the polypeptides (e.g., FOXP3 polypeptides, one or more transcription factors, therapeutic polypeptides, and/or binding agent polypeptides) described herein. Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) that include any of the vectors described herein. In some embodiments, the cells are any of the exemplary types of T cells described herein or known in the art.

[0095] In some embodiments of any of the methods described herein, the cell can be a eukaryotic cell. As used herein, the term “eukaryotic cell” refers to a cell having a distinct, membrane-bound nucleus. Such cells may include, for example, mammalian (e.g., rodent, non-human primate, or human) cells. Non-limiting examples of mammalian cells include Chinese hamster ovary cells and human embryonic kidney cells (e.g., HEK293 cells).

Methods of Treatment

[0096] Also provided herein are methods of treating a mammal (e.g., a human) having an autoimmune disease that includes administering to the mammal (e.g., human) a therapeutically effective amount of a cell (e.g., any of the exemplary T cells described herein) or any of the compositions (e.g., pharmaceutical compositions) described herein.

[0097] In some embodiments, these methods can result in a reduction in the number, severity, or frequency of one or more symptoms of the autoimmune diseases in the mammal (e.g., as compared to the number, severity, or frequency of the one or more symptoms of the autoimmune disease in the mammal prior to treatment). For example, a mammal having an autoimmune disease having been administered a T cell as described here can experience a reduction in inflammation or autoantibody production.

[0098] Any appropriate method of administration can be used to administer the T cells to a mammal (e.g. a human) having an autoimmune disease. Examples of methods of administration include, without limitation, parenteral administration and intravenous injection.

[0099] A pharmaceutical composition containing the T cells and a pharmaceutically acceptable carrier or buffer can be administered to a mammal (e.g., a human) having an autoimmune disease. For example, a pharmaceutical composition (e.g., a T cell along with a pharmaceutically acceptable carrier) to be administered to a mammal having an autoimmune disease can be formulated in an injectable form (e.g., emulsion, solution and/or suspension). In some embodiments, a pharmaceutical composition containing the T cells can include phosphate buffered saline.

[0100] Pharmaceutically acceptable carriers, fillers, and vehicles that can be used in a pharmaceutical composition described herein can include, without limitation, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0101] Effective dosage can vary depending on the severity of the autoimmune disease, the route of administration, the age and general health condition of the subject, excipient usage, the possibility of co-usage with other therapeutic treatments, and the judgment of the treating physician. An effective amount of a T cell can be any amount that reduces inflammation and autoantibody production within a mammal having an autoimmune disease without producing significant toxicity to the mammal. For example, an effective amount of T cells administered to a mammal having an autoimmune disease can be from about 1×10^6 cells to about 1×10^{10} (e.g., from about 1×10^6 to about 1×10^9 , from about 1×10^6 to about 1×10^8 , from about 1×10^6 to about 1×10^7 , from about 1×10^7 to about 1×10^{10} , from about 1×10^7 to about 1×10^9 , from about 1×10^7 to about 1×10^8 , from about 1×10^8 to about 1×10^{10} , from about 1×10^8 to about 1×10^9 , or from about 1×10^9 to about 1×10^{10}) cells. In some cases, the T cells can be a purified population of immune cells generated as described herein. In some cases, the purity of the

population of T cells can be assessed using any appropriate method, including, without limitation, flow cytometry. In some cases, the population of T cells to be administered can include a range of purities from about 70% to about 100%, from about 70% to about 90%, from about 70% to about 80%, from about 80% to about 90%, from about 90% to about 100%, from about 80% to about 100%, from about 80% to about 90%, or from about 90% to 100%. In some cases, the dosage (e.g., number of T cells to be administered) can adjusted based on the level of purity of the T cells.

[0102] The frequency of administration of a T cell can be any frequency that reduces inflammation or autoantibody production within a mammal having an autoimmune disease without producing toxicity to the mammal. In some cases, the actual frequency of administration can vary depending on various factors including, without limitation, the effective amount, duration of treatment, use of multiple treatment agents, route of administration, and severity of the condition may require an increase or decrease in frequency of administration.

[0103] An effective duration for administering a composition containing a T cell can be any duration that reduces inflammation or autoantibody production within a mammal having an autoimmune disease without producing toxicity to the mammal. In some cases, the effective duration can vary from several days to several months. In general, the effective treatment duration for administering a composition containing a T cell to treat an autoimmune disease can range in duration from about one month to about five years (e.g., from about two months to about five years, from about three months to about five years, from about six months to about five years, from about eight months to about five years, from about one year to about five years, from about one month to about four years, from about one month to about three years, from about one month to about two years, from about six months to about four years, from about six months to about three years, or from about six months to about two years). In some cases, the effective treatment duration for administering a composition containing a T cell can be for the remainder of the life of the mammal.

[0104] In some cases, a course of treatment and/or the severity of one or more symptoms related to autoimmune disease can be monitored. Any appropriate method can be used to determine whether the autoimmune disease is being treated. For example, immunological techniques (e.g., ELISA) can be performed to determine if the level of autoantibodies present within a mammal being treated as described herein is reduced following the administration of the T cells. Remission and relapse of the disease can be monitored by testing for one or more markers of autoimmune disease.

[0105] Any appropriate autoimmune disease can be treated with a T cell as described herein. In some cases, an autoimmune disease caused by the accumulation of autoantibodies can be treated with a T cell as described herein. Examples of autoimmune diseases include, without limitation, lupus, rheumatoid arthritis, multiple sclerosis, insulin dependent diabetes mellitus, myasthenia gravis, Grave's disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, Crohn's disease, Celiac disease, and polyarteritis nodosa.

[0106] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1. T Cell Transduced with Nucleic Acid Sequences Encoding FOXP3 and BLIMP1

[0107] A set of experiments is performed to assess the effect of co-expression of a BLIMP1 polypeptide and a FOXP3 polypeptide. In these experiments, CD4⁺ T cells are transduced with a lentivirus where the lentiviral vector includes a first nucleic acid sequence encoding a FOXP3 polypeptide harboring mutations in NES1 and NES2 that result in nuclear localization of FOXP3 and a second nucleic acid sequence encoding BLIMP1 polypeptide. The vector includes an EF1 α promoter. Lentivirus is produced in HEK293 cells according to standard protocols.

[0108] CD4⁺ T cells are counted and checked for viability. Next cells are re-suspended in fresh serum free ImmunoCult T cell expansion media at a concentration of 10⁶ cells/mL.

Then 500 μ L (~500,000 cells) of the cell suspension is aliquoted to each well. The cells are then cultured in the presence of CD3/CD28 for 1-2 days prior to addition of virus. Different concentrations of lentiviral particles are added to each well for the desired target MOI. The plates are then sealed with parafilm, and the cells are spun in a table top centrifuge at 300xg for 5 minutes. After spinoculation, the cells are incubated at 37° C. The cells are then assessed for FOXP3 expression and cellular localization, BLIMP1 expression, and expression of a T reg phenotype.

Example 2

[0109] Table 1 (below) shows the percentage of Mean Fluorescence Intensity (MFI) as compared to donor-matched expanded Tregs.

[0110] Each column represents values for synReg transduced with FOXP3 alone or co-transduced with FOXP3 and the indicated modifier. Each row displays data for the specified marker. Values are displayed as mean of 3 donors \pm SD, * p<0.05, ** p<0.01 by paired t-test of co-transduced modifier versus FOXP3 alone.

TABLE 1

Percentage of Mean Fluorescence Intensity (MFI) as compared to donor-matched expanded Tregs.							
	FOXP3 only	FOXP3 and ID2	FOXP3 and ID3	FOXP and GATA1	FOXP3 and GATA3	FOXP3 and XBP1	FOXP3 and SATB1
CTLA4	119.6 \pm 24.5	248.3 \pm 100.8	226.1 \pm 58.5, *	207.5 \pm 48.0	167.5 \pm 19.5, *	121.5 \pm 22.4	129.2 \pm 31.7
CD25	206.9 \pm 130.8	322.0 \pm 202.6	274.7 \pm 166.8	293.8 \pm 142.8	230.2 \pm 115.1	281.3 \pm 147.9, *	257.1 \pm 168.0
ICOS	239.9 \pm 123.0	564.1 \pm 355.1	467.8 \pm 284.5	205.3 \pm 115.2	242.7 \pm 119.8	249.7 \pm 138.2	239.3 \pm 134.4
LAG3	168.28 \pm 78.8	318.6 \pm 146.7	256.0 \pm 102.5, *	254.7 \pm 38.5	207.9 \pm 62.5	200.0 \pm 84.8, *	191.4 \pm 77.7, **

Other Embodiments

[0111] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

SEQUENCE LISTING

```

Sequence total quantity: 14
SEQ ID NO: 1          moltype = DNA length = 2159
FEATURE               Location/Qualifiers
source                1..2159
                     mol_type = genomic DNA
                     organism = Homo sapiens

SEQUENCE: 1
agtttccac aagcaggct gatccttttc tgtcagtccea cttcaccacag cctgcccttg 60
gacaaggacc cgatgcccaa ccccaggcct ggcaagccct cggccccttc cttggccett 120
ggcccatccc caggagcctc gccagctgg agggctgcac ccaaagcctc agacctgctg 180
ggggcccggg gccaggggg aaccttcag ggcgagatc ttcgaggcgg ggccatgcc 240
tcctcttctt cettgaacct catgccacca tcgcagctgc agctctcaac ggtggatgcc 300
cacgcccgga ccctgtgct gcagggtgcac ccctggaga gccagccat gatcagcctc 360
acaccacca ccaccgccac tggggcttc tccctcaagg cccggcctgg cctcccacct 420
gggatcaacg tggccagcct ggaatgggtg tccagggagc cggcaactgct ctgcaccttc 480
ccaaatccca gtgcaccag gaaggacagc accctttcgg ctgtgcccca gagctcctac 540
ccaactgctg caaatgggtg ctgcaagtgg cccggatgtg agaaggtctt cgaagagcca 600
gaggacttcc tcaagcactg ccaggcggac catcttctgg atgagaaggg cagggcacia 660
tgtctcctcc agagagagat ggtacagtct ctggagcagc agctggtgct ggagaaggag 720
aagctgagtg ccatgcaggc ccacctggct gggaaaaatgg cactgaccaa ggcttcatct 780
gtggcatcat ccgacaaggg ctctgctgct atcgtagctg ctggcagcca aggcctctgc 840
gtcccagcct ggtctggccc ccgggaggcc cctgacagcc tgtttgctgt cggaggccac 900
    
```


-continued

```

ctgtggggta gccatggaaa cagcacattc ccagagttcc tccacaacat ggactacttc 960
aagttccaca acatgcgacc ccctttcacc tacgccacgc tcatccgctg ggccatcctg 1020
gaggctccag agaagcagcg gacactcaat gagatctacc actggttcac acgcatgttt 1080
gccttcttca gaaacctacc tgccacctgg aagaacgcca tccgccacaa cctgagtctg 1140
cacaagtgtc ttgtgcgggg ggagagcgag aagggggctg tgtggaccgt ggatgagctg 1200
gagttccgca agaaacggag ccagaggccc agcagggtgt ccaaccctac acctggcccc 1260
tgacctcaag atcaaggaaa ggaggatgga cgaacagggg ccaaactggt gggaggcaga 1320
gggtgtgggg gcagggatga taggcctctg atgtgccac agggaccaag aagtgaggtt 1380
tccactgtct tgccctgcag gccccctgtt cccccctggg cagccacccc ctccccatc 1440
atatcctttg ccccaaggct gctcagaggg gccccggtcc tggccccagc cccccctcc 1500
gccccagaca cacccccag tcgagccctg cagccaaaaca gagccttcac aaccagcccac 1560
acagagcctg cctcagctgc tcgcacagat tacttcaggg ctggaaaagt cacacagaca 1620
cacaaaatgt cacaatcctg tccctcactc aacacaaaacc ccaaaacaca gagagcctgc 1680
ctcagtacac tcaaacaccc tcaaaactgc atcatcacac aatcacacac aagcacagcc 1740
ctgacaaccc acacaccccc aggcacgcac ccacagccag cctcagggcc cacaggggca 1800
ctgtcaacac aaggggtgtg ccagaggcct acacagaagc agcgtcagta ccctcaggat 1860
ctgagggtccc aacacgtctc cgctcacaca cacggcctgt tagaattcac ctgtgtatct 1920
cacgcatatg cacacgcaca gccccccagt gggctctctg agtcccgtgc agacacacac 1980
agccacacac actgccttgc caaaaatacc ccgtgtctcc cctgccactc acctcactcc 2040
cattccctga gccctgatcc atgcctcagc ttagactgca gaggaactac tcattttatt 2100
gggatccaag gcccccaacc cacagtaccg tccccataaa actgcagccg agctcccca 2159

```

```

SEQ ID NO: 2          moltype = DNA length = 232
FEATURE              Location/Qualifiers
source                1..232
                     mol_type = genomic DNA
                     organism = Homo sapiens

```

```

SEQUENCE: 2
cctgcctctg gacaaggacc cgatgcccac ccccaggcct ggcaagcctc cggccccctc 60
cttggccctt ggcccatccc caggagcctc gccagctggg agggctgcac ccaaagcctc 120
agacctgctg tgggcccggg gccagggggg aaccttccag ggccgagatc ttcgaggcgg 180
ggcccatgcc tctctctctt ccttgaaccc catgccacca tcgcagctgc ag 232

```

```

SEQ ID NO: 3          moltype = DNA length = 81
FEATURE              Location/Qualifiers
source                1..81
                     mol_type = genomic DNA
                     organism = Homo sapiens

```

```

SEQUENCE: 3
ctgggtgctgg agaaggagaa gctgagtgcc atgcagggccc acctggctgg gaaaatggca 60
ctgaccaagg cttcatctgt g 81

```

```

SEQ ID NO: 4          moltype = AA length = 9
FEATURE              Location/Qualifiers
source                1..9
                     mol_type = protein
                     organism = Homo sapiens

```

```

SEQUENCE: 4
QLQLPTLPL 9

```

```

SEQ ID NO: 5          moltype = AA length = 10
FEATURE              Location/Qualifiers
source                1..10
                     mol_type = protein
                     organism = Homo sapiens

```

```

SEQUENCE: 5
VQSLEQLVL 10

```

```

SEQ ID NO: 6          moltype = AA length = 105
FEATURE              Location/Qualifiers
source                1..105
                     mol_type = protein
                     organism = Homo sapiens

```

```

SEQUENCE: 6
IEVMYPPPYL DNEKSNGTII HVK GKHLCP S PLFPGPSKPF WVLVVVGGVL ACYLLLVTV A 60
FIIFWVRSKR SRLLSDSYMN MTPRRPGPTR KHYQPYAPPR DFAAY 105

```

```

SEQ ID NO: 7          moltype = DNA length = 5148
FEATURE              Location/Qualifiers
source                1..5148
                     mol_type = genomic DNA
                     organism = Homo sapiens

```

```

SEQUENCE: 7
aacacagaca aagtgtctgcc gtgacactcg gccctccagt gttgcccaga ggcaagagca 60
gcgaccgagg cacctgtccg cccggagctg ggaacggggc gccggggcgg ccggacgaag 120
cgaggaggga ccgcccaggt gcgcgtctgt gcggctcagc ctggcggggg acgcccggag 180

```

-continued

aatgtggact	gggtagagat	gaacgagact	tttctcagat	gttggatatt	tgcttggaaa	240
aacgtgtggg	tacgaccttg	gctgccccca	agtgtaaactc	cagcaactg	aggtttcagg	300
gattggcaga	ggggaccaag	gggaccatga	aaatggacat	ggaggatg	gatatgactc	360
tgtggacaga	ggctgagttt	gaagagaagt	gtacatacat	tgtgaacgac	cacctctggg	420
attctgggtg	tgatggcggt	acttcgggtc	aggcgggagc	atccttacca	aggaatctgc	480
ttttcaagta	tgccaccaac	agtgaagagg	ttattggagt	gatgagtaaa	gaatacatac	540
caaagggcac	acgttttggg	ccctcaatag	gtgaaatcta	caccaatgac	acagttctca	600
agaacgccaa	caggaaaat	ttttggagga	tctatccag	aggggagctt	caccacttca	660
ttgacggctt	taatgaagag	aaaagcaact	ggatgocgta	tgtgaatcca	gcacactctc	720
cccgggagca	aaacctggct	gcgtgtcaga	acgggatgaa	catctacttc	tacaccatta	780
agcccatccc	tgccaaccag	gaactctctg	tgtggtatgt	tcgggacttt	gcagaaaggc	840
ttcactaccc	ttatcccggg	gagctgacaa	tgatgaatct	cacacaaca	cagagcagtc	900
taaagcaacc	gagcactgga	aaaaatgaac	tctgcccaca	gaatgtccca	aagagagagt	960
acaacgtgaa	agaaatccta	aaattggact	ccaacccctc	caaaggaag	gacctctacc	1020
gtttcaacat	ttcaccctc	acatcagaaa	aggacctcga	tgactttaga	agacgtggga	1080
gccccgaaat	gacctttctac	cctcgggtcg	tttaccctac	cggggccctc	ctgccagaag	1140
actttttgaa	agcttccctg	gcctacggga	tcgagagacc	cacgtacatc	actcctctcc	1200
ccattccatc	ctccaccact	ccaagcccct	ctgcaagaag	cagccccgac	caaagcctca	1260
agagctccag	ccctcacage	agccctggga	atacgggtgc	ccctgtgggc	cccggctctc	1320
aagagcaccg	ggactcctac	gcttacttga	acgctccta	cggcaccgaa	ggtttgggct	1380
cctaccctgg	ctacgcacc	ctgccccacc	tcccgccagc	tttcatcccc	tcgtacaacg	1440
ctcactaccc	caagtctctc	ctgccccctc	acggcatgaa	ttgtaatggc	ctgagcctg	1500
tgagcagcat	gaatggcctc	aaacaactttg	gctctctccc	gaggtgtg	cctgtctaca	1560
gcaatctctc	cggtgggggc	agcctgcccc	acccccatgt	caaccccact	tctctcccga	1620
gctcgtctgc	ctcagatgga	gccccgaggt	tgtctcagcc	ggagcatccc	agggaggtgc	1680
ttgtcccggc	gccccacagt	gccttctctc	ttaccggggc	cgccgccagc	atgaaaggaca	1740
aggcctgtag	ccccacaagc	gggtctccca	cggcgggaa	agccgccacg	gcagaacatg	1800
ttgtgcagcc	caaagctacc	tcagcagcga	tggcagcccc	cagcagccac	gaagcctatg	1860
atctcattaa	aaacaaaaga	aacatgaccg	gctacaagac	ccttcccctac	ccgtgaaga	1920
agcagaacgg	caagatcaag	tacgaatgca	acgtttgcgc	caagactttc	ggccagctct	1980
ccaatctgaa	ggtccactctg	agatgcca	gtggagaacg	gcctttcaaa	tgtcagactt	2040
gcaacaaggg	ctttactcag	ctcgccccacc	tcgagaaaaca	ctacctggt	cacacgggag	2100
aaaagccaca	tgaatgccag	gtctgcccaca	agagatttag	cagcaccagc	aatctcaaga	2160
cccacctgog	actcattttg	ggagagaaac	cataccaatg	caaggtgtgc	cctgccaaatg	2220
tcaccaggtt	tgtgcacctg	aaactgcaca	agcgtctgca	caccggggag	cggccccaca	2280
agtgctcccc	gtgcccacaa	aaactacatcc	atctctgtag	cctcaaggtt	cacctgaaag	2340
ggaaactgog	tgccggccccg	gcgcctggga	tgcccttggg	agatctgacc	cgaatcaatg	2400
aagaaatcga	gaagtttgac	atcagtgaca	atgctgaccg	gctcagggac	gtggaggatg	2460
acatcagtg	gatctctgta	gtggagaagg	aaattctggc	cgtggtcaga	aaagagaaa	2520
aagaaactgg	cctgaaagtg	tctttgcaaa	gaaacatggg	gaatggactc	ctctcctcag	2580
ggtgcagcct	ttatgagtca	tcagatctac	ccctcatgaa	gttgcctccc	agcaaccac	2640
tacctctggt	acctgtaaa	gtcaaacaa	aaacagtga	accaatggat	ccttaagatt	2700
ttcagaaaac	actcattttg	ttcttaagt	tatgacttgg	tgagtcaggg	tgccctgtagg	2760
aagtggcttg	tacataatcc	cagctctgca	aaactctctc	gacagcaaat	ggtttcccct	2820
cacctctgga	attaaagaag	gaactccaaa	gttactgaaa	tctcagggca	tgaacaaggc	2880
aaaggccata	tatatata	tatatata	tgtatacata	ttatatacat	ttatttacac	2940
ctgtgtctat	atatttgccc	ctgtgtat	tgaatatttg	tgtggacatg	tttgcatagc	3000
cttcccatta	ctaagactat	tacctagtca	taattatttt	ttcaatgata	atcctcata	3060
atttatata	caatttatca	ttcagaaagc	aaataataaa	aaagtttaca	atgactggaa	3120
agattccttg	taatttgagt	ataaatgtat	ttttgtcttg	tggccattct	ttgtagataa	3180
ttctgcaca	ctctgataag	tacctaaagt	ttagttaaac	aaatataatg	cttcagtcaa	3240
cctctctctc	taataatgg	ttgaaaatga	ggtttgggta	attgccaatg	tgggacagtt	3300
gatgtgttca	ttcctggggt	cctatcattt	gaacagcatt	gtacataact	tgggggatg	3360
tgtgcaggat	taccacaaga	taacttaagt	agaagaaa	agaaggggaa	tcttctat	3420
ttttgtgat	agttcatggt	ttccccccag	ccacaatttt	accgggaagg	tgacaggaag	3480
gctttaccaa	cctgtctctc	cctccaaaag	agcagaatcc	tcccaccgcc	ctgccctccc	3540
caccgagctc	gttggccatt	cagagcggcc	acatgacttt	tgcatccatt	gtattatcag	3600
aaaatgtgaa	gaagaaaaaa	atgccatggt	ttaaaaccac	tgcgaaaaat	tccccaaagc	3660
ataggtggct	ttgtgtgtgt	gcgatttggg	ggcttgagtc	tgggtgggtg	tttgtgtgtg	3720
gthtttgggt	cttttttttt	tttttttttt	ttaatgtcaa	aattgcacaa	acatggtgct	3780
ctaccaggaa	ggattcgagg	tagataggct	caggccacac	tttaaaaaaca	aacacacaaa	3840
caacaaaaaa	gggttattct	agtcactctg	gggtaaaagc	gggtaaatgaa	catctctatc	3900
cccaacacat	caattgtatt	ttttctgtaa	aaactcagatt	ttcctcagta	tttgtgtttt	3960
tacattttat	ggttaattta	atggaagatg	aaagggcatt	gcaaagtgtg	tcaacaacag	4020
ttacctcatt	gagtggtgct	agtagtgcag	gaaatgatgt	cctatcctaat	gatttctctc	4080
tctagaggag	aaaccgagta	aatgtgctcc	agcaagatag	actttgtgtt	attctatctt	4140
ttattctgct	aagccccaa	attacatggt	ggtgttcaaa	gtgtagcaaa	aaatgatgta	4200
tatttataaa	ctctatttata	ccactatata	atatgtatat	atatttataa	ccacttaaat	4260
tgtgagccaa	gccatgtaaa	agatctactt	tttctaaggg	caaaaaaaaa	aaaaaaaaaa	4320
aaagaaact	cctttctgag	actttgctta	atacttggtg	acctcacaat	cacgtcggta	4380
tgatgtggca	cccttgccca	ctgtaagaga	ccctaaaacc	ttggtgcagt	ggtggggacc	4440
acaaaacaac	cagggaggaa	gagatacatc	attttttagt	attaaggacc	atctaagaca	4500
gctctatttt	ttttttgcca	ctttatgatt	atgtgggtcac	acccaagtca	cagaaataaa	4560
aaactgactt	taccgctgca	atttttctgt	tttctctctt	actaaatact	gatacattac	4620
tccaatctat	tttataatta	tatttgacat	ttgtttcaca	tcaactaatg	ttcaactgta	4680
gaagagaaca	aatttcgaat	aatccaggga	aacccaagag	ccttactggt	cttctgtaac	4740

-continued

```

ttccaagact gacagctttt tatgtatcag tgtttgataa acacagtcct taactgaag 4800
taaaccaaag catcacgttg acattagacc aaatactttt gattoccaac tactcgtttg 4860
ttctttttct cctttttgtgc tttcccatag tgagaatttt tataaagact tcttgcttct 4920
ctcaccatcc atccttctct tttctgctc ttacatgtga atgttgagcc cacaatcaac 4980
agtggtttta ttttttctc tactcaaaagt taaaactgac caaagttact ggctttttac 5040
tttgctagaa caacaaacta tcttatgttt acatactggt ttacaatggt atttatgtgc 5100
aatgtgcaa aatgtaaat aaatataaat gtccatgctt taccaaaa 5148
    
```

```

SEQ ID NO: 8          moltype = DNA length = 5382
FEATURE              Location/Qualifiers
source                1..5382
                     mol_type = genomic DNA
                     organism = Homo sapiens
    
```

```

SEQUENCE: 8
cccttctcag gtgaagctgc tgatggagat ggagccgcgc ccaccgcgcg ctctgagcgc 60
cgggtcctg gctccggccc ggcgactgcc gccgcctcag tgaccccact cccccgcac 120
tgggccgccc gggccagagt gggggacccc cgcccctcgc cctccctctc ccccaact 180
gtcccctctc cccaacccct cacagcctgc gcgcgcgcgg agacacctca gtctacatgg 240
ggaggacaga gaagcgcaaa gaacaagaga aaagatgcat ccactctgaga tctaaaagga 300
gacaatgaga atctctttaa aatggacata gaagactgca atggccgctc ctatgtgtct 360
gtaggaccaa tgaaggaatt attggcatgc actaaaggag atagcaagat gggtcagaca 420
cacatgatgag agtcatggc aacaccgggg taatgtaagg aatccacgct tctggaagg 480
tgagtggctg ggtcaccccc tgectgccac tgagacgcag acatgcatac accaccgcga 540
ctcccctgcc gtttccaagg cggcggccgc gttcgcaccc cagggtctca cgggcaagg 600
aaggataatc tggagagggg tcctcagga ggggtgtgtc cggatttctt gcctcaggcc 660
caagactcca accattttat aatggaatct ttattttgtg aaagttagcg ggactcatct 720
ctggagaagg agtccctcgg gcccccagtg gggccctcgg tgagcacccc caacagccag 780
cactcttctc ctgaccgctc aactcagtgcc aactccatca aggtggagat gtacagcagat 840
gaggagtcaa gcagactgct ggggccagat gageggctcc tggaaaagga cgacagcgtg 900
atttggaag attcatgtct tgagcccctg ggctactgtg atgggagtg gccagagcct 960
cactcccctg ggggcattcc gctgcccaat ggcaagctca agtctgacgt ctgcccagtg 1020
gtctgtattg gacccaactg gctcatggtg cacaaagcga gtcacactgg tgaaggccc 1080
ttccattgca accagtgtag tgccctcttc acccagaagg ggaacctgct ggcaccatc 1140
aagctgcact ctggggagaa ccctttaa tgctcctctc gcaactatgc ctgcccgcgg 1200
cgtgatgcac tcaactgtca cctccgcaca cactcagctc cctctcccac agtgggcaag 1260
ccctacaagt gtaactactg tggccggagc tacaacacgc agagtacctt ggaggagcac 1320
aaggagcggg gccataacta cctcacagat ctacagcactg aagcccaagc tttggctggc 1380
caaccaggtg ccgaataacg tgacctggag atgggtgccag actccatgct gcactcatcc 1440
tctgagcggc caacttctat cgatcgtctg gccaatagcc tcacaaaacg caagcgttcc 1500
acaccaccga aattttagg cgaaaagcag atgcccctca gccctccaga cctcccctat 1560
gatgtgaact cgggttgctg tgaaaaggat gtggagttag tggcacacca cagcctagag 1620
cctggctttg gaagttccct gccctttgtg ggtgcagagc atctgcgtcc cctccgctt 1680
ccaccaccga atggcatctc agaactccag cctgtcatca gctctgtcta caccagatg 1740
cagcccctcc ctggtcgact ggagcttcca ggatcccag aagcaggtga gggacctgag 1800
gacctggctg atggaggtcc cctcctctac cggcccgcag gcccccctgac tgacctggg 1860
gcatccccca gcaatggctc ccaggactcc acagacacag aaagcaacca cgaatgctgg 1920
gttgccgggg ggttatccct cctcagggtt cccccacccc agccacctcc caccattgtg 1980
gtggccgggc acagtctgc ctacgcccga gaggacccca agccacagga ggggttattg 2040
cggggcacc caggccctc caaggaagtg cttcgggtgg tggcgagag tggtgagcct 2100
gtgaaggcct tcaagtgtga gcactgccgt atcctcttcc tggaccactg catgttcact 2160
atccacatgg gctgccatgg cttcagagac cctttttagt gcaacatctg tggttatcac 2220
agccaggacc ggtacgaatt ctcttcccac atgttccggg gggagcataa ggtgggctag 2280
caacctctcc ctctctctc agtccaccac tccactgccc tgactacagg cattgatccc 2340
tgtccccacc atttcccagg gagttttgct ttgtagccct cactactggc cacctgacct 2400
cacacctgac cctgaccctt cctcacctat tctcttctc tatcctgacc gatgtaagca 2460
ttgtgatgaa acagatcttt tgcttatggt tttccttttt atcttctctc atcccagcat 2520
actgagttat ttattaatta gttgatttat ttttgccctt ttaaatttta acttatatca 2580
gtcacttgcc actccccac cctcctgtcc acaactcctt tccacttag gccaattttt 2640
ctctcttaga tcttccagca gccccagggg taggaagctc ctcttagtac taagagactt 2700
caagctctct gctttaaagtc ctcacccttt acattatcta attctcagt tttgatgctg 2760
atactgccc ccggccctac cttagctctg tggcattata tctcctctct gggacctctc 2820
aacctggtac tccatacctc ttgtgcccct tcaacttagg cagcttgacc tattctttaa 2880
tgaatgaaga attatttctc catttggaag taggagggac tgaagaatct cccccaggc 2940
actgtgggac tgagagctct attcccctag taataggctc tatcccctca gtaatatgag 3000
ttctcaagc ctacattcag gatctccctc taggatgtga tagatcgggt cctctcctt 3060
gaactacccc tccacacgct ctagtccctt caacctaccg gtctattaa ggtggcctt 3120
tctctcctg gagtgcccca attttatatt ctcagggccc aaggctaggt ctgcaacct 3180
ctgtctctga cagattggga gccacagggt cctaattggg aaccagggca tgggaaagga 3240
gtgggtcaaa attcttctct ttctctctca cctctcaaac ttcttcaact tagtgacctt 3300
cctaggtcct caggggctcc ttcagtcccc atcctatgag aaactagtgg gttgctgcct 3360
gatgacaagg ggtgtttcca gcccctagct catgctgcct tctgtgctc cctcccagca 3420
ggattcaccc tctcattccc gggctcctgg gccctgttct taggateagt ggcagggaga 3480
aacgggtatc tcttttctct cttctaattt tcagataaac caaaaattat cccagcatga 3540
gcacgggac gtgcccttca ccccatcca ccttgttccc agcaagactg ggatgggtac 3600
aactgaactg gggctctctc ttactacccc cttctacact cagctcccag acacagggt 3660
ggagggggga ctgctggcta ctgcagagac ccttggtctt ttgagtaacc taggattagt 3720
    
```

-continued

```

gagaaggggc agaaggagat acaactccac tgcaagtgga ggtttcttc tacaagagt 3780
ttctgcccac ggccacagcc atcccactct ctgcttcctt gagattcaaa ccaaaggctg 3840
ttttttotatg tttaaagaaa aaaaaaagta aaaaaccaac acaacacctc acaagttgta 3900
actcttggtc cttctctctc tccctttctc ttcccttctt tccccttcca tctttctttc 3960
cacatgtcct ttccttattg gctcctttac ctcctacttt tctcaactcc tatcagggat 4020
atthttggggg gggatggtaa aggggtggct aaggaacaga ccctgggatt agggccttaa 4080
gggctctgag aggagtctac ctgctctctc tatgggaagg gagaccctaa aaaactttct 4140
cctctttgtc ctcctttttc tccccactc tgaggtttcc ccaagagAAC cagattggca 4200
gggagaagca ttgtggggca attgttctct cttgacaatg tagcaataaa tagatgctgc 4260
caagggcaga aaatggggag gttagctcag agcagagtag tctctagaga aaggaagaat 4320
cctcaacggc accctggggg gctagctcct ttttagaatg tcagcagagc tgagattaat 4380
atctgggctt ttcctgaact attctgggta ttgagccctt cctgttagac ctaccgctc 4440
ccactctctc tgtgtctgct gtgtatttgg tgacacttca taaggactag tccctctctg 4500
ggatcagag ccttaggggt cccccatccc cttcccagc caactgtggc acctgtaacc 4560
tcccggaaaca tgaaggacta tgctctgagg ctataactctg tgcccatgag agcagagact 4620
ggaagggcaa gaccaggtgc taaggagggg agagggggca tcctgtctct ctccagacca 4680
tcaactgcact ttaaccaggg tcttaggtac aaaatcctac ttttcagagc cttccagctc 4740
tggaacctca aacatcctca tgctctctcc cagctccttt tgcaataaaa aaaaagtaaa 4800
gaaaaagaaa aaaaaataca cacacactga aaccacatg gagaaaaagag gtgtttctct 4860
ttatattgct attcaaaatc aataccacca acaaaatatt tctaaagtag cacttttcca 4920
gacctttgtt tttttgtgtc agtgtccaag ctgcagatag gattttgtaa tacttctggc 4980
agcttctctc cttgtgtaca taatatatat atatatatat ttttaacag 5040
aagttatgaa gaacaaaaag aaaaaataaa cacagaagca agtgcaatac cacctctctt 5100
ctccctctct cctagggttt cctttgtagc ctatgtttgg tgctctcttt gacctttacc 5160
ccttcactc cctctctctt ctctctgatt cctccccc cttttttaa gagttttct 5220
cctttctcaa ggggagttaa actagctttt gagacttatt gcaaagcatt ttgtatatgt 5280
aatatattgt aagtaaatat ttgtgtaacg gagatatact actgtaagtt ttgtactgta 5340
ctggctgaaa gtctgttata aataaacatg agtaatttaa ca 5382

```

```

SEQ ID NO: 9          moltype = DNA length = 1464
FEATURE              Location/Qualifiers
source                1..1464
                     mol_type = genomic DNA
                     organism = Homo sapiens

```

```

SEQUENCE: 9
acactgagct tgccacatcc ccaaggcggc cgaaccctcc gcaaccacca gccaggtta 60
atcccagag gctccatgga gttccctggc ctggggctcc tggggacctc agagccctc 120
ccccagtttg ttgatcctgc tttgggtgcc tccacaccag aatcaggggt tttctctccc 180
tctgggctg agggcttgga tgacagcagc tctccactgc ccccgagcac agccaccgct 240
gcagctgcgg cactggccta ctacagggac gctgaggcct acagacactc cccagcttt 300
caggtgtacc cattgtctca ctgtatggag gggatcccag ggggctcacc atatgccggc 360
tgggcctacg gcaagacggg gctctaccct gcctcaactg tgtgtcccac ccgagaggac 420
tctctcccc aggccgtgga agatctggat ggaaaaggca gcaaccagctt cctggagact 480
ttgaagacag agcggctgag cccagacctc ctgaccctgg gacctgact gccttcatca 540
ctccctgtcc ccaatagtgc ttatgggggc cctgactttt ccagtaacctt cttttctccc 600
accgggagcc cctcaattc agcagcctat tctctctcca agcttctgtg aactctcccc 660
ctgctcctct gtgaggccag ggagtgtgtg aactgaggag caacagccac tccactgtgg 720
cggagggaca ggaacagcca ctacctatgc aacgcctcgc gcctctatca caagatgaat 780
gggcagaaaca gcccctctat cggccccaag aagcgcctga ttgtcagtaa acgggcaggt 840
actcagtcca ccaactgcca gacgaccacc acgacactgt ggccggagaa tgccagtggt 900
gatcccctgt gcaatgcctg cggcctctac tacaagctac accaggtgaa ccggccactg 960
acctatggga aggatggtat tcagactcga aaccgcaagg catctggaaa agggaaagag 1020
aaacggggct ccagtctggg aggcacagga gcagccgaag gaccagctgg tggctttatg 1080
gtggtggctg ggggcagcgg tagcgggaat tgtggggagg tggctcagg cctgacactg 1140
ggccccccag gtaactgccc tctctaccaa ggccctggcc ctgtggctgt gtcagggcct 1200
gttagccacc tcatgctctt ccttgacc cttactgggt caccacagg ctcctctccc 1260
acaggcccca tgccccccac caccagcact actgtggtgg ctccgctcag ctcatgaggg 1320
cacagagcat ggcctccaga ggaggggtgt tgtcctctc cttttgtagc cagaattctg 1380
gacaacccea gtctctgggc cccaggcacc ccttggtctg aaccttcaaa gcttttgtaa 1440
aataaaacca ccaaagctct gaaa 1464

```

```

SEQ ID NO: 10         moltype = DNA length = 9484
FEATURE              Location/Qualifiers
source                1..9484
                     mol_type = genomic DNA
                     organism = Homo sapiens

```

```

SEQUENCE: 10
gctaaccctg ctctctctct aagatggagg aagtaaaac aggattacc ttagctacag 60
atccactgcc ttagtttcca ccaccaactg cagtgcacaa acacacgtta ggcacaggaa 120
agaaagaaa acagaggaca cattaacagt aaacacaaac aaaaggggtg tgggattatt 180
ttactgcatg cactgctgag cccgacattg tcacctctct tttgaggggt tagaagaagc 240
tgagatctcc cgacagagct ggaatgggtg atgaatcttt tttaatcaaa ggacaatttc 300
ttttcattgc actttgacta tggaaacaga ggctattgat ggctatataa cgtgtgacaa 360
tgagctttca cccgaaaggg agcactccaa tatggcaatt gacctcacct caagcacacc 420
caatggacag caatgctcac caagtccat gacaagcaca aatcagtaa agctagaagt 480
gcagagtgat gaagagtgtg acaggaacc cctgagccgt gaagatgaga tcaggggcca 540

```

-continued

tgatgagggt	agcagcctag	aagaaccct	aattgagagc	agcgaggtgg	ctgacaacag	600
gaaagtcag	gagcttcaag	gcgagggagg	aatccggctt	ccgaatggtg	aacgcccctt	660
ccactgtaac	cagtgtggag	cttcttttac	tcagaagggc	aaccttctga	gacacataaa	720
gttacactct	ggagagaagc	cgctcaaatg	tccttctgt	agctacgect	gtagaagaag	780
ggagcccctc	acaggaaacc	tcaggacca	ttctgtgggt	aaacctcaca	agtgcacta	840
ctgtggacga	agctacaagc	agcgcagttc	actggaggag	cacaaggaac	gctgccacaa	900
ctatctccag	aatgtcagca	tggaggctgc	tgggcaggtc	atgagtcacc	atgtacctcc	960
tatggaagat	tgt aaggaac	aagagcctat	tatggacaac	aatatttctc	tggtgccttt	1020
tgagagacct	gctgtcatag	agaagctcac	ggggaatatg	ggaaaacgta	aaagctccac	1080
tccacaaaag	tttgtggggg	aaaagctcat	gcgatcagc	taccagata	ttcactttga	1140
tatgaactta	acatatgaga	aggaggctga	gctgatgcag	tctcatatga	tggaccaagc	1200
catcaacaat	gcaatcacct	acctgggagc	tgaggccctt	cacctctga	tgagcacc	1260
gccaagcaca	atcgctgaag	tgcccagct	tataagctca	gcttattctc	aggctctatca	1320
tccaatagg	atgaaaagac	ccattagcag	ggaaactgct	gatagtcag	aaaaacaacat	1380
ggatggcccc	atctctctca	tcagaccaaa	gagtcgaccc	caggaaaagag	aggcctctcc	1440
cagcaatagc	tccctggatt	ccactgactc	agaaagcagc	catgatgacc	accagtccta	1500
ccaaggacac	ctgcctttaa	atcccaagag	gaaacaaaagc	ccagcttaca	tgaaggagga	1560
tgtcaaaagc	ttggatacta	ccaaggctcc	taagggtctc	ctgaaggaca	tctacaaggt	1620
cttcaatgga	gaaggagaac	agattagggc	cttcaagtgt	gagcactgcc	gagtcctttt	1680
cctagaccat	gtcatgtaca	ccattcacat	gggttggcat	ggctaccggg	accacttga	1740
atgcaacatc	tgtggctaca	gaagccagga	ccgttatgag	ttttcatcac	acattgttcg	1800
aggggagcag	acattccact	aggccttttc	attccaaaag	ggacccttat	gaagtaaaga	1860
actgcacatg	aagaataact	gcacttacia	tcccaccttt	cctcaaatgt	tgacatacct	1920
tttatttttt	ttaatatatt	tactgttgat	aattcttatt	ttgtggaggc	agtgtcattt	1980
gctctgccta	attacgataa	ggaagaaaac	gaagagagaa	ggggcgggaa	tattgtttct	2040
ttatcacctg	gcttgtttat	tttgtgggaa	tttaagagca	gtccatttct	accaaggcat	2100
atcatgcttt	gaaaaatcac	ttgatccta	aagattcacc	taagagattc	tgatttgcca	2160
ctgatattca	gaattatgat	ggaagacag	aaagttcaga	gttttctggg	taggactttg	2220
gtggtttaaa	aaatggtata	gtaactttat	tcttgaaga	agaatgtgt	tcaaacgtga	2280
aaccaatttt	ttgttcttca	gagatcatgg	aacacaaaac	catgttatt	ttcagtgata	2340
actcctaaga	ggagctgagt	gttgtgggt	tctatgttta	cttcccctat	ggaattata	2400
attcagtatg	ttttacactg	taccatatag	caaaactttt	aaactacagg	tagttaaggg	2460
ccacctacaa	tacatctgag	gtcctgtgat	cttatttttc	taaacgt aag	cactgttttt	2520
ccatagtttt	gatgactggc	attttataga	cacctggcca	gccttacttt	taacaccttt	2580
aaggaaatag	atttttatgt	agttttcaga	ataacataatg	gtctaagagt	ggataaaaag	2640
cagtcaataa	tttctgggag	ggactctcac	tttcataaat	ttgtttgaga	ggttttcttt	2700
taaaagtgtg	atgtgatggc	agcatagtat	atgtatttgt	ttctaaaagt	atgcttacga	2760
ttgtcacttt	atcagcattt	aatcagtggt	aaccagtcag	cagaaaaata	taattatgct	2820
aacagttagg	ggagaaaaac	cacttagaaa	tccctttctc	ggtatctctc	ttttcactag	2880
tttttttcaa	gtgtgacct	cccgggtgtc	tgctcatagt	tcattcctcc	tttactctc	2940
gagtagaagg	tcttaaaagt	cttctgtctg	gctgtttctt	tcaaaatctc	ctcagagcaa	3000
ttgtcaattt	ggcctgaatc	tggttaactg	aaccctgtaa	ggttacagaa	ctagggctat	3060
ttattttagc	atctctcag	tagtattttac	tactcttgtt	gcaaaagaaa	gggaatggga	3120
cttctttgta	acctgtacct	tggacaacag	ataaaagaaa	caaaaaata	agaaagttta	3180
cttttacctt	tcttggagtc	tagaatgtga	cagaaccccc	aaaggaaaag	cctgcacatt	3240
ttctgttttc	caaaacattt	aattgtgtaa	gtccttgtca	gaaatgaatc	tcaacctctt	3300
agtatagaat	tccccttaca	tggtataggt	tgccatattt	catgtgcaga	ttttaatttc	3360
atttatgtgg	gctctctgtt	ttttctttgc	agtcacagca	cattagaggg	gaggaaaccga	3420
gtgatattga	ttcaagtcct	tttaggggga	catacttgga	aggcagaact	tgctgtctct	3480
gtttggggag	gacagacctg	actgtgactg	gattatctga	taaccatttg	tgaactactga	3540
aattctgtta	ggcagtaact	gataactgct	ctaaaggatc	attaatagg	atgctgaaat	3600
tatgtatctt	aatacagtg	ggtatgagaa	ttaccaagtc	aagagaattg	tggacataag	3660
caagtttggc	cccactactg	ctcttaactc	attttccagc	ttactatttg	ctatttaaat	3720
ggtaggcacc	agctaaagcac	ttctaagcac	taacacagct	agaactaggc	aaaaatgggt	3780
agaaactcagc	tctcttctac	tagtccctgt	cataattatt	ttgggaaaa	gtccaaact	3840
gcccccttta	aatctaaggg	aatgcaccaa	aacagagata	tatagaatgt	caaccatttc	3900
attttttttt	ttctgcatgc	cttggtacat	agtgaaacata	caacctattt	aaagataaag	3960
catgtttttg	agactctctc	accctccccc	accacaccac	tcccaataaa	taattgggat	4020
gccatttttt	ttctttttgg	atgaggtaaa	taattttaag	gttcacaatt	ttgtctttta	4080
ctgcaattta	aggaacacatt	tggtatgtcag	tcaatattgt	cataattttg	gctgtgtgctg	4140
aaattctgtct	ggcattatct	atgaattttc	ttcctactta	tttttttttc	agtatatgaa	4200
caatcatgta	tctacctgcc	ccaggatgaa	actaaattta	gggtggacct	aaaccttatg	4260
aagacagtcg	tgaggcactt	tcctttttctg	atttcatctt	tttgggaaac	tgttttattg	4320
aaggtagtta	gtagtgtgaa	gtgcatttgc	tacaagcata	tacttgtatc	ttcctagctt	4380
catgaggaac	agaaagaggt	ggatattggc	caggggtgtg	caggggacaat	tgaggacaaa	4440
gtcaattcaa	atgtgtgggt	cagaaagaat	ttttgtggac	gtagtgtttt	tggagaaact	4500
ctggatgggt	atatgtgcat	gccttttctt	caaaaggaaa	tacgcaaggt	tgtagcatct	4560
aaaaataaac	ataagagtc	gacaccaaat	aaatcaagtt	ttacataaca	gttgatgccc	4620
cagttttgtt	aggtgagatt	tcacattaca	gaaagtattt	gaggagcatg	aaaaatgggt	4680
atctctctgta	ttttccagtt	tggcaaaaag	tcagaatttc	atcacattgc	tttgccctaa	4740
ttttgcccag	aatttttact	tagcctctct	ctgacagtga	tgaatcatgc	tcaaaagcca	4800
ttctaaatgg	acctttttta	gacagggaaa	gggatcagta	ggcggatttg	aagaaatttc	4860
aagtcatgta	aatattccat	tgagatttcc	taaagggaca	aaatgggaa	aatagaaac	4920
tacgacttag	atttggctac	gtagttagaaa	gtatctcccc	tacatacata	caggcaattg	4980
tatgtatgaa	tcattagggta	catagtgtg	tatactacac	acacattctt	ttaagagaaa	5040
ttcatgaaaa	aaaaagcag	tggagtgtc	agatgtattg	caaaacata	cagagaattt	5100

-continued

```

aatgacagt taatccaag aaattagttg ggtttacttt atcaggtcgt aataggaatc 5160
actaaagaag ttactagtgt gtctttagga ccagtggaac ctcttaactc aaaactttgg 5220
gtccttatta tctacttaca gaacaaagtg aaacaaacaa tgattaaagt gatttgat 5280
acattcaaag atatttaag taaagttttt tggaaacga agaaaattca gaaaataaat 5340
attatcaaca gttacttatt ggcaaataga gaaagacaag aatagtttag tgagccgggt 5400
atthttgttt tatagttttt atctcagttg tacaactcac aaaacctga agtctttggt 5460
atthtataaa tgtttaacaa aatttacatc agattaaggc atttagatga aaattattat 5520
gtttccacta tcttccaaat tttatttcac cctatctcca aaatgatttc ttagggtaca 5580
aaaagagcag acggggcgtg aaaaatatac gcaaaaaact gtgtgcccc agtcttcaggc 5640
agaacttaaa ctgtcagagg tactagctac atgatttggg ttttaacttt ggattgttca 5700
cgtccaaaaa tccagtttct acatttgggt ttatcatcag ttgcatttta tgtattattt 5760
taataaatac tatctgaatg aagactattc taaccagaaa aatccccaa atccaaaaga 5820
aaaaaaaagt ggggaagagg gaaattgaag tttgtgtata tgaaagtat cttagacata 5880
tttttaatct tccagtttct gcaaaaataa taaaatatac agtaactggg ctctcaaatc 5940
ctgaatttaa tgtattaaat acttatgttc tttatattgg tgctttttta aaatgcattg 6000
agagtgttgg ttagctgttg cacgtgtaca acacttttaa tatgcatttt taaaaatcac 6060
ttaaattga gtaactatata attcatctct gcatttttag tgcaaatctt tagagcaatt 6120
tctaatagag aaattttcag ctccagctgtt aaaaggaaaa ggaaactttg aaactagact 6180
ttactacctt tttagtttca tagtattttc gaatatgatt acaagattat gcaggtaaaa 6240
tatagagtga aactttacct gtgaattgaa ttataatttg tgtttttggt ttgtttttaa 6300
ggagaataaa gttctgtatc aaacaagaat ttattagata atthtttggg caataaaata 6360
cagtatctat ttggattttc atctccagac tagtattggt ctagtcttgg aatctgtatt 6420
ttctaatctg ttgaaaaata gagattgaaa attgatggaa taatgtgaaa aagcaggtaa 6480
ttaattctcc ttgaaacaaag caaaactgaa cagtcataac acattgctat tctccaaagc 6540
ataactctca atggtttctat atcatgggtg tgtattactt gcaatgggtg tgttaggata 6600
tgacagcttt ttaaaaaaat gagctgctgg ttatacaaaag caaatggcat atgaccaaga 6660
agctgtgata tgctagttgt tctttttatc atagtgtatt actaggccaa ataatgacac 6720
cttgaatatt tttacattta ttgcagaaac cttaaacctt ggaatttcca taaggttttt 6780
atgtaaatatt ctattttctag ctttttagtt ttatcttctg gtaactgtaag tttgaggata 6840
tttttcacct gcaactctag gaataagttc ataattctgt ttatggggct ttctcccat 6900
aacactgcac ttgtatattt ctgtataaaa atatgtgttg tgtattaacc tttatcccat 6960
acagagagtg gtacatgaat gactagtttt ctaagatgtc ctttttattg tgaataaaat 7020
ataaaagtta aaggccctct gctaagtcac ataaagtaca gcatataagt tcatatagtt 7080
acaaataaat gagttttcag tcttggggc cttcaaaata cctcaagtga cagatagtaa 7140
gaaaagcttc ttgagcaggt ggaggtcact gaaatccccta ctatgcactt accaagattt 7200
tacttacttt aatttactgg aaattgattt ttaaaaaaat gactacactg taacaaggga 7260
agggatctgg gtttttttgg tgttttattc ttgttttttt taagtgttcc aaattctgaa 7320
actgtgattt aaaaaatttt tccagtcacg cattctgatt ttgaaacata ctcccttccc 7380
ttctgtgata acaaaagttc ctctgtttat ccttaaaatt tgttacctct cctcagcct 7440
ctttctttgt ccgctctccc tctgtcattg tctatggatg tttacctctc tgttctccta 7500
aaagtttgaa gattaggtca actcttattt ctagtctcatt ggtaatttaa tcttaatttt 7560
ttttctgta tttttgttgg ttgtataatc tgcctgacgta ttttttactc caagtgtagt 7620
ttctatttaa aaagaaaagt ggttggatta aaaatagtaa gctatgtaac cctcatgta 7680
ctttcacttt caaatattgg gtacctaata cattacttca gagattatgt aatcctatta 7740
tagtatgttt gcttctcttt attggtggat ttacattctc gattttggct tctccaaaaa 7800
aatgtatata atgaaagact agacagttat ttgcaagtgt ttgaaaaggt gttaaaaaatg 7860
taaagcaaa agtcttaact ttctcctaag tgggagaaaa atgctttaac attactataa 7920
taataatcca ggtttggagg ggttctccag gccccatatt tgcctgtaat agttggacct 7980
tttagaccat gtgttatttg caatcccaga atgattgctt ctgctattag ttaaaaagat 8040
actattcttt tctttctgta caagtgcaat actccccttg aagctttaa aactatgggtg 8100
atthtttttt tttttctgac ctattctctc tttagctaat gacaaaaaga aactcataaa 8160
agtcatagta tgttaaaagc cacaaacaagc aaagagaaaa acactccaca atcaaaagat 8220
tacagaatgt ggaaccactc agtctgatct catggtatct ttatttaagc taaatttcca 8280
tggaatattg taatcttttg cttgaaaaat gtgtcctaaa gttgaacttt ttacagattg 8340
aatctctcta gacctcgc cccttttaga caatgctcta aattaagaac ctaatactta atatttttat 8400
ttactctctc cccttttaga aataaaactt taaataaaag caaagcactt agctgagttt 8460
taaacactta catatcacct attggagaaa ttttttttaa aaatatttgg agcagtcctg 8520
ttttcataca aatttaagta agaggtattt ttcttataca tatttatatg tagtgtgcta 8580
atthttcttt tttataactg tctccctgta gtaaaactgc tgtaataata atacatgttt 8640
tgttaaaaga taacattttc ttggcatttc ttttaaaggc agttactgca tttctgcatt 8700
tgtacagtat gtgtcttggc cattttagat attctttctt taacaatacc aaaggtaatt 8760
agactattht aaagactaat tgcctgacag tttctagggt atthttgtgt ttagaagcaa 8820
aaaaagaaaa aaaaataggt caaacagta aacctcattt tttttcaaac taataatttg 8880
gggaaataaa aactatgttt taaaaagaa atatatatat atatatata atatatatgt 8940
aaagtaaaaa tccatcacct tgtatgtcag gtttgcctaa tgaatgttag ttttttaaag 9000
gctcaaatac catacctcag aaaatgaggt ttactatgga aactactgaa cagtcctttgc 9060
agctgtgtga caagtcactc tactacatac tgatttggag acctccgcta aatagtttta 9120
tcaactgcaga ctaaaatgtg ggaactgtat cttctttggt ttaaatgcac acacatacat 9180
gttctgtgca tgtatgtggt tactgtgtat atgtgtatga gtgtgtata tgcattgtgtg 9240
agtgtgtgtc tgtatgtgtg tacaactaaa gaagctgcag aaactttgta atactttgtg 9300
aaaaaggatta tttataaag gtttgaactg tctgagtgca cagctactgg aataaaatth 9360
gggaatctca ggaacaagca ttaattttgt ccaagattta tttctctca gaagtgttag 9420
tgcagttttt aattctgtat attatttaat atthttacca taaaataaac ttctgacata 9480
aaaa

```

-continued

FEATURE	Location/Qualifiers
source	1..3083 mol_type = genomic DNA organism = Homo sapiens
SEQUENCE: 11	
gaacactgag	ctgectggcg ccgctcttgat actttcagaa agaatgcatt ccctgtaaaa 60
aaaaaaaaaa	aatactgaga gagggagaga gagagagaag aagagagaga gacggaggga 120
gagcgagaca	gagcgagcaa cgcaatctga ccgagcagggt cgtacgcgcg cgectcctcc 180
tctctctcgc	tcttccgtac ccaggtgacc cgaggaggga ctccgcctcc gagcggctga 240
ggacccccgt	gcagaggagc ttggctcgca gaattgcaga gtctgcgcc ctttttacia 300
cctggteccg	ttttattctg ccgtaccag tttttggatt tttgtcttcc ctttcttctc 360
tttgctaaac	gacccctoca agataatttt taaaaaacct tctcctttgc tcacctttgc 420
ttcccagcct	tcccattccc ccaccgaaag caaatcattc aacgaccccc gacccctcga 480
cggcaggagc	cccccgacct ccacggcggg ccgectccc tccccgcgcg cgggttcctg 540
gccccggcag	agggcggcag cacagccgag gccatggagg tgacggcgga ccagccgcgc 600
tgggtgagcc	accaccacc ccgctgctc aacgggcagc acccggacac gacccaccgc 660
ggctcagccc	actcctacat ggacgcggcg cagtaccgcg tgccggagga ggtggatgtg 720
ctttttaaca	tcgacggtag aggcaaccac gtcccgcctc actaccgaaa ctcggctcag 780
gccacggtag	agagtgacct tccgaccac cacgggagcc aggtgtgccg cccgcctctg 840
cttcatggat	ccctaccctg gctggacggc ggcaaaagccc tgggcagccc ccaaccgcgc 900
tccccctgga	atctcagccc ctctccaag acgtccatcc accacggctc cccggggccc 960
ctctccgtct	acccccggcg ctctcctccc tcttctctgg ggggcccagc cagcccgcac 1020
ctcttcacct	tcccgcctcc ccgcgcaag gacgtctccc cggacctcc gctgtccacc 1080
ccaggctcgg	ccggctcggc ccggcaggac gagaaagagt gcctcaagta ccaggtgccc 1140
ctgcccagca	gcataagctc cactccctgt gcagcatgac cgcctcgggt 1200
ggagcctcct	gctcgaccca ccacccatc accacctacc cgcctcagc gccccagtag 1260
agctccggac	tctccccccc cagcagcctg ctgggcggct cccccaccgg cttcggatgc 1320
aagtccaggg	ccaagggccc gtcagcaca gaaggcaggg agtgtgtgaa ctgtggggca 1380
acctcgaccc	cactgtggcg gcgagatggc acgggacact acctgtgcaa cgectgcggg 1440
ctctatcaca	aaatgaacgg acagaaccgg cccctcatta agcccagcgg aaggctgtct 1500
gcagccagga	gagcagggag ctctgtgctg aactgtcaga ccaccacaac cacactctgg 1560
aggaggaatg	ccaatggggg cctctctcgc aatgctctgt ggctctacta caagcttcac 1620
aatattaaca	gacccctgac tatgaagaag gaaggcatcc agaccagaaa ccgaaaaaatg 1680
tctagcaaat	caaaaaagtg caaaaaagtg catgactcac tggaggactt cccaagaac 1740
agctcgttta	accgggccc cctctccaga cacatgtcct ccctgagcca catctcgccc 1800
ttcagccact	ccagcccatg gctgaccacg cccacgcgca tgcacccgcc atccagcctg 1860
tcttttggac	cacaccacc ctcagcactg gtcacgcgca tgggttagag cctgctcga 1920
tgctcacagg	gccccagcg agagtccctg cagtcccttt cgacttgcac ttttgcagga 1980
gcagtatcat	gaagcctaaa cgcgatggat atatgttttt gaaggcagaa agcaaaatta 2040
tgtttgccac	ttgcaaaagg agctcaactg ggtgtctgtg tccaaccac tgaactgga 2100
ccccatctgt	gaataagcca ttctgactca tatcccctat ttaacagggc ctctagtgtc 2160
gtgaaaaaaa	aaatgctgaa catgtcatat aacttatatt gtaagaaata ctgtacaatg 2220
actttattgc	atctgggtag ctgtaaggca tgaaggatgc caagaagttt aaggaatatg 2280
ggagaaatag	tgtggaaatt aagaagaaac taggtctgat attcaaatgg acaaaactgcc 2340
agttttgttt	cccttccact gccacagttg tttgatgcat taaaagaaaa taaaaaaaag 2400
aaaaaagaga	aaagaaaaaaa aaagaaaaaaa gttgtaggcg aatcatttgt tcaaaagctgt 2460
tggcctctgc	aaaggaataa ccagttctgg gcaatcagtg ttaccgttca ccagttgccg 2520
ttgagggttt	cagagagcct ttttctagcc ctacatgctt tgtgaacaag tccctgtaat 2580
tgttgtttgt	atgtataaat caaagcacca aaataagaaa agatgtagat ttatttcac 2640
atattataca	gaccgaactg ttgtataaat ttatttactg ctagtcttaa gaactgcttt 2700
ctttcgtttg	ttgtttcaa tattttctct ctctctcaat ttttggttga ataaactaga 2760
ttacattcag	ttggcctaag gtgggtgtgc tcggagggtt tcttgtttct tttccatttt 2820
gtttttggag	gatatttatt aaatagcttc taagagctcg gggcactctg tcttgtccct 2880
attcctcgag	cctgtgctga gggtagcagt gtatgagcta ccagcgtgca tgtcagcgac 2940
cctggcccga	caggccaactg cctgcaatcg gcccggtgc ctcttcgccc tgtcgtgttc 3000
tgtgttagtg	atcactgcct ttaatacagt ctgttggaaat aatattataa gcataataat 3060
aaagtgaaaa	tattttaaaa cta 3083
SEQ ID NO: 12	moltype = DNA length = 7449
FEATURE	Location/Qualifiers
source	1..7449 mol_type = genomic DNA organism = Homo sapiens
SEQUENCE: 12	
gcgttgctc	tggagtaagc cggatcgcgg agccgcgcg actccgcga gccgggagcc 60
gggagggcgg	cagctcccgg gtccctccga ggctcctcgg ccagggcagc cccgcccggca 120
cgcggtagag	aagacggcgt cccctcggct gctggctgat acaaacagat ccccccttcc 180
aaacacgcgc	caagtcccgg tcccctccag atgcagagag aggcctgcgtt cagactccggg 240
cactgccatc	ccctccgcat catggggtct gtggaccaag aagagccgaa tgcacataag 300
gtcgcagacc	ccacctccgg accccatac cccgatgatg tccctggacta tggcctcaag 360
ccatacagcc	cacttctctg tctctctggc gagccccccc gccgattcgg agagccggat 420
agggttaggg	cgcaagaagt tctgagcgcg gccaaagccag caggggcctc gggcctgagc 480
cctcggatcg	agatcactcc gtcccacgaa ctgatccagg cagtggggcc cctcccgatg 540
agagacgcgg	ccctcctggg ggagcagccg cccctggccg ggggtggccc cagcccaggg 600
ttcaccctgc	cgctgcccgg cttcgagggc tacgcgcagc cgttttgcct gagccccgc 660
agcagcggct	cctctgcccag ctctcattct gacaccttct ccccatacac ctgcgcctgc 720

-continued

```

gtctcgccca ataacggcgg gcccgacgac ctgtgtccgc agtttcaaaa catccctgct 780
cattattccc ccagaacctc gcccaataatg tcacctcgaa ccagcctcgc cgaggacagc 840
tgctctggggc gccactcgcc cgtgccccctg ccggcctccc gctcctcacc gcctggtgcc 900
aagcggaggc attcgtgcgc cgaggccttg gttgccccgc cgccccgagc ctcaccccag 960
cgctcccggg cgcctctgccc gcagccctca tctcacgtgg caccccagga ccacggctcc 1020
ccggctgggt accccccctgt ggctggctct gccctgatca tggatgcccc gaacagcctc 1080
gccacggact cgccttctgg gatccccccc aagatgtgga agaccagccc tgacccctcg 1140
ccggtgtctg ccgccccatc caaggccggc ctgectcgcc acatctaccc ggccgtggag 1200
ttcctggggc cctgagagca gggcgagagg agaaactcgg ctccagaatc catcctgctg 1260
gttcgcgcca cttggcccaa gccgctggtg cctgcccatt ccactgagc catcccagtg 1320
actgcatccc tccctccact tgagtggccg ctgtcccagt agtcaggctc ttacgagctg 1380
cggatcaggg tgcagcccaa gccacatcac cgggcccact atgagacaga aggcagccga 1440
ggggctgtca aagctccaac ggaggccac cctgtggttc agctccatgg ctacatggaa 1500
aacaagctcg tgggacttca gatcttcatt gggacagctg atgagcggat ccttaagccg 1560
cacgctctct accagggtgca ccgaatcacg gggaaaaactg tcaccaccac cagctatgag 1620
aagatagtgg gcaacaccaa agtccctggg atacccttgg agcccaaaaa caacatgagg 1680
gcaacctcgc actgtgcggg gatcctgaaq cttagaaaacg ccgacatgga gctgcccggaa 1740
ggcgagagcg acatgtggaag aaagaacacg ccgggtgagac tgggtttccg agttcacatc 1800
ccagagtcca gtcggcagaat cgtctcttta cagactgcat ctaaccccat cgagtctctc 1860
cagcgatctg ctcacgagct gcccatgggt gaaagacaag acacagacag ctgcctgggtc 1920
tatggcggcc agcaaatgac cctcacgggg cagaacttta catccgagtc caaagtgtgt 1980
ttactggaga agaccacaga tggacagcaa atttgggaga tggaaagccc gggtggataag 2040
gacaagagcc agcccaacat gctttttgtt gagatccctg aatatecgaa caagcatatc 2100
cgcacacctg taaaagtcaa cttctacgtc atcaatggga agagaaaaacg aagtcagcct 2160
cagcacttta cctaccacc agtcccagcc atcaagacgg agcccacgga tgaatatgac 2220
cccactctga tctgcagccc cacccatgga ggccctgggga gccagcctta ctacccccag 2280
cacccgatgg tggccgagtc cccctcctgc ctgctggcca ccatggctcc ctgcccagcag 2340
ttccgcaagg ggctctcate cctgacggcc cgctaccagc aacagaaacc agcggccgta 2400
ctctaccagc ggagcaagag cctgagcccc agcctgctgg gctatcagca gccggccctc 2460
atggccgccc cgctgtccct tgcggacgct caccgctctg tgetggtgca cgcggctcc 2520
cagggccaga gctcagcct cctccacccc tctccgacca accagcagge ctgcgctgtg 2580
atccactact caccacccaa ccagcagctg cgctgcccga gccaccagga gttccagcac 2640
atcatgtact gcgagaatct cgcaccaggc accaccagac ctggcccgcg cccggctcagt 2700
caaggtcaga ggcctgagccc gggttcctac cccacagtca ttcagcagca gaatggcacg 2760
agccaaagag ccgcaaaaaa cggaccocccg gtcagtgacc aaaaggaagt attacctgcy 2820
ggggtgacca ttaaacagga gcagaacttg gaccagacct acttgatgta tgagctgata 2880
gacacacacc ttagtggat acaaaacata ttatgaaaca gaatgactgt gatctttgat 2940
ccgagaaatc aaagttaaag ttaatgaaat tatcaggaag gagttttcag gacctcctgc 3000
cagaaatcag agctaaaaaga agccattata gcaagacacc ttctgtatct gacccctcgg 3060
agccctccac agcccccacc ctctgtctct ctttctatgt catctcccag cccggagctc 3120
acacgcccgt caatgtatgg gcaactaagc gactctcact taaggagctc gccacctccc 3180
tctaaacacc agagagaact cttctttctg gtttatgttt taaatcccag agagcatcct 3240
ggttgatctt aatgggttct cgtccaaata gtaagcaccct gctgaccaaa agcacattct 3300
acatgagaca ggacactgga actctcctga gaacagagtg actggagctt ggggggatgg 3360
acgggggaca gaagatgtgg gcaactgtat taaaccccag cccttgctgt cgtttttcca 3420
ggctcacagat acagctcctg taccttttga aggcaaggag ttctcagagc aaccaaaagg 3480
acggtgaccca agagcccagc ttacagggctg aagaaaccca aaacctcga tagagacaga 3540
aactgaactg tcagctcctta gagctcgccc agtccatgcc acaactgggc cacagctaaa 3600
gctttatttt tgaattctca ttccaaaacc aaactgtcct gccagacaaa gatcctctgt 3660
taagactctt tggcgtaag ttatgacatg tatacgcggt tggttattat attttttctg 3720
ctttaaaagg ctaccagggg cacctagccc tggagctgtc ttggcagact gttctttaac 3780
ccctgcagca cgcagctcctg ctaacacaaat ttccatagac ttggggggct gacccaggct 3840
gcagagagca agcacctgtc tgtgcagct gtacaacctg gatgcttgc aaggttccgg 3900
cttgctttct tcctagcagc cagagtgctt ttccgtaaaq ccggtggagaa tctcaagcat 3960
gtgcatttaa ttgaggaata ccagaagggc taaagcaacc aagaaaagaa gtgtgggtat 4020
ttttgtaag taaaaacagc caagtgcctc tggagggtgg tttctaccaa gatagaggaa 4080
aagggctgaa ttccctctaa gtgggacagc cgagctcagg atgtgctcc cagcttccact 4140
ggttaatttg acctgaaacct atttaagat cccctctgccc cctgaagacc tatccgcact 4200
caaattctaa catgaagaaa tctactcgaa tgcactcctt accttgaatg agctctattc 4260
ggttgcagtg tatatgtgat ttccctctc ccaactgttt ccactgagcg caccagctct 4320
ccccagctct tctctgtggt gttgtatttt tgtgattttt acaaaacaaa ccttgaagt 4380
tcttggcaga tgtgtttggt tctgtttgca tgtactgacg ataccccagg acaagcgggg 4440
gattcatttt tcagccattc agtgttttcc tcaataatcc gcagcaaaat gaaaaattc 4500
ttagcactca gactgtactt agagtgtttt ctcagtcagc tctgtacagt ctgtaggcag 4560
aagcctcag aagaaagtca tggccactca gtgcccactg tgggcttgt aagtcctggc 4620
tctcccgtca aggttaccca gaggtaaaag cttcctggga gtggggccag gtgtgtttgg 4680
cactccagat agaaggcaaa atgctcagat tcgggcccgt gcactgtgat gcaacctgtc 4740
ggctgatacc tagcatttat ttttccctga caatgaaacga cctttccctc acccaacctc 4800
agctcaaaga gtttagcaaa attctctttt aaataaacag aatgccagta agaggttgac 4860
ccctaccatg gaactctcgg gatgctaaat acttccctcat gaacaaaaata agttccttat 4920
tataagttcc ttatactagc agcttccact aaagaatttt ctctccagca atattgactt 4980
cactggggaa aagccaagag tgtgtgggtg gtgattttgt ctcactcgac ctggctagga 5040
ctggctagga gctgtttttt gtacatgagg gaatttgggc tttcctcagt tatctgaatg 5100
ttttacccaa gtcctctcct gctattgtag caaagtgtct cagcttccct gtcccaggg 5160
tgaaaaagga ctaatgcatt ttccatcagt tttctaacta tgttagcaaa aacggcctcc 5220
tggtagctca acctcctgta cgcgtgtgtg tgtgtaatac acacacaaat aaacctctct 5280

```


-continued

```

gtttttctaa gacatcttag ctggatatta taggaagcac ttccataaac aactgtaaca 5340
aatcgcaaa gaaagagaaa caaaagcatt agatttgaga cataaacagg caagagaaa 5400
tgtattagga actgacagct atcaaggaag ttttgtcagt tacaatgct aggaggaaat 5460
tttgccaaga aggatggctc atgaaatatt tccagtcagg gaagaggcaa taagatcctc 5520
taagagaatg agaagtagg ggtgtctaaa tggtaaagat ggggtgtttg cacgtgtgtt 5580
agaaggatct cagttgagtg aagggttgca ctgctacatc taagttaatg taaatatgta 5640
gcactctgac aggtctaccg tgtgtctgaa tgtagtatat ttccaaagtt tgcaagctct 5700
cctgtattgt acaaaagatgc tctgcttga taatatgtat agcaatccag attagtatgt 5760
tattaaattt tattttctta cctgtatttt tatgtttttt acctgtcctc aaaatattac 5820
accctgttg gaattagatt tatatttata aatggtcaga aatcttttta agtgtctctt 5880
tttacacata ggttgatttt tttttcttaa gagaaatgat gtattcttga aacatttgtt 5940
actcattcca ggaacaaaa acccatataa taaaaccccc actcagagcc tgttagtcac 6000
ctctctagaa gatggcctgc caggagaagg aatggctttg tggagaagg aatcaccttt 6060
ttcttctca agaattatgc tgacttcagc cctgagcctg gatctggctc ctgagaatca 6120
tcaagtgtct agatcctccc cccaaaataa ctaatttagt aggtgatatt gattttaaaa 6180
aattgacacc aaaaccctgc ctgcattgta atggaattcg aaaagaattc atgttcacag 6240
aactcaacgt tcaggctaat atttacagaa gggaccacaa ctaaatcctg gtatataact 6300
cctgtatgct ttatccaaag gacaccoca gttttccagc atagatataa ccaaggatga 6360
attgattcct tcaagaagt gggaggcagc gatattgcat ttttgttta catccagtag 6420
ccaagacgcc tcagtgcacc agtcttgggc agaggctgtc acatttaggc agattggaag 6480
ttggtatggt ctaattctca ctctggacta cagtggagct gaatttata tgtaaaaaaa 6540
aaaaaaaaaa aaagaccttt ccaagtgctt tctattgctc agaattgaaa gaattgtttc 6600
atttcaagtt tacaagagcc atggatggag ttgtgacgtt cttgacaagc tgggtaacc 6660
tttcccgaac ttgtttccc gaggcaaggt gctcgggtgac ccagcgcac ttaaccttgg 6720
gtctcctagg ctctgaggtc gggcattacg tttcgtggaa ccaaagcagc caattgcata 6780
gcaagtattt cctgcatc caattaaatg cttaaagaaa agcagcatcc tataaaattg 6840
tgcataaaa catccatttt cctcagcttt tgtgagtcct ttgacttaca gccaacatca 6900
ctgtttaact cagctctgtt taaaacaaa ttttctgggt gttgataaca gagagtgct 6960
ccctgagcca tcagggtcct gggagctgga agtgaagggg ttattaacat tctacctta 7020
tgcagctggt ggtgaccagc aataaactcc ctgctgagtt caagcttga atggaatgga 7080
tgcfaatgat gttgtttcca ttagagcagg tgctcacagc attctgattg gcctgagcag 7140
accgaggcta tggctgttgg gacaagctta gcactctgga catcttgtca aagaacctca 7200
ctcaccctcc tggcctctac agccctcaga ggagagaaaa ccaattctcc aacaacagg 7260
tctctccaac atggttggtc tggcagcctt aggtttagaa aatcctgact gttaaaggcg 7320
tttgaatata tcacattcct atgcaaatgt ttttaactc cagtttaatg tagtttattt 7380
ttcctatatg taaagtattt ttatacggct tgtatcatga tagtttagca ataaaacagt 7440
tggaaacaa 7449
    
```

```

SEQ ID NO: 13      moltype = AA length = 164
FEATURE
source            Location/Qualifiers
                  1..164
                  mol_type = protein
                  organism = Homo sapiens
    
```

```

SEQUENCE: 13
MKWKALFTAA ILQAQLPITE AQSFGLLDPK LCYLLDGILF IYGVILTALF LRVKFSRSAD 60
APAYQQGNQ LYNELNLGRR EEYDVLDRR GRDPEMGGKP QRRKNPQEGE YNELQKDKMA 120
EAYSEIGMKG ERRRGKHDG LYQGLSTATK DTYDALHMQA LPPR 164
    
```

```

SEQ ID NO: 14      moltype = DNA length = 13013
FEATURE
source            Location/Qualifiers
                  1..13013
                  mol_type = genomic DNA
                  organism = Homo sapiens
    
```

```

SEQUENCE: 14
gagcatgctc ccgctgcagt taactagccc aacctatttc ttaattcag cccatccctt 60
cgtttccctt aagggatact tttagttaat ttaatatcta tagaacaat gctaatgact 120
ggtttgcgtg taataaatat gtgggtaaat ctctgttcag ggttctcagc tctgaaggtt 180
gtaagatccc tgatttccca cttcacacct ctatatctcc tttttttttt tttttttttt 240
tgagacagag tctcactctc gccaggctg gagtgcagtg gcacgatctc tgctcactgc 300
aagctccgcc tcccgggttc acgcccattct cccgcctcag ccttccagag agctgggact 360
acagggcctcc gccactacgc ccggctaatt ttttgtattt ttagtagaga cggggtttca 420
ccgtgttagc caggatggtc ttgatctcct gacttcgtga tccgcctgcc tgggctccg 480
aaagtgtcgg gattacaagc gtgagccacc gcgcccggcc tcacacctct atatttctgt 540
gtgtgtgtct ttaattcctc tagcactgct gggttagggt ctccctgacc gagctggctc 600
cggcagataa ggtttcaaca tgttgccagc gctggctcca aactcctgac ttcaggggat 660
ccccgcccca gcctcccaaa gagctgggat tacgggcatg agtcaccgtg cccagccaat 720
ttttttttgt tttttctttt gagacaggat ctcaactctg caccocaggct tgaatgcagt 780
ggtaaccatct cggctcactg cagcctcaat cttctgggct caaatgatcc tcccacctta 840
gcctcccagc cagctggggc tacaagtgca cactaccaag cccagctaat tttttttttt 900
tttttttttt tttgagacag agtcttgcgt tgcctctcac ccaggttgga gagcagtggt 960
tcgatcttgg ctcaactaaa cctctgcctc ccgtgttcaa gcaattctcg tgctcagcc 1020
tcctcagtag ctgggattac aggcacgtgc caccatgccc agttaatttt tgtattttta 1080
atagagacgg ggtttcgcca tgttgaccag gctgtctctg aaccocctgac ctcaagctcc 1140
caaagtgtcg agattacagg tgtgagccga catgctaggg ctatacattt caaaattatg 1200
ttgctatggt cataaagatg tatatatggt aacttgtacc ttcaatcaac atgaaatacc 1260
cttctttgtc cttttaatgc ctttatgata aattctgtct catattaata ttgctacata 1320
    
```

-continued

tgccttcttt	ccataaacat	ttccataaac	ataaaaatgg	ctggtgaagtc	attttccctt	1380
tttttaaaaa	aatttttggt	tttttagaggc	aggagctcat	tctgtctccc	aggttggagt	1440
acaatgggtc	aatcatagct	catagtttac	tgcagcctcg	aactcctggg	ttcaagggat	1500
cttaccacct	ccgctctocg	agcagctggg	actacaggtg	caagtcacca	cgctcggtta	1560
atthttttta	atthttttgta	gagacaaggt	cacaatatgt	ttcccagcct	ggtcttgaa	1620
tcctggctc	aagcaatcct	cctgccttga	gaaatatagt	aaacaaaaa	tgtgaaataa	1680
catggcagaa	ataagtcaca	ataaataaat	aatcaaaaat	aaatacaaat	gatttatatt	1740
ctcttcttaa	aagagagctc	tgagaaaccc	caaagccagc	tatatgttgt	ttataaagag	1800
acatacataa	aacaaaacag	catgattaag	aagataaat	aaccocatca	catttatggt	1860
ttattattta	tatatttggg	cttatctctg	ccatgttatt	ttctgttttc	tgcttaccag	1920
tgtacagtat	ttttctgttc	tcctctttct	ggaatgccta	tttattttctg	ttcctgtttt	1980
gtccaccctt	tcctgactga	ttctttctga	ataatgactt	tttttttttt	tttttttttt	2040
tttgagaag	tctcactctg	ttgaccagge	tggagtgcaa	tggcacaatc	ttggctaatt	2100
gcaacctctg	cctcccaggt	tcagaacatt	atcctgcctc	agcctcccc	gtagctgaga	2160
ttacaggcgc	ccccccacct	gtccggctaa	tttttggatt	tttagtagag	actgggttcc	2220
accatgttgg	ccaggctggg	ctcgaactcc	tgatctcagg	tgatctgccc	acctcgccct	2280
cccaaatgct	tgggattaca	gggggtgagcc	accgcgtttg	gcctcaaa	ccgagaactt	2340
tgtaatttat	atattttata	gctcttatca	caggtgtcta	gtaaatattt	ttaaacactt	2400
atggcacctg	atgcaagaat	taccaggttc	atthttataga	gaggatagta	aactgtccaa	2460
gggtttggac	tcacatgttc	aagactgcat	ggacagcaat	ctgtagtggg	tcaaatattt	2520
gttttttagta	tgattttaaag	tgtttgtcaa	aaatataaaa	gttttgaaaa	caagctgggg	2580
aagtgaattt	caatatcgca	ttaaataaga	tcaaaagtca	attcatcaac	cttttttccc	2640
catcccgcac	cctgtgcttt	cttactcag	ttactcacta	cacctgctg	gactaaaagg	2700
gtcctccagc	atthttcttc	ttcacacagtg	aaagacattc	tcttgccatt	aataaatggt	2760
cacttaataa	ataaaaaggg	ccgggctctg	tggttcctgc	ctgcaatccc	agcagtttgg	2820
gaggccaagg	caagagatgc	gcttgagcct	aggagtcca	gcctaggcaa	cggtggcgaaa	2880
cccagctcca	aaaaaaaaaa	aaaggaaaaa	aaaggcatca	aaaaataaaa	cgtaaacaggt	2940
ggcatgacat	gacatgactt	ttctaacagc	ctcttacagc	tttccaaggt	ctthttaat	3000
gaagctatag	gtctcggcta	gaagacacct	ccagactctt	ccccaaacat	ttcagaggcc	3060
eggagtaagt	ctccccacat	ctgaaggcac	atcagaacccc	agggtggccc	agctgatgag	3120
agttaaacag	gaagttgggt	tcttggtccg	gcagagactc	caatcacccc	cacctctttt	3180
ccaaccaca	ggacagcacg	tgctcaggag	gctctggagt	tgggacagcc	cagttaaaaa	3240
aaaaaaaaat	attgatctcc	ctcccacga	agagggagaa	aacacgttag	gagactcgtg	3300
gccagctcct	ggcaaaaac	aaaactatgt	cccttagag	ggcttagata	tcagagatg	3360
gacttgcttt	tagtcttttt	tcccactcctg	ttccctccct	acaaaaataa	aattgaccag	3420
ctaactccgac	ttaataaac	taagaatta	cttaggaacc	tgctatctta	acatttcaact	3480
ttttgcatat	ctccaaaata	ccaggtagca	gtcttactac	tgtttgcacc	cctagaacct	3540
ggaatagtgc	tgcccgcaga	ggaggaagca	ataattactt	gtagagaag	gtattgctgt	3600
gcatttctgg	ggaatttcaac	atthttgtaat	ttgctttaa	aaaagtggac	aggcatattt	3660
acgggggttt	ctcggacttc	ttcatgttaa	tattcgtgtg	tataaatcgc	tccgtctctg	3720
ctctctgggg	gcccctcttt	cacaaacacc	tggccacct	cacgccacaa	tggccaggca	3780
ggaaacctga	cctcccctcg	gagagggggc	tccaggtcaa	ccccggggct	tcagtctcta	3840
catgtgacgt	ttctctgtcc	cctcatttaa	ataaacaaga	ggctgggcgc	agtggtctac	3900
gectgtaac	ccagcacttt	gggaggccga	ggcggggcat	cacgaggtca	ggagatggag	3960
accactcctg	ccaacacggg	gaaaccccgc	ctctactaaa	ctacaaaaaa	ttagccgggt	4020
gtgggtggcg	gagcctctag	tcccagctac	tcgggaggct	gaggcaggag	aatgtcttga	4080
acccggaggc	gaaggttgca	gtgagctgag	atctcggcc	tgcactccag	cctgggtgaca	4140
gagctgact	cctctcaaaa	aaataagaaa	aaaaataaaa	ataaaaaata	tagaggccga	4200
agcgggaggt	tcacttgagc	tcagaagttc	gagatcagcc	tgggcaacac	agtgagacct	4260
cgthttctatt	taaaaaataa	aataaaacta	aatthaaaaa	aatgcacgct	catagtacaa	4320
actttagaaa	tggaaagaaa	aaactaaaat	gaaggtatct	ccctccaacc	cagagataac	4380
acctatcggt	tattaaagccc	tcactattgt	taaaacttagt	tttaaagggc	acgatctcat	4440
ttcttaaaga	cttctattcc	gcagaatttc	tttccaggct	ttttcttttt	tctttttttg	4500
agacggagtc	tcgctctgtc	gcccaggccg	gggtgcagtg	gcgcgatctc	ggctcactga	4560
aaactctgtc	cagctctttc	gaacccaagg	cccaactgcg	ctctatctcg	actttcggct	4620
ccactcggat	cccgaagtgg	gcacagagat	aaaatgttgt	caggctgagg	taattctctg	4680
ttagtcccgg	taaaaattcg	tcagtctgga	aagctctcgg	tttggaaata	aatctctgtca	4740
ctccggatgg	aaataagctc	gcttaagggg	ggaaaatccg	tttgggagg	acacgctccc	4800
gcacgtaacc	ccccgcggaa	aatgacccca	agtaaccttg	gccagggat	gcccgtgcc	4860
cgccggactc	catagccaag	gtcctgaaac	gcccgcggcg	gcaggccgga	ccaatggagc	4920
ccagctcggg	ccgtgcgtca	gcgacgctg	gccaatcgcg	gagggccacg	accgtagaaa	4980
ggccggggcg	ggcgaggctg	ggcgtggggc	ggctgcccgc	gcgggtgcgc	ggtgcgtagt	5040
ctggagctat	ggtggtggg	gcagccggcg	cgaaccccgc	cgacgggacc	cctaaagttc	5100
tgcttctgtc	ggggcagccc	gctccggccg	ccggagcccc	ggccggccag	gcccctgccg	5160
tcatgggtcc	agcccagaga	ggggccagcc	cgagggcagc	gagcgggggg	ctgcccaggg	5220
cgcccaagcg	acagccctcc	acgcacctga	gcccggagg	gaaggcctg	aggaggtggg	5280
cgagggggcg	gggtctgggg	ccagatctga	agccgggact	agggacaggg	gcagggggcag	5340
gggctgggag	cggggaccca	gcaactggcg	ccccgcaggg	ctccgtcgcc	ttggccctgg	5400
cggtcggtg	ccagcgtggc	gcggggcggg	gcaggaagcc	cggactgacc	ggatccgcc	5460
cgctggggaac	ctagggcggg	ccagggctct	ttctgtact	ttthtaactct	ctcgttagag	5520
atgaccagag	ctggggatgc	gggcaacctg	cttccaggcc	ctcttctgtg	gtggcccgag	5580
actgggtggt	cagcctctta	actcggacat	gaggtcgaat	aatctgtttt	ggtttactgc	5640
tatttctgga	gagggcggga	gctgaaataa	cagagctgtt	gaaagggctg	ggaattctgc	5700
gaggtcact	ggtctagctc	agtatctgcg	ttcttaaaat	ggaacctact	tcatgaggtc	5760
ttgggggaga	ttgagactg	gatataatgt	gcttagcact	tagtctccg	taaatgttca	5820
ctctttgtg	atcattgtgc	cttctgtgat	ttatgaagtg	tctctctga	gtaattctct	5880

-continued

ttaaaaaaaa	aagtgtctcc	tccaacagac	acggacccat	cagcaggtca	ctgcctagga	5940
tctcaacact	agagatcagg	gagtgccatc	agcctctccc	ttttctaaat	tggactgggg	6000
gacggagggt	tgatgtcata	gcaagattgc	agcctctcact	agattaatga	ggccagggtg	6060
gatcctgttt	aagagaactg	gagacaggaa	gcagcggggg	aatagatggg	gaaagaggaa	6120
agttccttat	gatgcaagat	gaatagtgtg	tgtgtccagc	cccagtgctg	tgacggggat	6180
gagctcgagg	tggacggatg	atgcaatata	ggagagaata	aagcaggtct	tcgagctaga	6240
ttgacagaag	actgtatttt	ttatttgggt	ttattgaggg	gaggagcctg	aagtgtattt	6300
tatcattagt	ctgtcttata	ctgtaataaa	aaatgaaagc	accagctggg	aaagttttca	6360
aataaagaca	taaataaggt	ttgatatgac	tcagtgtggt	atgttccctc	tcttccctagg	6420
aaactgaaaa	acagagtagc	agctcagact	gccagagatc	gaaagaagcc	tcgaatgagt	6480
gagctgggac	agcaagtggg	agatttagaa	gaagaggtaa	aactacttaa	ggtaaaactc	6540
ttttatccat	tgtataccct	tccttgggtg	atgttctgat	atgttctccc	catcccgaag	6600
tgtttcagcc	cctattagaa	tacaattgaa	tatatgatta	aaagttaaac	taggtcgggc	6660
atgggtggct	atgectgtaa	tcccagcact	ttgggagcct	gagttgggca	gatcacttga	6720
agccagcagt	ttgagacacg	cctagccaac	atggtaaaat	cccgtctcta	cccaaaaata	6780
taccaaaaaa	ttgaaaaaaa	aaaaggccaa	gcgtgagtg	ctgtagtccc	agctactcgg	6840
gaggttgagg	ttggagaggt	gtttgaacct	gggagagggg	ggttgcagtg	agctgagatc	6900
gcaccactgc	actccagcct	gggcaacaga	gtgagactct	gtctcaagaa	aaaaaaaaaa	6960
agtttgctgg	gcaccggggg	tcacacotgt	aatcccagca	ctttgggagg	ccaaggtggg	7020
tagataaact	gagatcagga	gttcgagacc	agcctgacca	acgtgggtga	accccatctc	7080
tattaaaaat	acaaaaatta	gcccgggtgt	gtggcaggca	cctgtaatcc	cagctgctcc	7140
ggaggctgac	gcaggagaat	cacttgaacc	caggaggcgg	aggtgcagct	gagctgagat	7200
cacgagatca	tgccactgca	ctccagctct	ggccagacag	caaaaaacct	gtctcaaaaa	7260
aaaaaaaaaa	gttaatctaa	gttaggacag	agagttggtg	aagtggtgaa	gcttgttgag	7320
ggcagaagtg	attgcaattg	tgccatttgg	tgctagatgt	atctcaaaag	agatggattt	7380
aaacaatgtt	attgagtttg	tagtaagaaa	ttagcaaggg	ctaataggaa	ataatgctt	7440
aaactttaca	ttcttctctg	catggccaga	aattcaactaa	aggttccctt	ccccctctag	7500
ggtccacctg	ttaatcaact	ttaaattgtt	gccaattaca	catctgaaat	acataagagt	7560
tatttataat	gtttttttaa	ccccttggtc	aatttgcata	tattgagctt	tttaaaagtt	7620
taactcattg	ttgttctctc	taagaatcat	gagtcaggag	cagggatatt	ttttaactta	7680
ttttggattt	atagtcacca	ctaccacttt	tattattacc	tgccagttca	agatagttat	7740
ttatttttat	tttatattat	tattattatt	attatcatca	tcattatttt	gagatggagt	7800
ctcactctgt	tgcccaggct	ggagtgagct	ggtgcaatct	cggctcactg	caacctctgc	7860
ctcccagttc	caagcaattc	tcctctgctc	agcctccaga	ttagctggga	ttacagccac	7920
ccctcaccc	atccagctaa	tttttggatt	tttttagtag	gatgggggtt	tgccatggtg	7980
gccaggctgg	ttttgaaact	ttgacctcag	gtgatccacc	tgcttggccc	tcccaaaagt	8040
ttaggattac	aaagtgtgag	caccgagcct	ggccaagata	gtttaaaaaa	aaaattatat	8100
ctacattaaa	gccacaagtc	accctttgct	gaagtcagta	ttagtagttg	gaagcagttg	8160
gttattctct	accctatgaa	gtggcactta	ttaagtagct	tgcttttcca	taattatggc	8220
ctagcttttt	aaaacctact	atgaaacacca	caagcataga	gttttccaaa	agttcaagaa	8280
ggaaaaggaaa	ccaattatac	tgaatcaggt	agattcttaa	ctgaaataat	tagatgtttt	8340
aatagccctc	tatgaaacttt	cttccagaa	caaaaaactt	tgctagaaaa	tcagctttta	8400
cgagagaaaa	ctcagggcct	tgtagttgag	aaccaggagt	taagacagcg	cttgggggatg	8460
gatgcccctg	ttgctgaaga	ggaggcggaa	gccaaggtaa	atcatctcct	ttatttgggtg	8520
cctcatgtga	gtactggttc	caagtgacat	gaccocagca	ttatggttac	agctcggact	8580
tctgatcaag	agcgttctct	aaatttctct	tcagttttaa	gacattttca	tgccagccaga	8640
gtgttctctc	cctaaaggca	cttgacactc	attttttaag	tggttagtga	acagtaacta	8700
gatctaataa	tgaaaaacag	ttacatggct	ccctaagaac	aagtaactaac	aaatgcagta	8760
gccaacaaga	ttaccatgca	atcatlaagg	agaaccaaaag	taagagagcc	actcaaacca	8820
gattttgaa	gctactaaaa	ttaaagtatg	tctttgatga	atatgaaatg	gtagggaaa	8880
gattctttgt	aatagtgata	cctctgtggt	aagagaaggg	tggtatgtga	gttttagttc	8940
acagattatg	gcaaatcctg	tgacaacaat	caaatggtct	aagattgaca	gtagccagct	9000
ttactctctg	gaaggtaatg	ttcaggacaa	atttcaagaa	aactagaaaa	ccattcttta	9060
cagctgaaat	ctttccctaa	ccattgttat	ttccactttt	aagtcctcaa	gagatgagaa	9120
aaggagggta	aggcttctct	atacatttcc	tgcaaatgaa	aacatttttc	ctcctccagg	9180
caaaagattca	agcagaactg	gcaaatatct	tatcttgtct	ttctcaataa	taataatggt	9240
gttagataat	aaagttctat	agcaatttaa	ccctagaatc	tttttgaaaa	gtaattcttt	9300
aaagttgaga	atcacagctg	ctagcaagc	atttccttgg	gcacttgaag	ctgtttattc	9360
actttggctc	ttcctcccag	gggaatgaag	tgaggccagt	ggccgggtct	gctgagctcc	9420
cagcactcag	actacgtgca	cctctgcagc	aggtgcaggg	ccagttgtca	ccccccaga	9480
acatctcccc	atggattctg	gcggatttga	ctcttcagat	tcagaggtag	ggatcattct	9540
gacttattaa	agagctatat	aaccagttaa	ttccatctgt	ttgatgcttg	acatccctaa	9600
ctagacagat	gaggggtgaa	gttagttttt	ggtgggggtg	gaggtgaaca	tcaactacct	9660
tccatgctcc	aggtaatata	gaacatggag	tgaagtgtag	ataaatgggt	ctggtgggtc	9720
ccgaggtcat	cttatcacat	aatgactaat	ttacattatg	gaaccagta	caaaagtttc	9780
cagtttagatt	ttccattgta	ttctgacagt	tgtacttcat	ttaatttttg	cctcttacag	9840
tctgatatcc	tgttgggcat	tctggacaac	ttggaccagc	tcagtgtctt	caaatgccct	9900
tcccagagc	ctgcccagct	ggaggagctc	ccagaggtct	accagaagg	accagttcc	9960
ttaccagcct	ccctttctct	gtcagtgagg	acgtcatcag	ccaagctgga	agccattaat	10020
gaactaatcc	ggtttgacca	catatatacc	aagcccctag	tcttagagat	accctctgag	10080
acagagagcc	aaactaatgt	ggtagtgaaa	atcaggaaga	cacctctcag	ccccagag	10140
aatgatcacc	ctgaattcat	tgtctcagtg	aaggaagaac	ctgtagaaga	tgacctcgtt	10200
ccggagctgg	gtatctcaaa	tctgctttca	tccagccact	gcccagaagc	atcttctctg	10260
ctactggatg	cttacagtg	ctgtggatc	gggggttccc	tttccccact	cagtgacatg	10320
tctctctctg	ttgggtttaa	ccattcttgg	gaggacactt	ttgccaatga	actcttctcc	10380
cagctgatata	gtgtcctaag	aatgatccaa	tactgttggc	cttttctctg	actattacac	10440

-continued

tgccctggagg	atagcagaga	agcctgtctg	tacttcattc	aaaaagccaa	aatagagagt	10500
atacagtcct	agagaattcc	tctatttggt	cagatctcat	agatgacccc	caggatttgt	10560
cttttgacat	ccagcagtc	aaggatttga	gacatattac	tggaaagt	aaatattact	10620
ataattgaga	actacagctt	ttaagattgt	acttttatct	taaaaggggt	gtagtttcc	10680
ctaaaatact	tattatgtaa	gggtcattag	acaaatgtct	tgaagtagac	atggaattta	10740
tgaatgggtc	tttatcattt	ctcttcccc	tttttggcat	cctggcttgc	ctccagtttt	10800
aggctcctta	gtttgcttct	gtaagcaacg	ggaacacctg	ctgagggggc	tctttccctc	10860
atgtatactt	caagtaagat	caagaatcct	ttgtgaaatt	atagaaaattt	actatgtaaa	10920
tgcttgatgg	aattttttcc	tgctagtgt	gcttctgaaa	gggtccttct	ccatttattt	10980
aaaactacc	atgcaattaa	aaggtacaat	gcagcatcct	tgtttgattt	cttctagggc	11040
cgtaagtctt	gttttctctc	cagatgttta	tctgtgtgct	gtggtaggaa	ttaatccaac	11100
tgaagtggag	ctaaccgttt	ttaaagtgac	tgaaggcttt	tccaccttaa	ttactgcctg	11160
ctttaattct	ggactgacct	aagtgatata	agctataatt	tgagcagtta	ctgtctttct	11220
gagacagatt	cttgagccta	actgaccaat	atcacagcta	gtaagtgtaa	gagctagaac	11280
cctaaccact	atttgctaca	ccatcttata	aatgttaaac	aaggacacac	catcacatat	11340
cgagattctc	ttggccttat	tatgggaatt	aagagcattt	tctagactga	aaactccctat	11400
tttcaactct	gccactggta	agctgggtaa	cccaggggtt	atatataatc	acttatttcc	11460
tcatctgtaa	agttggataa	tggtatctct	aaaggttaag	attcaagag	acgatgcatt	11520
ataagcattt	agtatatgct	agggccatc	ctaaacactg	gaaagttagt	tagttattat	11580
ctcctaacc	actttggaag	ggttttaatc	tcttccagaa	ttatatttac	tcaagaattt	11640
gtttcatcaa	agaataaacc	tcgccagggc	gcggtggctc	atgctgttaa	tcccagcact	11700
ttgggaggct	gaggcgggtg	gatcacgagg	tcaggagatc	gagaccatcc	tgcttaacat	11760
ggggaaaacc	tgtctctact	aaaattacaa	aaaattagcc	agggcgtggg	gtgggcccct	11820
gtaatcccag	ctacttggga	ggctgaggca	ggagaatggc	gtgaaccggg	gaggcggagc	11880
ttgcgggtgag	gggagatcgc	gccactgcac	tccagcctgg	gcaacagagc	gagactctgt	11940
ctcaaaaaat	aaataaaata	ataaataaat	aaataaaata	acctcttcaa	gaaaaaatcc	12000
tagtgatatt	aatacaactc	ccaagactt	gataaacctc	tcatccttca	tagcatcttt	12060
tcttggaata	tcttacaagg	ttttacagga	ctttacttat	ttataaaaat	ttcacctatg	12120
ccagtagatg	aaatcattct	atgcccaatt	agcattttaa	tgetatgttc	ccaacttaca	12180
aagactaact	ctggggagggt	caaagtgaat	gagtagaaaa	aaggcaggat	tcagagaatc	12240
ccaagcagca	agccaaagtg	gattatagaa	tacctttggg	gtaggccagg	tgtagtggct	12300
cacgcttgta	atcccaacac	ttttgggaggc	tgaggtgggc	ggatcacctg	aggtcaggag	12360
ttcatggcca	gcctgaccaa	catagtgaaa	ccccatctct	agtaaaaaata	caaaatttagc	12420
tgggtgtggg	ggcgcatatg	cctgtaatcc	cagctactca	ggaggctgag	gcggcagaat	12480
cacttgaacc	cgggaggcag	aggatgcagc	gagccgagat	cgtgccattg	cactccagcc	12540
tgggcaacaa	gagcgaactc	ccatttaaaa	aagaaaaaaa	aaaatagaat	gcctttcatg	12600
tagtgactgg	aggcaagtca	gctagctgcc	ttcaagatcc	ggtcgttgaa	gccagggccc	12660
aatcctgggtg	ctcagcaata	caaaacttget	taggetctta	agtttcttca	gaaacaggcc	12720
aggcatgggtg	gctcacacct	ataatcccag	cactttggga	ggccgaggcc	agcagatgct	12780
ttggttcaag	actagcctgg	acaacatggc	aaaccctctc	ctccatgaaa	agtaaaaaaa	12840
aatagccagg	catgggtggg	tgcactgggtg	gtcacagcca	ctcaggaagc	tgaggtggga	12900
ggatcgcttg	aggccagggg	gcagaggttg	cagtcagcca	agatcgcagc	actgcactcc	12960
agactgggtg	aaaagcaag	actgcctaaa	aaaaaaaagg	ttctgtatat	aag	13013

What is claimed is:

1. A vector comprising:
 - (i) a first nucleic acid sequence encoding a FOXP3 polypeptide; and
 - (ii) a second nucleic acid sequence encoding one or more transcription factor(s) selected from the group consisting of: ID2, ID3, GATA1, GATA3, XBP1, and SATB1.
2. The vector of claim 1, wherein the one or more transcription factor(s), when present in a human cell, elicit (s) a T reg phenotype in the human cell as compared to when the one or more transcription factor(s) is/are not present in the human cell.
3. The vector of claim 1, wherein the one or more transcription factor(s) is ID2.
4. The vector of claim 1, wherein the one or more transcription factor(s) is ID3.
5. The vector of claim 1, wherein the one or more transcription factor(s) is GATA1.
6. The vector of claim 1, wherein the one or more transcription factor(s) is GATA3.
7. The vector of claim 1, wherein the one or more transcription factor(s) is XBP1.
8. The vector of claim 1, wherein the one or more transcription factor(s) is SATB1.

9. The vector of claim 1, wherein the vector further comprises a promoter operably linked to the first nucleic acid sequence.

10. The vector of claim 1, wherein the first nucleic acid sequence is positioned 5' relative to the second nucleic acid sequence in the vector.

11. The vector of claim 10, wherein the vector further comprises an additional nucleic acid sequence between the first nucleic acid sequence and the second nucleic acid sequence, wherein the additional nucleic acid sequence operably links the second nucleic acid sequence to the first nucleic acid sequence, and the additional nucleic acid sequence (i) encodes an internal ribosome entry site (IRES) sequence or a self-cleaving amino acid, or (ii) comprises a promoter or an enhancer.

12. The vector of claim 1, wherein the second nucleic acid sequence is positioned 5' relative to the first nucleic acid sequence in the vector, and the second nucleic acid sequence is operably linked to a promoter.

13. The vector of claim 12, wherein the vector further comprises an additional nucleic acid sequence between the second nucleic acid sequence and the first nucleic acid sequence, wherein the additional nucleic acid sequence operably links the first nucleic acid sequence to the second nucleic acid sequence, and the additional nucleic acid

sequence (i) encodes an internal ribosome entry site (IRES) sequence or a self-cleaving amino acid, or (ii) comprises a promoter or an enhancer.

14. The vector of claim **1**, wherein the vector further comprises a third nucleic acid sequence encoding a therapeutic gene product.

15. The vector of claim **14**, wherein the therapeutic gene product is an antibody or antigen-binding fragment that is capable of specifically binding to an IL-6, an IL-16R, an IFN alpha receptor, or a TGF beta receptor polypeptide.

16. The vector of claim **14**, wherein the third nucleic acid sequence is operably linked to a promoter.

17. The vector of claim **14**, wherein the vector further comprises a fourth nucleic acid sequence encoding a binding agent, wherein the binding agent is an antibody, an antigen-binding fragment, or a chimeric antigen receptor.

18. The vector of claim **17**, wherein the fourth nucleic acid sequence is operably linked to a promoter.

19. The vector of claim **17**, wherein the chimeric antigen receptor comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises an antibody or antigen-binding fragment that is capable of specifically binding to an antigen on an autoimmune cell, and the intracellular domain comprises a cytoplasmic signaling domain and one or more co-stimulatory domain(s).

20. The vector of claim **19**, wherein the extracellular domain specifically binds to a cell adhesion molecule selected from the group consisting of: ICAM-1, VCAM-1, and MAdCAM-1.

21. The vector of claim **19**, wherein the cytoplasmic signaling domain is a CD3 zeta domain and the one or more co-stimulatory domain(s) comprise(s) at least one of a CD48

domain, a 4-1BB domain, an ICOS domain, an OX-40 domain, and a CD27 domain.

22. The vector of claim **1**, wherein the vector comprises a viral vector selected from the group consisting of: a lentiviral vector, a retroviral vector, an adenoviral vector, and an adeno-associated viral (AAV) vector.

23. A composition comprising:

(i) a first vector comprising a first nucleic acid sequence encoding a FOXP3 polypeptide and a promoter operably linked to the first nucleic acid sequence; and

(ii) a second vector comprising a second nucleic acid sequence encoding one or more transcription factor(s) selected from the group consisting of: ID2, ID3, GATA1, GATA3, XBP1, and SATB1, and a promoter operably linked to the second nucleic acid sequence.

24. The composition of claim **23**, wherein the one or more transcription factor(s), when present in a human cell, elicit (s) a T reg phenotype in the human cell as compared to when the one or more transcription factor(s) is/are not present in the human cell.

25. The composition of claim **1**, wherein the one or more transcription factor(s) is ID2.

26. The composition of claim **1**, wherein the one or more transcription factor(s) is ID3.

27. The composition of claim **1**, wherein the one or more transcription factor(s) is GATA1.

28. The composition of claim **1**, wherein the one or more transcription factor(s) is GATA3.

29. The composition of claim **1**, wherein the one or more transcription factor(s) is XBP1.

30. The composition of claim **1**, wherein the one or more transcription factor(s) is SATB1.

* * * * *